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T cell exhaustion is found in various disorders including chronic infections 
and cancer. In these diseases, T cell exhaustion shares a core of common 
features, namely sustained high expression of multiple inhibitory receptors, 
deficiency of cytokine production and loss of memory potential, leading to 
impeded control of pathogens or cancerous cells. Reversing or ameliorating T 
cell exhaustion is the focus of many therapeutic interventions in cancer. Recent 
studies have implicated various roles for transcription factors and epigenetic 
imprinting on the development of T cell exhaustion. Here, we describe the cur-
rent status on the molecular and cellular signatures of T cell exhaustion, espe-
cially novel developments in the understanding of the mechanisms that drive T 
cell exhaustion. We also highlight strategies of rejuvenating exhausted CD8+ T 














During viral and other intracellular infections, cytotoxic CD8+ T lymphocytes (CTL) play a 
crucial role in eliminating infected cells and thereby prevent pathogen dissemination. During 
initial recognition of viral antigens by the immune system, naïve CD8+ T cells differentiate into 
effector cells, which expand and exert effector functions. These effectors lyse the infected 
cells by production and release of, amongst other immune mediators, perforin and granzyme 
B (GzmB). Upon the clearance of infection, the effector cell population shrinks mostly due 
to apoptosis. However, a small subset of CD8+ T cells differentiate into long-lasting memory 
CD8+ T cells that are equipped with the capacity of self-renewal, allowing for rapid recall 
response upon re-infection (1). 
In recent years, a different state of T cell differentiation, namely exhaustion, has been 
described. This state of T cells is still being characterized and intensely researched. In the 
case of chronic viral infection or cancer, CD8+ T cells are persistently stimulated due to ele-
vated and unremitting antigen load (2). This continuous stimulation is demonstrated to be 
the main factor that drives the development of exhausted CD8+ T cells (3-5). T cell exhaus-
tion is characterised by loss of pathogen control and memory potential, and is accompanied 
by altered metabolism and a unique transcriptional and epigenetic program (6, 7). The differ-
entiation toward the exhausted state follows a distinct and progressive trajectory compared 
to memory and effector T cells.
Along with the in-depth understanding of the features of T cell exhaustion as well as the 
mechanisms leading to the related phenotypes, attempts have been made to restore the 
function or prevent the development of exhausted T cells. Understanding factors that con-
tribute to T cell exhaustion is important for the development of interventions. Reversing the 
dysfunctional T cell state that arises in cancer and chronic viral infections is the focus of ther-
apeutic interventions and key to restoring successful T cell immunity. This thesis has focused 
on understanding the factors that lead to T cell exhaustion and identifying the potential 
strategies that reverse/prevent CTL exhaustion to reinvigorate T cell immune responses in 
chronic infection and cancer.
In the introduction of this thesis, I will first review the functional, molecular and sig-
nalling changes that characterize exhausted T cells. I will then go on to present the factors 
and mechanisms that induce and regulate T cell exhaustion. Currently, there has been some 
progress in finding strategies to reverse or prevent T cell exhaustion with the objective of 
restoring effective CD8+ T cell responses. These potential novel approaches and the associ-
ated mechanisms, will be discussed. In the end, I will discuss the limitations in our knowledge 
about T cell exhaustion in the context of treating associated diseases. 
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Cellular, functional and molecular features of exhausted CD8+ T cells 
 
Cellular features associated with T cell exhaustion 
One of the most notable features of the CTL progression to exhaustion is a gradual 
and hierarchical loss of the capability for cytokine production, and this is accompanied by 
a decreased capacity to lyse target cells (8). As CTL become increasingly exhausted, they 
initially lose IL-2 production, then TNF-α and finally IFN-γ secretion. This loss of the ability to 
make more than one cytokine by the exhausted cells is known as loss of polyfunctionality. 
Exhausted CTL, despite having more granzyme B, present with impaired ability to degranu-
late, an essential requirement for target lysis. As CTL progress to exhaustion, they lose their 
proliferative potential. Concurrently to the loss of effector functions and ability to proliferate, 
multiple inhibitory receptors accumulate on the cell surface, which mediate inhibitory sig-
naling that are induced by ligation of corresponding ligands presented in the environment 
(9, 10). The end result of the exhaustion process is apoptosis (2, 11). Exhaustion is believed 
to be a strategy employed by the host in an effort to prevent immune overreaction and the 
associated immunopathology during autoimmunity (12, 13).
CTL exhaustion and inhibitory receptors
A characteristic of exhausted CTL is the simultaneous expression of multiple inhibitory 
receptors. There are different types of inhibitor receptors that can be detected on exhausted 
T cells (Figure 1). In contrast to exhausted CTL, most of the inhibitory receptor expression 
is transient on effector cells during acute infection and diminishes on memory cells (14). 
Therefore, classifying T cells as exhausted by using single inhibitory receptor expression is 
unreliable, because this receptor expression could simply be a marker of recent T cell acti-
vation. The most well-studied inhibitory receptor in T cell exhaustion is PD-1, a CD28-family 
member. PD-1 was shown to be continuously overexpressed on virus-specific CD8+ T cells 
during chronic viral infection and in tumor infiltrating lymphocytes (TILs) during tumor pro-
gression (15, 16). An immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immu-
noreceptor tyrosine-based switch motif (ITSM) in the intracellular domain of PD-1 mediate 
its suppressive function. Upon binding to its ligands (PD-L1 or PD-L2), PD-1 forms clusters 
with the TCR (17). Subsequent phosphorylation of its intracellular tyrosine domain results in 
the recruitment of proteins that inhibits TCR signaling. It has been shown that the ITSM could 
recruit the tyrosine-protein phosphatase SHP1 (also known as PTPN6) and/or SHP2 (also 
known as PTPN11) (18, 19). However, this has not been validated in in vivo studies (20). It is 
also poorly understood what role the ITIM plays in PD-1’s suppressive function. Downstream, 
activation of PD-1 was shown to lead to the upregulation of the basic leucine zipper tran-
scription factor, activating transcription factor ATF-like protein (BATF) (21). Upregulation of 













An important inhibitory receptor that is linked with PD-1 expression as a result of sus-
tained CD8+ T cell activation is Lymphocyte Activation Gene-3 (LAG-3), an MHC class II ligand 
with structural similarities to CD4 (23). Downstream effects of LAG-3 signaling during T 
cell exhaustion, which are mediated through inhibiting TCR signaling, include reduction in 
cytokine production and proliferation. It has been shown that LAG-3 through binding to its 
ligand, Fibrinogen-like protein 1 (FGL1), inhibits the in vitro and in vivo CD8+ T cell response. 
Mechanistically, LAG-3 is associated with the inhibition of calcium flux, which compromises 
downstream TCR signaling (23). 
Expression levels of T-cell immunoglobulin and mucin domain 3 (TIM-3) have also been 
shown to be correlated with the severity of exhaustion although the exact mechanism is 
not clear. It has been shown that as CD8+ T cells progress to the more terminal stage of 
exhaustion and lose their ability to produce cytokines, TIM-3 is concomitantly upregulated. 
TIM-3 is known to bind multiple ligands that lead to context-specific downstream effects (24, 
25). In addition to the above mentioned inhibitory receptors, there are still more which are 
Figure 1. Inhibitory receptors and their ligands as well as the associated signalling cascades
There are multiple inhibitory receptors upregulated on the exhausted CTLs, such as PD-1, CTLA-4, et al. At the same 
time, there are correlated ligands expressed on tumor cell surface or antigen presenting cells. By binding to its li-
gand, inhibitory signaling would be transduced into the CD8+ T cells and regulating different pathways, finally inhibit 
the effector function of exhausted CTLs.
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associated with exhaustion such as T cell immunoglobulin and ITIM domain (TIGIT), CD160, 
CD244 (2B4) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (the related inhibi-
tory signaling is schematically shown in the Figure 1).
Molecular and transcriptomic changes associated with T cell exhaustion 
All published reports on gene expression profiling agree that exhausted T cells possess 
a distinct transcriptome compared to that of naïve, effector or memory cells (6, 26, 27). 
Although there is no true metric for accurately determining how different exhausted cells 
are from their naïve and memory counterparts, there are numerous differentially expressed 
genes identified as well as key transcription factors driving the observed transcriptomic 
changes that create the exhaustion profile.
A number of transcription factors play complex roles in driving T cell exhaustion. There are 
two T-box transcription factors, T-box transcription factor TBX21 (T-bet) and Eomesodermin 
(Eomes), which were first reported to play key roles in regulating both functional and dys-
functional CD8+ T cell responses. During chronic viral infections, downregulation of T-bet 
was associated with greater dysfunction of antigen-specific T cells. During acute infection, 
in the absence of T-bet, the development of T cells underwent central memory skewing (28, 
29). T-bet directly regulates PD-1 expression on exhausted cells through repression of the 
PD-1 encoding gene (30). In HIV infected patients, CTL from elite controllers were observed 
to express higher levels of T-bet than the chronic progressors and its high expression was 
positively correlated with effector function (31). At the same time, increased expression of 
Eomes at the mRNA level was observed in acute viral infection compared to memory cells 
(8). Eomes is indispensable in memory development (32). While Eomes’ contribution to T 
cell exhaustion remains controversial, it has been shown to correlate with the dysfunctional 
phenotype but also works as a maintainer of the effector function. Eomes was observed to 
be up-regulated in exhausted CD8+ T cells during chronic infection, but the Eomeshi popu-
lation was still able to proliferate (33). Furthermore, in Eomes-deficient mice, CD8+ T cells 
were found to expand less during chronic infection. Due to the fact that transcription factors 
may affect multiple stages of T cell differentiation, the study of the function of transcription 
factors in vivo is very challenging.
Other transcription factors that have been found to correlate with the development of 
T cell exhaustion include transcription factors that belong to the nuclear factor of activated 
T-cells (NFAT)-family. These were one of the first transcription factors to be implicated in the 
development of T cell exhaustion, whereby increased expression was observed in T cells 
isolated from mice chronically infected with lymphocytic choriomeningitis virus (LCMV) (8). 
Transcription factors belonging to the nuclear receptor 4A (NR4A)-family have been shown to 
play an important role in T cell exhaustion of both TILs and virus-specific CD8+ T cells (34, 35). 













levels of the transcription factors IRF4 and BATF, which are linked to TCR-responsiveness. 
NFAT1 and NFAT2 were shown to be required to induce IRF4 expression. IRF4, BATF and NFAT 
were found to bind to exhaustion-specific gene promoters genome-wide. Reduction in IRF4 
expression was shown to favor the formation of TCF1-expressing memory-like antigen-spe-
cific T cells through restoration of anabolic metabolism (27). Enforced expression of BATF 
was sufficient to cause T cell proliferation and cytokine secretion impairment. Confirming 
this regulation of function, silencing BATF in T cells was shown to rescue HIV-specific T cell 
function (21). 
Another transcription factor important for T cell exhaustion and T cell development is T 
cell factor 1 (TCF1; corresponding gene name Tcf7). TCF1, originally found to be crucial for 
memory T development, has recently been linked to progenitor exhausted T cells in both 
viral infections and tumors (26, 36, 37). The question about the existence of progenitor 
exhausted T cells or memory-like subpopulations within exhausted CD8+ T cells was raised 
because exhausted antigen-specific T cells undergo large expansions after transfer to naive 
mice (38). TCF1+ CD8+ T cells were subsequently identified as one subpopulation of memo-
ry-like exhausted antigen-specific CD8+ T cells in chronic infection. This subpopulation rep-
resents an earlier developmental state of exhaustion. Although TCF1-expressing CD8+ T cells 
sharing some characteristic of conventional memory cells, they also exhibit the hallmarks of 
exhaustion. After Tcf7-/- mice were infected with lymphocytic choriomeningitis virus clone 
13 (LCMV Cl13), a strain of virus that induces a chronic viral infection, antigen-specific CD8+ 
T cells could expand as much as the wild-type cells on day 8, however, the expansion could 
not be maintained and viral control was lost by day 56 (26). Furthermore, exhausted CTL 
from chronically infected Tcf7-/- mice lost proliferation capacity when engrafted into acutely 
infected hosts. The reduction of TCF1+CD8+ T cells was accompanied by higher amounts 
of antigen and prolonged viral loads. Therefore, when antigen persists, TCF1+CD8+ T cells 
(the progenitor exhausted CTL) gradually differentiate into TCF1-CD8+ T cells (the termi-
nally exhausted CTL) (39). The differential program of exhausted CTL has been illustrated in 
figure 2.
The tissue distribution of progenitor and terminally differentiated exhausted CTL indi-
cated additional differences. The latest findings suggest that TCF1+ and CXCR5+ T cells can 
only be found in the lymphoid organs of chronically infected animals (40). Progenitor or 
“stem-like” exhausted CTL bear different epigenetic and transcriptomic signatures from 
that of central memory CTL in acute infection. These “stem-like” quiescent CTL reside in 
lymphoid tissues, which provide a protective niche and maintain the resource to generate 
“effector like” CTL during chronic infection (41). In contrast terminally exhausted CTL reside 
in blood and infected organs. In tumor patient studies, the presence of antigen presenting 
cell dense regions was shown to serve as an intratumoral niche for PD-1+ TCF1+ “stem-like” 
T cells, which contribute to sustaining the terminally differentiated T cell population as well 
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as contributing to the anti-tumor immune response (42). It has been proposed that between 
“stem-like” progenitor exhausted CTL and terminally exhausted T cells, a transitory cell stage 
exists identified by CD101- Tim-3+ (41). After check point blockade treatment, progenitor 
exhausted CTL give rise to transitory effector cells with cytotoxic and proliferative capacity, 
which can be detected in lymphoid and non-lymphoid organs. The transitory CTL can further 
differentiate into CD101+ Tim3+ terminally differentiated exhausted CTL. Importantly, the 
“stem-like” progenitor exhausted CTL in chronic infections or cancer are necessary for the 
animal or individual to respond to check point blockade (16, 43). 
Recently, thymocyte selection associated high mobility group box protein (TOX) was 
found to play a critical role in programming and maintaining exhausted cells in chronic viral 
Figure 2. Different developmental stages of exhausted T cells as well as the key markers of identification
When there is an antigen presented, naïve CD8+ T cell could recognize the antigen, be primed and undergo differen-
tiations. However, depending on the how long the antigen stimulation persists, their fates would be rather different. 
In the acute infectious diseases, the antigen could be cleared rapidly by the expanded effector T cells. After that, 
small pool of effector T cells further differentiated into memory precursor cells and finally become memory cells, 
which are polyfunctional and have the potential to quickly respond as the same antigen present again. On the other 
side, In the context of chronic viral infection or cancer, where the antigen persists. Naïve T cells would differentiated 
to the exhausted cells. It remains to be a question, if there is “potential pre-exhausted T cells” stage before they 
become exhausted. Before being terminally exhausted, at the early stage of the disease, the exhausted cells are pro-
genitor exhausted T cells, which can be identified by the TCF1 and CXCR5 expression. The expression of TOX would 
drive the cells to be exhausted. There is an exhausted-like memory T cells would formed when the chronic antigen 
is eliminated. It is unclear, when the antigen reappears, whether exhausted-like memory T cells would function 
like real memory cells that responds rapidly and eliminate the infected cells or tumor cells. However, if the antigen 
maintained, the terminally exhausted T cell, marked by increasing PD-1 and downregulated T-bet expression will 













infection and tumors (44-48). Mass cytometry studies of human CD8+ T cells found that TOX 
was expressed in the vast majority of exhausted T cells from patients with HIV infection and 
lung cancer (49). Interestingly, it was shown to be largely dispensable for the formation of 
effector and memory T cells (45). By using single cell RNA-seq, Yao C et al found that the pro-
gression to exhaustion was initiated before the peak of the CD8+ T cell response, where the 
progenitor-like CD8+ T cells in chronic infection distinguished themselves from memory pre-
cursor cells by their enrichment of the gene module containing TOX (47). TOX also promotes 
the long-term persistence of virus-specific CD8+ T cells during chronic LCMV infection. The 
expression of TOX is induced by high antigen stimulation of the TCR. In the absence of TOX, 
initially CD8+ T cells mediate increased effector function but cause more severe immunopa-
thology (44). In chronic viral infection, in the absence of TOX, the number of antigen-specific 
T cells was decreased dramatically. Similarly, in the context of tumors, it was confirmed that 
expression of TOX was driven by chronic TCR stimulation and NFAT activation (45). Deletion 
of TOX in TILs abrogated the exhaustion program and T cells retained high expression of the 
transcription factor TCF1. Despite this however, they remained dysfunctional. Therefore it 
seems that sustained TCR activation causes the upregulation of TOX, whereby TOX works 
as a primary regulator to induce the exhaustion program which prevents the overstimula-
tion of T cells and limits host immunopathology (50). These landmark findings dramatically 
influenced the understanding of the molecular mechanisms regulating exhaustion. However, 
given the multiple effects and roles transcription factors can have, one needs to be cautious 
in assigning exclusive roles in exhaustion. TOX is an example of this, as TOX was found to 
be expressed by most human blood effector memory CD8+ T cell subsets, including poly-
functional CTL, and was not exclusively linked to exhaustion (51). Despite these limitations, 
identifying critical transcription factors, associated with the origins and drivers of exhausted 
T cells provides further elucidation of exhaustion at the molecular level. 
DNA methylation 
The distinct gene expression profile of exhausted T cells, requires in addition to the 
interplay of multiple transcription factors, also the promotor accessibility of the gene loci. 
This accessibility is controlled by DNA methylation and chromatin accessibility. It has been 
shown that multiple forms of epigenetic modifications are present in exhausted cells. Due 
to the limitations of material and techniques, initial epigenetic modifications detected from 
exhausted cells were mainly focused upon single genes. Youngblood B et al first identified 
that the regulatory region of Pdcd1 (corresponding gene of PD-1) was de-methylated in 
exhausted cells and the methylation status was unchanged even after viral clearance. This 
was in sharp contrast to acute viral infection, where the Pdcd1 locus transiently lost DNA 
methylation in the effector stage but re-gained methylation in functional memory cells (52, 
53). This finding was correlated at the protein level with the upregulation of PD-1 expression 
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on effector cells and diminished expression on memory cells. Unlike in acute resolving 
infection, exhausted T cells maintained high expression levels of PD-1. This transient DNA 
demethylation in effector cells, however, may reflect the replacement of these cells in the 
memory pool by memory precursor effector cells which may retain DNA methylation on 
the Pcdc1 locus. Recently, global methylation sequencing was performed to compare the 
epigenetic landscape modifications between exhausted cells and functional counterparts 
(7, 54). Pauken et al revealed that exhausted T cells acquired a distinct epigenetic profile 
compared to effector and memory cells, which supported the idea that exhausted T cells are 
a distinct lineage (54). PD-1 blockade therapy was shown to be incapable of rewriting the 
epigenetic landscape of exhausted cells, which was suggested by the limited reengagement 
of effector circuitry in exhausted cells (54, 55). Related to DNA methylation, the enzyme, de 
novo methyltransferase 3a (DNMT3a) has been shown to contribute to de novo methylation 
during cell proliferation and development (56). DNMT3a plays a critical role in directing early 
CD8+ T cell effector and memory fate decisions (57). In the context of T cell exhaustion, the 
demethylation of the Pdcd1 locus was due to the reduced expression of DNMT3a isoform 2. 
Chromatin accessibility 
Compared to DNA methylation sequencing, the results from chromatin accessibility assays 
are more directly correlative with transcriptional changes. When compared to memory cells, 
it has been shown that exhausted T cells in cancer and chronic viral infection present dis-
tinct accessible chromatin landscapes (7). The exhaustion-specific accessible regions in TILs 
were identified by filtering out activation-related accessible regions. Importantly, accessible 
regions were found to be shared by exhausted T cells from chronic viral infection and cancer 
(58). To confirm that epigenetic modifications play an important role in the establishment 
of T cell exhaustion, Zhang F et al showed that histone deacetylase inhibitors can restore 
de-acetylated histone H3 levels of exhausted CD8+ T cells in vitro and demonstrated func-
tionally that their immune response to the antigen was improved (59). These effects were 
maintained even after adoptively transferring the inhibitor-treated cells into virus infected 
animals. 
Using these methods, an enhancer site of the Pdcd1 locus was discovered in exhausted T 
cells (60). Exhaustion-specific chromatin accessibility regions also aided in identifying strongly 
enriched Nr4a and NFAT binding motifs in exhausted T cells from both chronic infection and 
tumor settings (58). In the meanwhile, the chromatin accessibility landscape between HIV-
specific and LCMV-specific CD8+ T cells show high degree of similarity based upon transcrip-
tion factor binding motif comparisons (7). This finding suggested that a shared core of T cell 
exhaustion features in chronic viral infections and tumor is governed epigenetically. 
What factor induces these epigenetic changes that impart T cells with an exhausted 













melanomas and human melanomas which shed light on this question (45, 48, 61). TOX drives 
exhaustion by recruiting the HBO1 complex that consists of multiple chromatin remodeling 
proteins, including proteins that are capable of acetylating histones H3 and H4 (45). The 
downstream effects of TOX resulted in both the shutting down of effector function associated 
genes and the opening of exhaustion associated genes. Overexpression of TOX was sufficient 
to induce a transcriptional program that leads to epigenetic changes in exhausted T cells. 
All things considered though, not all the exhaustion-related molecular changes, such as 
the upregulation of inhibitory receptors, can be directly attributed to epigenetic modifica-
tions. This suggests that other complex regulatory mechanisms and circuitries contribute to 
the exhaustion-related changes and remain to be further identified.
Post-transcriptional regulation
There are variety of mechanisms by which gene expression is regulated at the post-tran-
scriptional level. By binding to a specific sequence or secondary structure of RNA transcripts, 
microRNA (miRNA) and RNA binding proteins (RBP) can control gene expression in differ-
ent tissues and various biological processes. MiRNAs are 18-22 nucleotide long non-coding 
RNA molecules. Typically, by complementary binding, often to particular sequences in the 3 
‘untranslated region (3’-UTR) of the target mRNA, miRNA can cause translational silencing 
or the degradation of mRNA (62-64). Initial experiments demonstrated the importance of 
miRNAs in T cell development when Dicer, an enzyme critical for the maturation of miRNAs 
(14), was deleted specifically in T cell compartments (65). By knocking out the enzyme, which 
results in the absence of mature miRNA in T cells, the function of the T cell compartment 
was heavily influenced. When Dicer was knocked out specifically in CD8+ T cells, it affected 
effector CD8+ T cells (66). Thus, it is reasonable to hypothesize that miRNAs could play a 
critical role in T cell exhaustion. Previous studies have reported that ex vivo subsets of human 
CD8+ T cells demonstrated unique expression patterns of miRNAs, notably the upregulation 
of miR-21, miR-155 and miR-146a and the downregulation of miR-19b, miR-20a, miR-92, and 
miR-26a in differentiated effector cells (67). However, as antigen stimulation and the local 
inflammatory environment during an active infection can heavily impact CTL differentiation 
(68), the miRNA expression profiles of exhausted CD8+ T cells are expected to differ from 
that observed for effector cells. 
Although the changes in miRNA expression in relation to T cell exhaustion have yet to be 
delineated, experiments with individual miRNA have shown that these can regulate the induc-
tion of T cell exhaustion or alter the dysfunctional state of exhausted CTLs. One of the most 
prominent and widely studied miRNAs is miR-155. Previous studies have highlighted the con-
tribution of miR-155 to CD8+ T cell responses in both virus and cancer models (69, 70). The 
expression of miR-155 is induced by TCR activation and increased expression was observed 
in terminally exhausted T cells during chronic LCMV infection (70, 71). Overexpression of 
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miR-155 leads to preservation of progenitor exhausted T cells and enhances their differen-
tiation towards a terminally exhausted state while promoting the proliferation of terminally 
exhausted CTL (71). In cancer, Martinez-Usatorre et al found that the expression of miR-155 
correlated with the responsiveness to antigen in the tumor microenvironment (TME) and 
thus increased tumor control (72). As an underlying mechanism, miR-155 enhances Batf and 
Nfat while repressing the transcription of Fosl2, a component of the AP-1 pathway, resulting 
in reduced signaling of inflammatory cytokines (69, 70, 72). Another miRNA that is sharply 
upregulated as a result of chronic TCR stimulation in mice and humans is miR-31 (73, 74). By 
using the LCMV model, Moffett et al showed that sustained stimulation of the TCR leads to 
the expression of miR-31 and attenuates the effect of IFN-β signaling in T cells. MiR-31 was 
demonstrated to suppress T cell effector function in chronic viral infection. The deficiency 
of miR-31 was largely beneficial to animals recovering from LCMV infection compared to 
wild-type mice (74). The above underscore the potential of post-transcriptional regulation in 
affecting T cell exhaustion.
Factors leading to the development of CTL exhaustion 
Persistent antigen stimulation
It is well established that persistent infections both in humans and animal models induce 
T cell responses that display progressive dysfunction, which is thought to contribute to the 
further persistence of the pathogen in the host (Illustrated in Figure 3). T cell exhaustion was 
originally observed in human immunodeficiency virus-1 (HIV-1) infected patients in 2006, 
when it was shown that HIV-specific CD8+ T cells strongly upregulated PD-1 in untreated 
patients (15, 75, 76). Moreover, upregulation of PD-1 expression was found to be correlated 
with impaired functionality and disease progression, as measured by viral load and CD4+ T 
cell counts. In human chronic viral infection, it is not surprising that lower antigen burden 
correlates with less exhausted CTL. Indeed, patients that were treated with antiviral ther-
apy showed reduced viral load which correlated with a decrease in expression of PD-1 on 
HIV-specific CD8+ T cells, indicative of less T cell exhaustion (77). Similar profiles of CD8+ T 
cell exhaustion have been shown in other chronic viral infections, namely, hepatitis B virus 
(HBV) and hepatitis C virus infections (HCV) (78-80). In these diseases, earlier intervention 
with antiviral therapy is recommended as it is linked to decrease antigen and preserves anti-
gen-specific CD8+ T cell function (81-83).
In contrast to these chronic viral infections, other persistent viral infections, such as 
cytomegalovirus (CMV) and Epstein-Barr virus (EBV) do not seems to cause CTL exhaustion, 
although the individuals do not completely eradicate the virus (2, 84). Despite the increased 
and sustained high levels of PD-1 expressed on CMV-specific CD8+ T cells, these levels are 













cells have been described as expressing an exhausted-like phenotype, yet still remain func-
tional (86). These results can be explained by the dormant periods present during CMV and 
EBV infections in which antigen-specific CD8+ T cells are not persistently stimulated with 
cognate antigen. 
LCMV infection is the most frequently used mouse model to study T cell exhaustion. 
When infected with the Armstrong strain (Arm) of LCMV, the animals develop an acute infec-
tion where the virus is cleared by day 8-10 post-infection. During this acute infection, func-
tional effector and memory CD8+ T cells are generated. In contrast, although there are only 
two amino acid variations, the LCMV Cl13 strain causes chronic infection. Importantly, the 
immunodominant CTL epitopes are shared between these two strains, allowing researchers 
to investigate and compare the dynamics of the CD8+ T cell responses in acute and chronic 
infection (87). 
The concept of persisting high levels of cognate antigen presentation contributing to CTL 
exhaustion was further supported in animal models. One such model, utilizes bone marrow 
(BM) chimeric mice, in which non-BM derived cells were MHC class I deficient. Infection of 
Figure 3. Multiple factors contribute to the development of CTL exhaustion
CTL exhaustion is mainly induced by persistent antigen presenting. Besides that, in the tumor microenvironment, 
there are different types of cell, like increased M2 cells and MDSCs that contribute to CTL exhaustion. The presence 
of inflammatory cytokines, such as IL-10 and TGF-β also play a role in CTL exhaustion. The other factors, like the 
accumulation of adenosine and glucose depriving, the existence of extracellular matrix could also play a role in CTL 
exhaustion development in the tumor. These factors lead to the epigenetic changes of CTL in chronic infection and 
cancer. The exhausted CTLs, which lost proliferation potential, hieratically reduced cytokine production, increase 
sensitivity to apoptosis and gradually upregulate inhibitory receptors, finally developed.
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these mice with LCMV Cl13 results in a chronic infection and CTL exhaustion. Mueller SN et 
al, reported more antigen specific CD8+ T cells in the mice lacking MHC I on non-BM derived 
cells, despite antigen load being less than in the class I-sufficient mice. These results provided 
direct evidence that persistence of antigen-MHC complexes drive functional exhaustion in T 
cells in the setting of an infection, leading to antigen-specific CD8+ T cells which were rapidly 
exhausted within 4-6 weeks (4).
Another interesting question, relevant to exhaustion, is what kind of antigens can cause 
the T cells to be exhausted? By using recombinant antigen variant-expressing LCMV strains, 
Utzschneider D T. et al revealed that low-level antigen exposure promotes the formation of 
T cells with an acute effector phenotype in chronic infection (5). Thus, whether one antigen 
can induce exhaustion or not depends critically on the frequency of T cell receptor (TCR) 
engagement and less upon the strength of TCR stimulation, i.e. the quantity of the antigen 
is more significant than the affinity to influence T cell exhaustion. However, LCMV infection 
models cannot completely exclude that the effect of chronic antigen stimulation on T cell 
exhaustion also requires the presence of inflammatory cytokines. This was addressed by 
repeatedly challenging animals with i.p. influenza virus in vivo, an approach that does not 
induce systemic inflammation (3). These studies demonstrated that chronic antigen stimula-
tion alone is sufficient to drive CD8 T cell exhaustion (3). Thus it is not the nature of antigen 
but the dose of the antigen and the length of the antigen persistence that drives T cells to a 
dysfunctional and exhausted state. 
Evidence that chronic antigen stimulation drives CTL exhaustion, also arose from HIV 
infection in patients. As mentioned above, combined antiretroviral therapy (cART), an anti-
viral therapy that strongly suppresses HIV replication and therefore viral loads, decreases 
the exhaustion phenotype of HIV-specific CD8+ T cells (77). As mentioned, in HCV infection, 
HCV-specific T cells are exhausted (78, 80) and checkpoint blockade therapy could benefit 
the HCV-specific CD8+ T cell antiviral response (88). In contrast to HIV suppression however, 
HCV clearance by direct-acting antivirals failed to restore the functionality of exhausted HCV-
specific CD8+ T cells (89). These findings could be explained by the persistence of antigen 
months after the virus was cleared, however, this remains to be proven. Thus more evidence 
is needed to confirm the role of antigen in human chronic infections.
Similarly to chronic infection, the presence and persistence of antigen in the tumor envi-
ronment, is what leads to tumor-specific T cells being dysfunctional at an early developmen-
tal stage in cancer (90). The difference therefore between T cells undergoing commitment 














Cytokines and inhibitory immune cells 
Besides sustained high levels of antigen, there are other factors that correlate with CTL 
exhaustion. Many inflammatory or immunosuppressive cytokines play distinct roles in both 
chronic viral infections and the tumor microenvironment and therefore can influence CD8+ 
T cell exhaustion.
IL-10 is an immunosuppressive cytokine secreted by amongst other cell types, regula-
tory CD4+ T cells (Tregs). When wild type mice are infected with LCMV Cl13, antigen-spe-
cific CTL are rapidly lost. However, in IL-10-deficient mice infected with LCMV Cl13 or after 
blockade of the IL-10 receptor (IL-10R) with a neutralizing antibody, the functional activity 
of CD8+ T cells is preserved (91, 92). Antigen-specific CD8+ T cells from Il10r-/- mice during 
chronic LCMV infection retained polyfunctionality and they expressed decreased levels of 
PD-1 expression (91). Concordantly, increased IL-10 levels have been observed during HIV 
infection. Multiple peripheral blood mononuclear cell subsets (PBMC) in HIV-infected sub-
jects, particularly monocytes, T, B, and natural killer (NK) cells were confirmed to be major 
sources of IL-10. In line with the findings in animal models, blocking IL-10 has been shown 
to enhance T cell function in HIV-infected subjects (93). In addition to having a direct effect 
on CD8+ T cells, IL-10 can also affect exhaustion by inducing ligands to inhibitory receptors. 
Studies have shown this in cancer where IL-10 promotes tumor growth and induces PD-L1 
expression in melanoma cells. Indeed, blocking IL-10 can increase tumor control by tumor 
infiltrating lymphocytes (TILs) (94).
Another immunosuppressive cytokine that was found to be highly expressed during 
chronic viral infection is tumor growth factor β (TGF-β). Mechanistically, TGF-β causes 
functional defects and promotes apoptosis in CD8+ T cells which ultimately compromises 
viral control (95). By selectively blocking TGF-β signalling in T cells, persistence-prone virus 
failed to establish a chronic infection. Blocking TGF-β signalling in T cells, increased the num-
bers of polyfunctional CD8+ T cells and enabled their development into memory cells while 
it eradicated the virus. In cancer models, it was shown that TGF-β induced a transcription 
factor known as Maf which induced functional defects (functionally by repressing GzmB) 
and some but not all features of exhaustion independent of antigenic stimulation (96). This 
effect may be mediated via IL-10 production (96). Additionally, other studies in cancer have 
shown that TGF-β enhances the induction of PD-1 expression under the influence of chronic 
antigen stimulation (97). Combination therapy of anti-TGF-β and tumor peptide vaccine 
has been shown to induce an increased number of tumor antigen-specific CTL with potent 
antitumor capacity, which indicated that TGF-β may contribute to CTL exhaustion in tumor 
models. However, systemic TGF-β blockade did not have any effect on T cell exhaustion in 
mice and therefore additional studies are required to determine the exact role of TGF-β in T 
cell exhaustion (98-101). The above indicate that IL-10 and TGF-β could contribute to some 
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of the functional T cell defects and the development of T cell exhaustion induced by chronic 
TCR signalling. 
 The type I interferon (IFN-I) response plays a prominent role during infections as it 
induces an antiviral state in cells (102) but also promotes the cytotoxic CD8+ T cell response 
(103-105). Type I interferon receptor (IFNR)-stimulated genes (ISG), signal transducer and 
activator of transcription (STAT) genes as well as the IFN-I regulatory factors (IRF) and viral 
clearance have similar kinetics in chronic infection (106, 107). Exogenous addition of IFN-α to 
HIV-infected samples in vitro has been shown to suppress viral replication (108). In both HIV-
infected patients or simian immunodeficiency virus (SIV)-infected animals, IFN-α levels during 
the later stage of infection were found to be increased (109, 110). Peak plasma IFN-α levels 
and viral loads correlate negatively during acute SIV infection supporting a potential antiviral 
role for IFN-α, but during chronic SIV infection IFN-α levels and viral loads show a positive 
correlation, indicating that either the viral loads drive IFN-α production or chronic IFN-α 
contributes to the loss of viral control (111). This indicated that there was a link between 
prolonged IFN-I signalling and immunosuppression in chronic infection. Furthermore, type 
IFN-I renders T cells more sensitive to apoptosis, which was associated with abnormal 
expression of pro- and anti-apoptotic molecules in HIV-infected patients (111). In the LCMV 
model, genes downstream of the IFN receptor were shown to be upregulated in PD-L1hi 
IL-10hi expressing cells and blocking IFN-α resulted in an increased number of polyfunctional 
CD8+ T cells (TNF-α+IFN-γ+) and better control of viral infection (112-114). However, these 
effects of blocking type I IFN appear to be mediated by CD4+ T cells and their IFN-γ secretion 
(112-114). Moreover, the correlation between type I IFN and resistance to tumor treatment 
indicates a similar role for the type IFN-I response for TILs (94, 115). Despite the evidence, 
the exact role and direct contribution of Type IFN-I production to the development of CD8+ 
T cell exhaustion remains unclear (116).
Despite the accumulated evidence of the aforementioned immunosuppressive cytokines 
and their role in compromising CD8+ T cells in exerting their effector function in chronic 
infection, the regulator pathways that are related with these cytokines and how the immu-
nosuppressive cytokines are regulated are far less clear. In vivo animal experiments showed 
that the bystander inflammatory environment could have an impact on the memory CD8+ 
T cell development, but would not induce CD8+ T cells to be exhausted (117) which might 
suggest the requirement of additional factors or that the inflammatory environment does 
not directly drive CD8+ T cells to become exhausted. In chapter 4 of this thesis, the data from 
our group illustrates that beyond immunosuppressive cytokines, the use of cognate antigen 
alone is sufficient to induce murine CD8+ T cell exhaustion in vitro. 
The CD8+ T cell response in both chronic viral infection and tumors is dependent on CD4+ 
T helper cells. T helper cells are critical sources of IL-2 and IL-21, cytokines that both have 













wild type mice depleted of CD4+ T cells present with a more severe T cell exhaustion pheno-
type (118) and reduced T cell functionality. The indirect reason for this could be that CD4+ 
T cell depleted animals harbour increased viral load which induced more CTL exhaustion. 
Alternatively, CD4+ T cell depletion could promote CTL exhaustion because of reduced IL-2 
and IL-21 production. During chronic viral infection in both mice and humans, IL-2 was shown 
to maintain the memory-like potential of CD8+ T cells as evidenced by decreased expression 
of inhibitory receptors and upregulation of CD127, which is the IL-7R and associated with 
greater memory potential (119, 120). Additionally, exhausted TILs from melanoma patients 
were capable of proliferating when supplied with exogenous IL-2 in vitro (121). IL-21 is 
another cytokine that has been associated with CD8+ T cell exhaustion. T follicular helper 
(THF) and Th17 CD4+ T cells are the most important sources of IL-21. Cell-autonomous IL-21 
receptor (IL-21R)-dependent signaling plays an especially important role in chronic infection 
as it was shown to sustain the CD8+ T cell response (122, 123).There were fewer antigen-spe-
cific CD8+ T cells and higher viral titers in LCMV Cl13 infected IL-21R-/- mice on 30 days 
post-infection (122, 123). Furthermore, treatment with IL-21 enhanced CD8+ T cell function 
as well as viral clearance in CD4+ T cell depleted LCMV Cl13 infected mice (124). These find-
ings highlight the importance of CD4+ T cell help during the CD8+ T cell response in chronic 
infection and tumors. Overall the cytokines IL-2 and IL-21 derived from CD4+ T cells suppress 
the development of T cell exhaustion in chronic viral infection and tumors by counteracting 
the induction of exhaustion features. 
The role of immune regulatory cells in CTL exhaustion
Immune regulatory cells, normally assigned to dampen immunity and control autoreac-
tivity have also been implicated in regulating CTL exhaustion. The two major cell types that 
have been investigated in the context of exhaustion are regulatory T cells (Treg), myeloid-de-
rived suppressor cells (MDSC). Below, I will discuss these in the context of chronic infection 
and will discuss them separately in cancer.
Beyond classical helper function, subsets of CD4+ T cells can affect CTL exhaustion by 
their immunoregulatory effects. Tregs were suggested to play an important role in driving 
T cell exhaustion as they secrete the immunosuppressive cytokines, IL-10 and TGF-β (125, 
126). Depletion of Tregs during chronic LCMV infections resulted in an improved CD8+ T cell 
response (127), which was reflected by a much higher expansion of functional antigen-spe-
cific CD8+ T cells. However, the viral load remained unchanged despite the augmented 
virus-specific CD8+ T cell population. Strikingly, this was caused by an upregulation of PD-L1 
in various cells, leading to inhibition of virus-specific CD8+ T cell effector function (127). Thus 
Tregs appear to have a dual role in exhaustion. While suppressing CTL numbers and pro-
moting CTL exhaustion, they also repress immune activation and the expression of ligands 
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for inhibitory receptors on exhausted CTL. A similar role for Tregs has been described in the 
tumor microenvironment (128-130), which will be discussed later.
MDSC may regulate CD8+ T cell responses negatively in human chronic infectious dis-
ease (131). MDSC have been found to be enriched in cancer and chronic infection (132, 
133). However, the role of MDSC in human chronic viral infectious disease remains contro-
versial (134). Norris B et al studied MDSC effects on T cell immunity by using LCMV Cl13. 
Similarly, it was shown that the number of Ly6Chi monocytic and Gr-1hi neutrophilic cells, 
which resembled MDSC and play a suppressive role, was higher in chronic LCMV Cl13 than in 
acute infection. Further, in the animals when this population was depleted, enhanced T cell 
function was detected (135). Therefore, MDSC contributes to the dysfunction of CD8+ T cells 
in chronic infection and tumors (136, 137). 
Thus immune regulatory cells such as Treg and MDSC appear to play a conflicting role 
in cancer and chronic infections, on the one hand suppressing T cell immunity while also 
suppressing T cell exhaustion at the same time. Depending on the environment and context, 
the outcome of this conflicting effect can be either reduced or enhanced protection. In the 
overwhelming majority of tumor studies, depletion of Treg or MDSC resulted in better pro-
tection most likely due to prevention of their negative effects on effector T cell expansions 
which is critical for this protection.
 
Cancer-specific factors that promote T cell exhaustion
In cancer, CTL dysfunction may not only be the result of CTL exhaustion. CTL dysfunction 
in cancer has been attributed to factors and cells within established tumors, including the 
immunosuppressive microenvironment (e.g., MDSC) (137), tumor-associated macrophages 
(136), FOXP3+ Tregs (acting via IL-10, TGF-β, indoleamine-2,3 dioxygenase [IDO]) (138, 139), 
checkpoint inhibitory signaling pathways (e.g., PD1 and PD-L1) (140), and physiological 
changes (e.g., hypoxia and low nutrient levels) (Figure 3). Additionally, tumor neo-antigens 
recognized by CD8+ T cells are only weakly immunogenic and antigen recognition and 
co-stimulation is impaired in both the tumor microenvironment (TME) and draining lymph 
nodes. Thus, different to the T cell dysfunction developed in chronic infection, the dysfunc-
tional status of CD8+ T cells in cancer could be induced by the complex immunosuppressive 
environment faced by TILs in the TME (138, 139). 
Firstly, tumor cells express high levels of PD-L1 and B7 superfamily member 1 (B7S1), 
whose expression is mediated by IL-10 and IL-6. Both PD-L1 and B7S1 are capable of bind-
ing receptors on exhausted CD8+ T cells. Ligation of these receptors results in downstream 
reduced cytokine production and proliferation (138, 140, 141). In addition to the effects 
discussed before, TGF-β and IL-10 lead to increased expression of PD-L1 and promote the 













cells in turn produce high levels of IL-10 and TGF-β, further increasing the immunosuppres-
sive microenvironment and the accumulation of Tregs. 
Beyond their production of immunosuppressive cytokines, Treg cells exert other func-
tions that compromise CD8+ T cell effector functions. Expression of the ectoenzymes CD39 
and CD73 on the Tregs surface, which can produce extracellular adenosine, further serves to 
inhibit CD8+ T cells in the TME (143, 144). The adenosine receptor (A2aR) has been detected 
on multiple immune cell types including CD8+ T cells and activation of this receptor results in 
impaired effector function (145). A2aR signaling has also been shown to induce CTL exhaus-
tion (146). Thus, the infiltration of Tregs in the TME results in a high concentration of PD-L1, 
cytokines and adenosine, all of which contribute to T cell exhaustion of antigen-specific TILs 
within the TME.
Another immunosuppressive cell in the TME is the tumor associated macrophage (TAM), 
which is recruited through the secretion of, amongst other molecules, vascular endothelial 
growth factor (VEGF) produced by tumor cells. VEGF secretion recruits monocytes into the 
TME that can then differentiate into TAMs. In the tumor tissue, two classes of macrophages 
compose the TAM population, they are known as classically active macrophages (M1) and 
alternatively activated macrophages (M2). The M2 tend to be more abundant due to the 
environment established by the tumor (147, 148). Instead of playing a phagocytosis role, 
these cells contribute to the immunosuppressive environment and help tumor cells survive, 
by secreting IL-10 and TGF-β, further suppressing proliferation of CD8+ T cells (148) and 
promoting CTL exhaustion as mentioned above. 
The fast and uncontrolled tumor growth rate also poses an additional feature that inhib-
its TIL function. CD8+ T cells in the TME must adjust to the unsupportive metabolic environ-
ment, which highly influences the effector function of CD8+ T cells (129, 140). As a result of 
gene defects, malignant cells use glycolysis as the main means to generate energy, a pathway 
that is similar to the one used by activated CD8+ T cells and therefore both cell popula-
tions compete for metabolites, namely glucose. Additionally, tumor cells excrete excessive 
amounts of by-products (e.g., Adenosine) in the TME, adding to the suppressive conditions 
CD8+ T cells must overcome and most likely contribute to the development of exhaustion 
(140). Taken together, tumor cells establish a stifling immunosuppressive network rich in 
factors that contribute to CD8+ T cell exhaustion on multiple levels.
Exhaustion however does not only affect the endogenous T cell response in cancer but 
also adoptively transferred T cells. Chimeric antigen receptor (CAR) T cell therapy in patients 
brought considerable success on curing hematological malignancies (149-151). However, 
clinical results with CAR T cell therapy for solid tumors have been less promising (152-154). 
It seems multiple factors contribute to this failure (155) and one of these is that the tumor 
antigen together with suppressive TME can drive the CAR T cells to become dysfunctional or 
exhausted (156). To overcome these obstacles, CAR T cell therapy has been proposed to be 
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combined with cytokine administration, checkpoint blockade (157) and/or tumor vaccines 
(158, 159).
Distinguishing T cell exhaustion from anergy
Although exhausted T cells were compared with other forms of T cell dysfunction (141), 
it is important to briefly compare T cell exhaustion to T cell anergy. Distinguishing CD8+ 
T cell exhaustion from CD8+ T cell anergy, however, suffers from the paucity of data on 
CD8+ T cell anergy. According to studies published thus far, many similarities in terms of 
phenotype can be ascribed to both exhausted and anergic cells (141). Both demonstrate 
poor responsiveness to antigen re-stimulation, namely, reduced expansion and cytokine pro-
duction, especially, IL-2 production (160). However, there are defining differences between 
exhaustion and anergy. Anergy is caused by defective priming of cells. When naïve T cells are 
activated by antigen in the absence of co-stimulatory signaling, an anergic program ensues 
(161). Exhaustion, however, is driven by sustained antigen stimulation. Accompanying this 
repeated antigenic stimulation, exhausted cells accrue multiple inhibitory receptors on 
their cell surface. Anergic cells do not exhibit these features. Further, IL-2 not only prevents 
anergy, but also is used to reverse it (162). Similarly, other cytokines, IL-7 and IL-15, were 
shown to be capable of overriding the induction of anergy (161). In contrast, exhausted cells 
are no longer sensitive to IL-7 or IL-15 treatment. In previous research from our lab as well 
as others, the molecular features of exhaustion and anergy were compared and these were 
found to be different forms of T cell dysfunction (8) (this thesis Chapter 4). However, more 
systematic comparisons remain to be performed.
Therapeutic targeting of T cell exhaustion to treat chronic viral infection, 
cancer and autoimmunity 
Check point blockade therapies can reinvigorate exhausted CTLs response
It has been shown that genetic deletion of PD-1 at the onset of chronic infection will not 
protect T cells from exhaustion, and contrary to what may be expected, some phenotypes of 
exhaustion were more severe. The absence of PD-1 led to increased cytotoxicity but forced 
cells toward further terminal differentiation (163). Thus, PD-1 plays a critical role in preserv-
ing the exhausted T cell population from overstimulation. Why then, does in vivo blockade 
of the PD-1 pathway mediate decrease viral load or tumor burden? Is it because this therapy 
can reinvigorate the exhausted T cell response, or maybe a subset of the population? Or 
are the effects attributable to another novel T cell population? When the effects of blocking 
PD-1 related pathways are evaluated in terms of efficacy, it is apparent that both tumor 
growth and viral load were better controlled (164-166). These effects made check point 













this immunotherapy’s successes, however, the mechanisms behind the beneficial effects are 
only gradually being further elucidated.
Initial observations of the antigen-specific T cells from animals or non-human primates 
receiving anti-PD-1 or anti-PD-L1 therapy, demonstrated CD8+ T cells producing more IFN-γ 
and having greater polyfunctionality, which resulted in decreased viral load (166, 167). 
Furthermore, ex vivo experiments utilizing anti-PD-1 or anti-PD-L1 treatment enhanced 
the in vitro HIV-specific CD8+ T cell function and improved their capability to proliferate in 
response to cognate peptide stimulation. Clinical benefit, however, has yet to be demon-
strated for anti-PD-L1/PD-1 antibody therapy (often referred to as checkpoint blockade) in 
HIV infection, despite HIV+ cancer patients being treated with checkpoint blockade (168, 
169). In SIV-infected animals there remains a lack of clear evidence with contradicting results 
on whether checkpoint blockade can improve viral control (170, 171). Checkpoint blockade 
therapy, however, has been intensively utilized to treat cancer patients, but despite signifi-
cant antitumor effects in some patients, outcomes are considerably variable (11, 172, 173). 
Simultaneously, the effects on different types of tumors are also variable and it remains diffi-
cult to predict which patients will benefit from these treatments (165, 174).
Early studies using the LCMV model found that there were different subpopulations of 
exhausted T cells. The terminally exhausted subset, identified by PD-1hiCD44int expression, 
did not respond to treatment with anti-PD-L1. However, the PD-1intCD44hi subset did respond 
to treatment, yielding an expansion of virus-specific CD8+ T cells and increased protective 
immunity (172). Indeed, later studies have shown that the epigenetic imprinting of the ter-
minally exhausted T cell populations in both chronic viral infection and tumors was irrevers-
ible and anti-PD-L1 treatment does not result in epigenetic remodeling of genes involved in 
exhaustion. Thus, it seems anti-PD-L1 is not capable of reversing the exhausted status of T 
cells (54, 55, 58, 90).
More recent research has focused on further characterizing the exact subsets of exhausted 
T cells that respond to anti-PD-1/anti-PD-L1 treatment. There are several strategies to identify 
these populations by combining different markers. Im et al described that CXCR5+ progenitor 
exhausted T cells responded to anti-PD-L1 treatment which induced their proliferation to 
give rise to a new pool of CXCR5- terminally exhausted T cells. These terminally exhausted 
T cells were highly cytolytic, which resulted in better control of the viral infection (43, 175). 
These findings were further confirmed by comparison of LCMV-specific CD8+ T cells and 
TILs from melanomas (16). Other studies also identified progenitor exhausted T cells based 
on high TCF1 expression and lower expression of inhibitory receptors (16, 26, 176). To cir-
cumvent technical problems, surrogate markers were identified to discriminate the pro-
genitor and terminally differentiated populations of exhausted CTL. TIM-3+ cells normally 
lose TCF1 expression and are more terminally differentiated (43). Similar to chronic murine 
infection model systems, CD127+PD-1int HCV-specific CD8+ T cells exhibited similar features 
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to progenitor exhausted cells, which may serve to support the immune response following 
resolution of infection (37). TCF-1 and signaling lymphocyte activation molecule family 6 
(Slamf6) were found to be highly co-expressed by progenitor exhausted cells. Therefore, the 
combination of Slamf6 and TIM-3 should identify progenitor and terminally differentiated 
exhausted cells (16). More recently, additional stages of exhausted CD8+ T cells are being 
distinguishing based on the expression of Slamf6 and CD69 (177). 
At the same time, the markers to identify progenitor exhausted cells in chronic infec-
tions, were further validated by using tumor bearing animal models, where the progenitor 
exhausted population could reduce tumor growth and generate more TILs. These results 
indicated that the expansion capability of progenitor exhausted population was revived 
by check point blockade therapy (164). Besides examining anti-PD-L1 treatment in animal 
models, this treatment has also been intensively studied in cancer patients, though the exact 
mechanism that how anti-tumor immunity is enhanced is disputed (173). 
The progenitor and terminally exhausted subsets of T cell exhaustion play an important 
role in checkpoint blockade therapy. In tumor experiments, it was found that the responses 
to check point blockade are heterogeneous and highly dependent on the type of tumor 
(173). For example, melanoma, which tends to have high mutational burden and strong 
immunogenicity, normally responds well to check point blockade. By sequencing the TCR 
before and after the check point blockade therapy, it was discovered that the expansion of T 
cell clones was not derived from pre-existing tumor-infiltrating T lymphocytes. Instead, the 
expanded clones were derived from novel clonotypes that had not previously been observed 
in the same tumor (178). In vitro results demonstrated that addition of anti-PD-L1 to the 
purified antigen-specific CD8+ T cells did not increase their cytotoxicity effects (9), which 
indicated that check point blockade might not affect the exhausted T cells per se. Taken 
together, check point blockade therapy induces a protective immune response when there 
are “progenitor” cells in lymphoid organs, which will further differentiate to cytolytic cells 
to kill the target cells. In the early stages of chronic viral infection or high mutation-bearing 
tumors, progenitor cells are better preserved. Because check point blocked therapy cannot 
remodel the pre-existing status of the exhausted cells, other approaches are necessitated to 
improve the T cell response. 
One similar immunotherapy approach is targeting other inhibitory receptors or targeting 
combinations of more than one inhibitory receptors. TIM-3+ PD-1+ antigen-specific T cells in 
the tumor were found to be most dysfunctional, therefore TIM-3-TIM-3L blockade was tested 
as a checkpoint blockade strategy. By treating PBMCs from chronic HCV infected patients 
with TIM-3-TIM-3L blockade, enhanced cytokine production and proliferation were observed 
after stimulation with cognate peptide ex vivo (179). Furthermore, TIM-3-TIM-3L blockade 













cytotoxicity and proliferation of virus-specific CD8+ T cells from HIV and HCV infections (88, 
181). 
Likewise, blocking LAG-3 alone had no result during chronic LCMV infections, though com-
binational therapy using PD-1 and LAG-3 blockade exerted a synergistic effect on reinvigorat-
ing CD8+ T cells (9). Importantly, improved pathogen control was observed in LCMV-infected 
mice and Plasmodium falciparum infected patients after blocking both PD-1 and LAG-3 (182, 
183). CTLA-4 blockade therapy has been widely used in treating cancer patients (184-186). 
Whereas, its effects on chronic virally infected patients were not comparable to the effects 
observed in cancer patients (187). It could be surmised that the observed reinvigoration 
was CD4+ T cell-dependent, indirectly affecting exhausted CD8+ T cells. Thus, it is intriguing 
to understand why blockade of CTLA-4 in vivo failed to contain viral load or improve CD8+ 
T cell function in SIV infection (188). Other checkpoint blockade strategies target additional 
inhibitory receptors, such as TIGIT. TIGIT acts to transduce an inhibitory signaling cascade in 
CD8+ T cells by competing with CD266 and binding to CD155 on the tumor cell surface, thus 
anti-TIGIT or combining it with anti-PD-1/PD-L1 therapy could revive the anti-tumor immune 
responses in multiple cancers (189). 
“Shock and kill” strategy to cure HIV requires a functional CTL response
As one of the most widespread chronic viral infectious diseases, HIV infection, is also 
the most well-studied in the field of human CD8+ T cell exhaustion. Since the inception of 
cART, the mortality of HIV-infected individuals has been significantly reduced. However, 
little progress has been made to develop a protective vaccine or find a drug to cure HIV 
infection. Exhaustion of HIV-specific CD8+ T cells, and thus incomplete clearance of the virus 
necessitates reinvigoration of the CD8+ T cell response against HIV-1 and remains extremely 
important for curing of the disease.
Latent infection is the biggest hurdle to overcome in the curing of HIV. This latent infection 
gives rise to the latent HIV reservoir that can harbour virus for many years. The proviral DNA 
is transcriptionally silent, which results in latently infected cells being virtually undetectable 
by the immune system. Persistence of the virus results from the latent reservoir being mainly 
found in quiescent cells (190, 191). A number of factors have been proposed to reactivate 
latent HIV, these have been termed latency reversing agents (LRAs), and they include Histone 
Deacetylase inhibitors (HDACi), protein kinase C (PKC) agonists, bromodomain and extrater-
minal domain protein (BET) inhibitors and BRG-Brahma associated factor (BAF) inhibitors. 
Targeting latent infections is critical for curing HIV infection, and thus the “shock and kill” 
approach has been proposed. In this therapy, simultaneous application of LRAs to reactivate 
HIV-1 provirus transcription is employed alongside cART to prevent the infection of new 
cells. This reactivation of infected cells makes latent cells immunologically visible and thus 
targets to be lysed by cytotoxic cells (192, 193). In order to kill the infected cells, apparently, 
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it is essential that an effective immune response can be mounted, especially functional HIV-
specific CD8+ T cells capable of eliminating target cells. In theory, the combination of LRAs, 
cART, and sufficient immune responses could achieve HIV latent reservoir elimination and 
thereby cure HIV infection. However, thus far, attempted functional cures of HIV infection 
have failed (194, 195). This could be due to lack of an effective way to eliminate infected cells 
(196). 
Although several reagents have demonstrated the capacity to reactivate latently HIV 
infected cells, there are several issues to be solved before a successful intervention can be 
reached. Firstly, the LRAs should not adversely affect the functions of other cells, especially 
CD8+ T cells. We and others have found that different classes of LRAs greatly vary in their 
cytotoxic effects on immune cells (196) (this thesis chapter 2). Given the above described 
epigenetic changes in exhausted CD8+ T cells, LRAs that are epigenetic modifiers could 
directly affect exhausted CTL. In this thesis chapter 2, we present data on different LRAs 
toxicity effects on immune cells from healthy donor and HIV+ patients, the potential of these 
reagents to reverse or rejuvenate CD8+ T cell function is also discussed. Identifying LRAs that 
improve exhausted CTL would be most valuable as preserved or rejuvenated cytotoxic T cells 
are likely necessary to guarantee an effective cure for HIV.
Induction of exhaustion to benefit autoimmune disease patients
Whereas T cell exhaustion in tumors and chronic infections favors disease progression, the 
opposite might be true for T cell exhaustion in autoimmune disorders. Indeed, expression of 
T cell exhaustion associated markers in multiple autoimmune disorders has been associated 
with a better prognosis during the course of disease (12). Furthermore, checkpoint blockade 
therapy to treat cancer induced in some cases as a side effect autoimmunity (197, 198) and 
has even led to fatal cases where patients developed lethal immune-mediated diseases as a 
result of autoreactive T cells (13). This provides strong evidence that inhibitory receptors are 
important component of peripheral tolerance. Thus, inducing T cell exhaustion in T cells of 
patients with autoimmune disorders might be an interesting therapeutic approach. 
 A study by McKinney et al has found that in vitro incubation with Fc-chimeric PD-L1 
induced exhaustion features in CD8+ T cells (13). Future studies should clarify whether 
inducing CD8+ T cell exhaustion incurs adverse effects like viral relapse or the development 
of malignancies. A study by Kulshrestha et al proposed that dysregulation of T cell exhaustion 
might be at the very foundation of autoimmune disorders (199). Mice that expressed trans-
genic autoimmune regulator (Aire), a transcription factor that promiscuously transcribes sets 
of tissue related antigens, under the control of a DC-specific promoter were not observed 
to develop immune-mediated diabetes. Notably, this was attributed to increased exhausted 
CD4+ and CD8+ T cell populations. These cells possessed a poor expression profile of IFN-γ 













exhaustion and autoimmune disorders might represent a failure of the induction of the T cell 
exhaustion program. However, the role of T cell exhaustion in autoimmune diseases, remains 
far less conclusive than the much more studied relationship between T cell exhaustion and 
chronic infection or cancer.
CONCLUDING REMARKS
The foundations of T cell exhaustion are primarily based on results from the LCMV Cl13 
mouse model. The knowledge gained from this model has become the stepping stones for 
therapies that are currently being employed to treat patients with various types of cancer. 
Despite its success, immune checkpoint blockade with antiPD-1/antiPD-L1 and antiCTLA-4 
has demonstrated inconsistent results and variations in outcome have been found depend-
ing on the cancer type. These variations have been related to the mutation load of tumors 
(150, 200-202), but could also be a result of context-specific heterogeneity within the T cell 
exhaustion subpopulations, which is highly dependent on the microenvironment in which 
CD8+ T cells encounter their cognate antigen in chronic infection or tumors. 
In order to search for therapeutic interventions or novel compounds that work as immune 
regulators to reverse CD8+ T cells exhaustion, a systematic analysis is necessary. On one side 
genome-wide screens revealed critical factors influencing T cell development and effector 
function (203, 204). On the other side, there has been attempts to screen candidate drugs 
to enhance exhausted T cell function (205). Major hurdles still exist for the assaying of these 
compounds, for instance the lack of an in vitro model to assess candidate efficacy prior to 
assessment in clinical trials. Discover the strategies of reversing or preventing CTL exhaustion 
is depending on a deeper understanding of T cell exhaustion biology and the collaboration 
of different fields of researchers. In this thesis, I examine the effect of LRAs on T cell exhaus-
tion and survival (chapter 2), and then describe the establishment of an in vitro model of 
CD8+ T cell exhaustion that has the potential to be used for drug screens (chapter 3). In 
chapter 4, we studied the effects of miR-139 on regulating effector, memory and exhausted 
CTL differentiation. In chapter 5, I examine the effect of interleukin-2-inducible T-cell kinase 
(ITK) inhibition and the amelioration of continuous TCR activation on T cell exhaustion. The 
discussion in chapter 6 puts these findings in context and discusses future studies. 
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Combination antiretroviral therapy reduces morbidity and mortality in HIV 
infected patients. However, the cure of HIV infection is hindered by the per-
sistence of the latent HIV reservoir. Latency reversing agents (LRAs) are devel-
oped to target the HIV latently infected cells for HIV reactivation. In addition to 
reversal of HIV latency, the eradication of HIV latently infected cells will require 
effector HIV-specific CD8+ T cells. Therefore it is imperative to understand how 
LRAs affect immune cells. We have performed a comparative in depth analysis 
of the cytotoxicity of several compounds belonging to four LRA classes on T 
cells, B cells, and NK cells. In addition, the effect of these LRAs on activation 
and inhibitory receptor expression of CD8+ T cells was examined. We show that 
the HDAC inhibitors romidepsin and panobinostat are highly cytotoxic for CD4+ 
and CD8+ T cells, whereas the PKC agonists bryostatin and prostratin and BET 
inhibitors JQ1 and OXT-015 were less cytotoxic. The BAF inhibitors CAPE and 
pyrimethamine exhibit no cytotoxicity. Drug-specific cytotoxicity on CD8+ T 
cells was comparable between healthy controls and cART-treated HIV-infected 
patients. Bryostatin and both BET inhibitors downregulated the expression of 
CD279 on CD8+ T cells without affecting their activation. Our comparison of 
LRAs identified differences in cytotoxicity between LRA classes and members 
within a class and suggests that some LRAs such as bryostatin and BET inhibi-
tors may also downregulate inhibitory receptors on activated HIV-specific CD8+ 
T cells. These findings may guide the use of LRAs that have the capacity to 
preserve or restore CD8+ T cell immunity. 
Keywords: Cytotoxicity; T cells; HIV infection; latency reversing agents.
Cytotoxicity
Latency Reversing 















































The morbidity and mortality of HIV-infected individuals have been significantly reduced 
mainly due to the effectiveness of combination anti-retroviral therapy (cART). However, the 
functional cure of HIV infection has proven elusive (reviewed in [1]). During infection HIV 
integrates into the DNA of infected cells as proviral HIV DNA and establishes a reservoir of 
latently infected cells. This provirus is transcriptionally silent, making latently infected cells 
undetectable by the immune system. The latent reservoir is mostly found in resting memory 
CD4+ T cells [2,3]. A promising approach to reactivate HIV and purge the latent reservoir is 
the “shock and kill” strategy [4,5]. In this strategy, reactivation of HIV is accomplished with 
latency reversing agents (LRAs) which will induce the transcription of the provirus in latently 
infected cells while concurrent treatment with ART prevents the infection of new cells. 
However, because the cytopathic effect of the virus is not sufficient to kill all HIV infected 
cells [6], it is essential that the immune system and specifically HIV-specific CD8+ T cells 
eliminate HIV infected cells. If successful, the combined effects of LRAs, cART and immune 
system could lead to the elimination of the HIV latent reservoir and therefore may cure HIV 
infection. 
In recent years it was proposed that one underlying reason for the failure of HIV-specific 
CD8+ T cells to control HIV infection is the exhausted state of these cells [7-12]. Because 
such CD8+ T cell exhaustion associates with inhibitory receptors expression [10-14] and this 
has been linked to epigenetic changes [15-18], LRAs may also affect the expression of such 
inhibitory receptors and the functionality of these cells. Determination of the therapeutic 
potential of LRAs should therefore include not only the compound’s cytotoxicity and capacity 
to induce HIV re-activation in CD4+ T cells but importantly also its potential effects on CD8+ 
T cells exhaustion and function. 
Over the last years, different classes of LRAs were developed to overcome one or more 
of the many different mechanisms which control the latency of integrated HIV provirus. 
Major LRA classes include histone deacetylase inhibitors (HDACi), protein kinase C (PKC) ago-
nists, bromodomain and extraterminal domain protein inhibitors (BETi), and BRG-Brahma 
Associated Factor inhibitors (BAFi). Several of these LRAs are already being used in clinical 
trials [19]. Histone deacetylases (HDACs) deacetylate lysine residues on histones, resulting in 
a chromatin structure that is more compact and less accessible to activating transcriptional 
regulators but renders the recruitment of repressive factors that together inhibit transcrip-
tion of the HIV provirus [20]. HDACi such as romidepsin, panobinostat and vorinostat/SAHA 
have been shown ex vivo and in vitro to induce reactivation of the HIV latent reservoir in 
CD4+ T cells from HIV infected patients [21-24]. Since HDACs deacetylate not only lysine res-
idues on histones but also on non-histone proteins including transcription factors and signal-
ling molecules, HDACi have effects beyond altering the structure and function of chromatin 
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(reviewed in [25,26]). The PKC agonists prostratin and bryostatin activate classical and novel 
PKC [27,28]. One of the downstream effects of PKC activation is the nuclear translocation of 
NF-κB and the recruitment of activating histone acetyltransferase complexes and the positive 
transcription elongation factor b (P-TEFb), leading to the activation of the HIV long terminal 
repeats (LTR) and HIV transcription [28-31]. Although neither the phorbol ester prostratin 
nor non-phorbol ester bryostatin by itself induce proliferation of T cells, they can enhance 
T cell proliferation in the presence of IL-2, CD28 costimulation or CD3 stimulation [32,33]. 
Induction of the elongation phase of HIV gene transcription is another mechanism to reverse 
latency. In actively HIV infected cells, HIV Tat binds P-TEFb and the complex is recruited to the 
HIV LTR leading to transcription elongation [34]. However, in HIV latently infected cells, the 
bromodomain-containing protein 4 (BRD4) competes with Tat for the binding of P-TEFb and 
therefore prevents transcriptional elongation. BETi like JQ1 and OXT-015 are small molecules 
which bind BRD4, therefore inhibiting P-TEFb binding to BRD4, resulting in the release of 
P-TEFb. This allows the recruitment of P-TEFb by Tat to the HIV-1 promoter [35,36], leading 
to HIV reactivation [36,37]. The BAF chromatin remodeling complex is another cellular factor 
contributing to latency by positioning the transcriptionally repressive nucleosome nuc-1 in 
the HIV LTR and altering DNA accessibility [38,39]. Indeed BAFi like caffeic acid phenethyl 
ester (CAPE) and pyrimethamine were shown to act as LRAs in human HIV-infected PBMC 
[38,40].
Since the shock and kill strategy depends on an effective immune system to kill reacti-
vated latent HIV-infected cells, the question arises what effect these LRAs have on immune 
cells. In recent years, cytotoxicity of LRA has been studied mostly in latently infected cell lines 
and primary CD4+ T cells [6,31,36,38,41-44]. Some studies have examined the effect of LRA 
on viability of natural killer (NK) cells, since these cells also play a role in killing HIV-infected 
cells [45]. The HDACi SAHA (vorinostat) at concentrations up to 500 nM had no cytotoxic 
effect on NK cells after 24 hours and 4 days incubation [46,47], whereas higher concentra-
tions of SAHA [47] and the HDACi panobinostat and romidepsin [46] reduced viability. Within 
the LRA class of PKC agonist, no reduction of NK cell viability was observed when prostratin 
and ingenol were used [46]. Several studies have investigated the effect of LRAs on viability 
of PBMC and cytotoxic CD8+ T cells (CTL) [6,48-53], the main immune cell population elimi-
nating HIV-infected cells in an antigen-specific manner. However, a direct comparison of the 
cytotoxicity of different LRA classes and also between members of a LRA class based on these 
studies is challenging since studies differ both in experimental set up and LRA exposure time. 
SAHA was shown to be non-toxic for CD8+ T cells when exposed for 7 days [6], nor was prolif-
eration or killing function of CD8+ T cells impaired when these cells were pre-incubated with 
SAHA for 24 hours [51]. Although resting CD8+ T cells from one healthy donor did not show 
any cytotoxicity after incubation of PBMC for 4 and 21 hours with romidepsin, panobinostat 














significant cytotoxicity was observed for the HDACi romidepsin and panobinostat but not for 
SAHA [50]. In contrast, romidepsin-mediated cytotoxicity was reported for CD4+ and CD8+ T 
cells, and NK cells when PBMC were exposed for 24 hours [49]. When cells were exposed to 
romidepsin for 6 hours, washed and analyzed after additional 42 hours of cultivation in the 
absence of romidepsin, reduced viability was observed for CD8+ T cells from HIV-negative 
controls [53] as well as for PBMC from cART-treated HIV+ patients [48]. However, the cyto-
toxic effect of the PKC agonist bryostatin and prostratin differed between these two studies, 
with one showing no cytotoxic effect on day 2 [53], whereas the second reported significant 
reduction in viability for both PKC agonists [48]. 
To allow for a direct comparison of the cytotoxic effect of LRAs on immune cell subpop-
ulations, we included two members of 4 different LRA classes at concentrations shown to 
reverse HIV latency. The cytotoxicity of these LRA using PBMC from healthy individuals and 
HIV-infected patients were analyzed. We chose two time points, a short term (18 hours) and 
a long-term (72 hours) continuous exposure to the compound. Since LRAs have to enter 
the cells and act intracellularly either in the cytoplasm or the nucleus to induce epigenetic 
modifications, the LRAs accumulate in the cells, leading to a higher concentration within a 
cell compared to plasma [54]. This may also suggest that intracellular LRA will not follow the 
pharmacokinetics indicated for plasma concentrations of LRAs, and that it may take more 
time to reach a steady-state intracellular concentration. We furthermore compared the effect 
of the LRAs on viability of unactivated and activated T cells. For LRAs with low cytotoxicity we 
additionally investigated the effect these LRAs have on the expression of the chronic activa-
tion marker CD38 and three different inhibitory receptors (CD279, CD160, CD244) on CD8+ 
T cells. Our findings demonstrate that LRAs greatly vary in their cytotoxicity on immune cells 
with the HDACi romidepsin and panobinostat showing the highest cytotoxicity. Importantly, 
T cell activation did not affect the cytotoxicity of most of the LRA analyzed. LRA cytotoxicity 
on CD8+ T cells did not differ between HIV-uninfected controls and cART-treated HIV-infected 
patients. Finally, some LRAs such as PKC agonists and BETi could modulate inhibitory recep-
tors expression on CD8+ T cells, suggesting that these LRAs may also modulate the function 
of these cells.
MATERIALS AND METHODS
Cell samples and ethical approval
Buffy coats from healthy donors were purchased from Sanquin Amsterdam. Leukapheresis 
from three HIV-infected patients were included in this study after receiving approval from 
the Erasmus MC Medical Ethics Committee and receiving written informed consent. All three 
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patients initiated cART during chronic HIV infection and were on stable cART for at least 
three years with effective viral suppression below 50 copies/ml for at least 12 months.
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient centrifuga-
tion (Ficoll-Hypaque, GE Healthcare life sciences). Cells were frozen in freezing media (90% 
Fetal bovine serum (FBS) supplemented with 10% DMSO) and stored at -80°C or in liquid 
nitrogen.
Cell culture 
After thawing, cells were cultured in culture media RPMI 1640 (Life Technologies) sup-
plemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, and 100g/ml streptomy-
cin-sulfate at a concentration of 1x106cells/ml in 24-well plates (Thermo Scientific) that were 
either uncoated (unactivated cells) or coated with anti-human CD3 (1µg/ml, clone UCHT1, 
no azide/low endotoxin, BD Bioscience) and anti-CD28 (10µg/ml, clone CD28.2, no azide/low 
endotoxin, BD Bioscience) monoclonal antibodies (activated cells). LRAs at indicated concen-
trations were added 60 min after cells were added to the plate. Since LRAs were dissolved 
in dimethyl sulfoxide (DMSO), DMSO was added to the DMSO control culture at 0.1%, the 
DMSO concentration of the highest compound concentration to control for the effect DMSO 
may have on cell viability. Cells were cultured at 37°C in 5% CO2 incubator for either 18 or 
72 hours.
Reagents
The following LRAs were used in this study: HDAC inhibitors romidepsin (Sigma, cat 
number SML1175), panobinostat (Cayman Chemical, 13280-50) and SAHA/vorinostat (Selleck 
Chemicals, S1047), BAF inhibitors pyrimethamine (Sigma, 46706) and CAPE (MP Biomedicals, 
0219586005), BET inhibitors OTX-015 (ApexBio, A3692) and JQ1 (Cayman Chemical, 11187-
1), and PKC agonists bryostatin (Santa Cruz, sc-201407) and prostratin (Sigma, P0077). All 
drugs were reconstituted in DMSO. Concentrations of LRAs included in this study were based 
on previously published studies: HDACi romidepsin 1 nM – 100 nM [22,44], panobinostat 1 
nM – 50 nM [22,43,44,55], and SAHA 350 nM [46,52]; BAFi pyrimethamine 1 µM – 10 µM 
[38], and CAPE 0.1 µM – 1 µM [38]; BETi OTX-015 0.1 µM – 5 µM [37], and JQ1 0.01 µM – 10 
µM [31,37,43,53]; PKC agonists bryostatin 0.1 nM – 50 nM [43,44,53], and prostratin 0.1 
µM – 2.5 µM [28,31,37]. 
Flow cytometry and viability measurement
For staining of surface antigens, 0.6-1.0x106 cells were washed with FACS wash (FW; 
Hanks buffered saline solution (HBSS, Life Technologies), 3% fetal bovine serum (FBS, Life 














concentrations of monoclonal antibodies for 30 min at 4° C, washed two times with FW and 
fixed with 1% paraformaldehyde in PBS.
The following directly conjugated monoclonal anti-human antibodies were used to ana-
lyze CD8+ T cells (CD3+CD8+), CD4+ T cells (CD3+CD4+), B cells (CD3-CD19+), and NK cells 
(CD3-CD56+): CD3-BV421 (UCHT1), CD4-BV650 (SK3), CD8-BV786 (RPA-T8), CD14-PE-Cy7 
(61D3, eBioscience), CD19-PerCP-Cy5.5 (HIB19, eBioscience), CD56-PE-Cy5.5 (CMSSB, eBio-
science), Annexin V-PerCP-Cy5.5 or AnnexinV-Cy5.5, CD279-BV711 (CD279, EH12.1), CD160-
Alexa Fluor 488 (clone BY55), CD38-PE-Cy7 (HIT2), CD244-PE (eBioC1.7, eBioscience). All 
antibodies were purchased from BD Biosciences unless otherwise indicated. When Annexin 
V was used to measure cell death and exclude dead cells, 2.5 mM CaCl2 was added to all solu-
tions. Between 1-4x105 events were collected per sample on a LSRFortessa (BD Biosciences, 
4 lasers, 18 parameters) and analyzed using FlowJo software (version 9.7.4, Tree Star). For 
cell death analysis, doublets were excluded and percentage of apoptotic (Annexin V+) cells 
determined of CD3+CD8+ T cells, CD3+CD4+ T cells, CD19+ B cells and CD3-CD56+ NK cells 
(Supplementary Figure 1A). To analyze expression of the activation marker CD38 and inhib-
itory receptors CD160, CD244, and CD279, first doubles were excluded and then within live 
(Annexin V-) cells, the expression of these antigens were determined using Fluorescence 
Minus One samples (FMO) for gate definition (Supplementary Figure 1B).  
Data are represented as frequency within a defined population. Drug-specific cell death 
was calculated using the following formula [56]:
[(% Drug-induced cell death – % cell death in DMSO only)/(100 - % cell death in DMSO 
only)]*100
Statistical analysis
Statistical analyses were performed using Prism software (GraphPad Prism5 for Windows, 
Version 5.04). For statistical analysis of the effects LRAs have on immune cells, repeated 
Measures ANOVA with Tukey’s Multiple Comparison Test was performed (paired analysis). 
To compare the cytotoxic effect these LRAs have on CD8+ T cells from healthy controls and 
HIV-infected individuals, one-way analysis of variances with Tukey’s Multiple Comparison 
Test (unpaired analysis) was performed. P values equal or lower than 0.05 were considered 
statistically significant with the numbers of stars in the figures indicating the p value: * = P ≤ 
0.05, ** = P ≤ 0.01, and *** = P ≤ 0.001. If no star is indicated in figures, then the comparison 
was not statistically significant. 
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HDACi exhibit cytotoxicity for T cells at low concentrations
We tested the HDACi romidepsin and panobinostat at concentrations of 1 nM – 100 nM 
and 1 nM – 50 nM, respectively. These concentrations are in the range of those used pre-
viously for ex vivo and in vitro HIV reactivation and observed in plasma of treated patients 
[22,43,44,53,55]. We found significant differences in HDACi cytotoxicity depending on the 
length of drug exposure of PBMC from healthy donors. HDACi induced low yet significantly 
increased cytotoxicity when CD4+ and CD8+ T cells were incubated for short term (18h) 
even with the highest concentration of 100 nM for romidepsin and 50 nM for panobinostat 
(Supplementary Table 1). B cells showed slightly lower survival rates than T cells with up to 
22±6.3% (mean±SE) cell death for romidepsin and 27±7.3% for panobinostat (Supplementary 
Table 1). Both HDACi exhibited low cytotoxicity for NK cells (Supplementary Table 1).
When cells were continuously exposed to these two LRAs for 72h, both HDACi at 10 nM 
concentration induced significantly increased cell death in unactivated and activated CD8+ 
T cells (Figure 1A, B, C). Romidepsin and panobinostat showed a similar cytotoxic effect on 
CD4+ T cells with 10 nM induced significantly reduced survival (Figure 1B, C). B cells were 
very sensitive to HDACi in long-term cultures as concentrations of 10 nM and higher of either 
romidepsin or panobinostat decreased the survival of these cells significantly (Table 1). NK 
cells also showed high sensitivity to the cytotoxic effect of panobinostat after 72 hours cul-
ture, as already the lowest concentration induced significantly increased cell death (Table 1). 
NK cells were less sensitive to the cytotoxic effect of the lowest concentration of romidepsin, 
however higher concentrations also induced significant cell death (Table 1). 
We also tested the T cell-specific cytotoxicity of a third HDACi, SAHA (vorinostat) in 
the long-term cultures at 350 nM, the concentration most frequently used in cell culture 
experiments [46,52]. As shown before [6,50,51], SAHA does not statistically significantly 
increase cell death of unactivated (2.0±3.0% and 2.2±1.5% specific cell death for CD4+ and 
CD8+ T cells, respectively, n=4) and activated CD8+ T cells (1.6±0.6% specific cell death, n=4). 
Activated CD4+ T cells however showed a small but statistically significant increase in cyto-
toxicity after long term culture with SAHA (11±2.1% specific cell death, n=4, p ≤ 0.001). The 
above suggest that not all HDACi exhibit T cell toxicity and suggests careful consideration of 
this property when selecting these for HIV latency reversal.
Cytotoxic effect of PKC agonists is drug dependent 
The PKC agonists bryostatin and prostratin were used at concentrations that were 
reported to reactivate HIV ex vivo and in vitro [28,31,37,43,44,53]. In short-term cultures, 
bryostatin did not increase significantly cell death of unactivated and activated CD8+ T cells 














concentration dependent significant cytotoxicity on unactivated and activated CD8+ T cells 
(Supplementary Table 1). Unactivated and activated CD4+ T cells were more sensitive to PKC 
agonists as bryostatin and prostratin induced significant cell death with several of the con-
centrations tested (Supplementary Table 1). We observed a low non-significant drug-specific 
cytotoxicity when B cells and NK cells were analyzed (Supplementary Table 1).
In long-term cultures, the PKC agonist bryostatin did not induce significant drug-specific 
cell death in unactivated and activated CD8+ T cells and activated CD4+ T cells (Figure 1D) 
whereas unactivated CD4+ T cells showed reduced survival with bryostatin concentrations 


































































































































































































































































































































































Figure 1. HDACi are cytotoxic for unactivated and activated CD4+ and CD8+ T cells.
PBMC from healthy donors were incubated with the indicated LRAs for 72 hours either under unactivated condi-
tions or activated with anti-CD3/anti-CD28 antibodies. Cell death was analyzed using flow cytometry and Annexin V 
staining. (A) Representative Facs plots depicting AnnexinV+ CD8+ T cells. Numbers in plot depict frequency of gated 
cells. Pooled data of drug-specific cell death is shown for CD4+ and CD8+ T cells for the HDACi romidepsin (B) and 
panobinostat (C) and for the PKC agonists Bryostatin (D) and Prostratin (E). Each symbol represents one healthy 
donor (n = 4-5 from 4 independent experiments). Statistical significance is indicated by stars (* = P ≤ 0.05, ** = P ≤ 
0.01, *** = P ≤ 0.001, no star = not significant = P > 0.05), solid line depicts statistical comparison within unactivated 
and activated cultures and dashed line depicts comparison between unactivated and activated cultures treated with 
the same concentration of LRA.
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effects on CD4+ T cells with a concentration of 1µM and higher (Figure 1E). No significant 
increase of cell death was observed for unactivated CD8+ T cells when treated for 72 hours 
with bryostatin (Figure 1E). Although prostratin induced significant cytotoxicity in activated 
CD8+ T cells, this was still below 20% drug-specific cell death (Figure 1E). No significant drug 
induced cytotoxicity was observed for B cells and NK cells when PKC agonists were tested in 
long-term cultures (Table 1). 







Romidepsin    
 1nM 47±25%^ 12±3.3% 
 10nM 79±19%* 53±12%*** 
 100nM 79±20%* 69±8.1%*** 
Panobinostat   
 1nM 84.5±5.8%*** 32±9.7%* 
 10nM 97.8±0.8%*** 80±2.7%*** 




Bryostatin   
0.1nM -14±8.1% 8.4±3.0% 
1nM -17±9.3% -4.1±0.5% 
10nM -17±8.9% -4.2±1.3% 
50nM -16±8.7% -4.1±1.3% 
Prostratin   
0.1µM -13±7.5% -3.8±0.9% 
1µM -3.4±7.5% 6.5 ±4.2% 
2.5µM -2.0±7.6% 12±8.8% 
rotibihni TEB
 
JQ1   
0.01µM 0.01±2.8% 3.5±3.2% 
0.15µM 25±12% 12±3.0% 
1µM 56±12%*** 39±13%*** 
10µM 76±12%*** 61±8.7%*** 
OTX-015   
0.1µM 18±8.3%** 5.9±4.0% 
0.5µM 52±14%*** 16±7.3% 
1µM 62±17%*** 20±5.8%* 
5µM 72±19%*** 38±8.1%*** 
rotibihni FAB
 
Pyrimethamine   
1µM 1.8±2.3% 2.0±2.2% 
5µM 2.8±2.0% 1.4±1.6% 
10µM 4.8±1.9% 3.9±2.8% 
CAPE   
0.1µM 2.7±1.9% 0.0±1.0% 
0.5µM 0.9±1.7% -0.3±0.5% 
1µM 4.1±2.0% -0.8±0.4% 
 
Table 1. Drug-specific cell death in long-term cultures
^Mean±SE 
N = 3 - 5 from 3 - 5 independent experiments
Statistical analysis: * = P ≤ 0.05, ** = P ≤ 0.01, and *** = P ≤ 0.001 compared to DMSO control; values without a star 














BETi at low concentrations show little cytotoxic effect
We investigated the effect of two BETi, JQ1 and OXT-15, on viability of immune cells at 
concentrations known to reactivate HIV in vitro [31,37,43,53]. When incubated short term, 
both drugs have a low effect, although partially statistically significant, on survival of unac-
tivated and activated CD8+ and CD4+ T cells (Supplementary Table 1). The survival of B cells 
and NK cells was also only slightly reduced when PBMC are treated for 18 hours with the BETi 
(Supplementary Table 1).
The BETi JQ1 induced in long term cultures significant drug-specific cell death in T cells 
when concentrations above 0.15 µM were used (Figure 2A). OTX-015 was non-cytotoxic for 
unactivated CD4+ T cells and unactivated and activated CD8+ T cells with the exemption of 
the highest concentration (5 µM) which showed a small but statistical significant increase in 
drug-specific cell death (Figure 2B). Activated CD4+ T cells were more sensitive to the cyto-
toxic effect of OTX-015 with already a significant small increase in drug-specific cell death 
with 0.5 µM of OTX-015 (Figure 2B). However, even the highest BETi concentration did not 
induce more than 20% drug-specific cell death in CD4+ and CD8+ T cells. In contrast, B cells 
and NK cells showed a concentration dependent significant sensitivity to the death-inducing 
effect of BETi with >70% drug-specific cell death for B cells and >40% for NK cells at the 
highest concentrations (Table 1). These findings demonstrate that BETi are safe for T cells 
even at the highest concentrations tested.
BAFi CAPE is non-cytotoxic for immune cells
BAFi are a new class of LRAs which showed promising results in HIV reactivation [38]. 
When PBMC were cultivated in the presence of two representatives of BAFi at concentra-
tions previously shown to induce HIV latency reversal [38] for 18 hours, neither CAPE nor 
pyrimethamine induced significant cytotoxicity in the immune subpopulations examined 
(Supplementary Table 1). The survival of B cells and NK cells was also not significantly com-
promised after long-term culture in the presence of both BAFi (Table 1). When unactivated 
or activated T cells were analyzed after long-term exposure to pyrimethamine (Figure 2C), 
no significantly increased cytotoxicity was observed for unactivated CD4+ and CD8+ T cells 
(Figure 2C). A small but statistically significant increase of drug-specific cytotoxicity was 
observed however for activated CD4+ T cells with pyrimethamine concentrations of 5µM 
and above and for activated CD8+ T cells for the highest pyrimethamine concentration used 
(Figure 2C). CAPE, the second BAFi tested, did not show any cytotoxic effect on unactivated 
or activated CD4+ and CD8+ T cells (Figure 2D). These findings indicate that the BAFi show 
very low cytotoxic potential for immune cells even after longer exposure periods. 
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The toxicity of LRAs for CD8+ T cells does not differ significantly between 
PBMC from HIV-infected individuals and healthy donors 
The targeted patient group for LRA-induced purging of the latent HIV reservoir are HIV-
infected patients with undetectable plasma viral loads due to cART. Given the chronic acti-
vation, exhaustion and propensity of CD4+ and CD8+ T cells to undergo apoptosis in HIV 
infection [56-60], we also evaluated the effect of these LRAs on CD8+ T cells from three 
cART-treated HIV-infected patients with undetectable plasma viral loads. HDACi in short 
term cultures resulted in significantly increased drug-specific cell death in unactivated and 
activated CD8+ T cells when higher concentrations of LRAs were used (Supplementary Figure 
2A). No significant induction of cell death was observed when PBMC from HIV-infected 
patients were incubated for 18 hours (Supplementary Figure 2B). The BETi JQ1 did not show 
any cytotoxicity whereas OTX-015 induced significant but low level cell death in unactivated 
CD8+ T cells with only the highest concentration included and on activated CD8+ T cells with 



















































































































































































































































































































































































Figure 2. Cytotoxicity of BET and BAF inhibitors on unactivated and activated CD4+ and CD8+ T cells.
Either unactivated or anti-CD3/anti-CD28 activated PBMC from HIV-uninfected donors were cultured in the pres-
ence of the BETi and BAFi for 72 hours. Pooled data of drug-specific cell death is shown for CD4+ and CD8+ T cells 
for the BET inhibitors JQ1 (A) and OTX-015 (B) and for the BAF inhibitors Pyrimethamine (C) and CAPE (D). Each 
symbol represents one healthy donor (n = 5 from 4 independent experiments). Statistical significance is indicated by 
stars (* = P ≤ 0.05, ** = P ≤ 0.01, no star = not significant = P > 0.05), solid line depicts statistical comparison within 
unactivated and activated cultures and dashed line depicts comparison between unactivated and activated cultures 














of the two BAFi included in this study reduced significantly the viability of unactivated or 
activated CD8+ T cells from HIV+ patients (Supplementary Figure 2D).
In long term cultures of PBMC from HIV+ patients, the HDACi romidepsin and panobi-
nostat induced significant drug-specific cell death in unactivated CD8+ T cells already with 
the lowest concentration and this increased up to 62±4.4% and 55±7.1%, respectively with 
the highest concentration used (Figure 3A). Activated CD8+ T cells were less sensitive to the 
lowest concentrations of both HDACi but showed significant cytotoxicity to higher concen-
trations of these LRAs (Figure 3A). The PKC agonists bryostatin did not induce significant 
drug-specific cell death in unactivated and activated CD8+ T cells (Figure 3B) while pros-
tratin, at the highest concentration (2.5 µM), induced only a slight but significant increase 
of cell death in unactivated (15±3.5%) and activated (11±3.8%) CD8+ T cells (Figure 3B). 
As observed for CD8+ T cells from healthy donors, CD8+ T cells from HIV-infected patients 
showed only low cytotoxicity when cultivated in the presence of the BETi JQ1 and OXT-015 
(Figure 3C), with JQ1 drug-induced cell death reaching significance for only the highest con-
centration, whereas all concentration of OTX-015 induced low but significant cell death. The 






















































































































































































































































































































































ActivatedUnactivated ActivatedUnactivated ActivatedUnactivated ActivatedUnactivated
Figure 3. Cytotoxicity of LRAs in long term cultures of CD8+ T cells from HIV+ patients.
PBMC from HIV-infected patients were either activated with anti-CD3/anti-CD28 antibodies or left untreated (unac-
tivated) and cultured in the presence of the indicated LRAs for 72 hours. The frequency of drug-specific cell death 
is shown for the HDACi romidepsin and panobinostat (A), PKC agonists bryostatin and prostratin (B), BETi JQ1 and 
OTX-015 (C) and BAFi pyrimethamine and CAPE (D). Each symbol represents one HIV-infected donor (n= 3 from 3 
independent experiments); Statistical significance is indicated by stars (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, 
no star = not significant = P > 0.05), solid line depicts statistical comparison within unactivated and activated cultures 
and dashed line depicts comparison between unactivated and activated cultures treated with the same concentra-
tion of LRA.
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cells from HIV-infected patients when cultivated for 72 hours under unactivated or activating 
conditions.
To investigate whether the LRAs included in this study exhibit a similar toxicity on CD8+ 
T cells from healthy controls and HIV-infected individuals, the drug-specific cell death after 
short-term and long-term culture was compared between these two groups. No significant 
difference of the cell death frequency of unactivated and activated CD8+ T cells was found for 
romidepsin, CAPE, pyrimethamine, JQ1, OTX-015 and bryostatin (data not shown). Statistical 
significant differences in drug-specific cell death was only observed for unactivated CD8+ 
T cells from HIV-infected individuals after long-term culture in the presence of the highest 
concentration of prostratin (2.5µM) (p≤0.05) and for activated CD8+ T cells in the presence 
of 10 nM panobinostat (p≤0.05) (data not shown).
These findings indicate that the LRAs investigated in this study have a comparable effect 
on CD8+ T cell viability when CD8+ T cells from healthy donors and HIV-infected patients are 
compared. 
BETi reduce frequency of CD279-expressing CD8+ T cells
One of the mechanisms leading to the failure of the immune system to control HIV infec-
tion is exhaustion of HIV-specific CD8+ T cells. The inhibitory receptor CD279 (Programmed 
cell death protein 1, PD-1) is upregulated on exhausted CD8+ T cells [11,12,14] which is due 
to epigenetic modification of the CD279 promotor region [15,17]. Since LRAs may reactivate 
HIV by directly or indirectly altering the epigenetic silencing of the HIV LTR, we reasoned that 
LRAs-induced epigenetic changes may affect CD279 expression. Because CD279 and other 
inhibitory receptors are not only upregulated during chronic antigen stimulation but also 
during acute activation and some LRAs may affect the activation status of cells, we analyzed 
the expression of the activation marker CD38 on CD8+ T cells from HIV infected patients. We 
did not include HDACi in this analysis due to their high cytotoxic effect on T cells. 
PKC agonists at concentrations > 1nM for bryostatin and > 0.1µM for prostratin induced 
a significant upregulation of CD38 on unactivated CD8+ T cells from HIV+ individuals (Figure 
4B). In activated CD8+ T cells, neither the PKC agonist bryostatin nor prostratin altered sig-
nificantly the expression of CD38 (Figure 4B). BETi did not change significantly the frequency 
of CD38-expressing unactivated CD8+ T cells (figure 4A, C). However, both BETi at the highest 
concentration significantly reduced the frequency of CD38+ cells within activated CD8+ T 
cells compared to cells cultured in the presence of DMSO only (Figure 4A, C). We did not 
observe a significant change in the frequency of CD38+ CD8+ T cells in the presence of the 
BAFi pyrimethamine and CAPE in long term cultures (Figure 4D). 
We next examined whether LRAs alter the frequency of CD279-expresssing CD8+ T cells. 
We observed a small, significant increase of CD279+CD8+ T cells when unactivated CD8+ T 














T cells was however significantly reduced when activated PBMC were treated with 10 and 50 
nM bryostatin and 1 µM and 2.5 µM prostratin, respectively (Figure 5B). The expression of 
CD279 on unactivated CD8+ T cells was not significantly altered by the BETi JQ1 and OTX-015 
(Figure 5C). Both BETi induced significant downregulation of CD279 on activated CD8+ T cells 
at higher concentrations (Figure 5A, C). The BAFi pyrimethamine and CAPE had no significant 
effect on CD279 expression on either unactivated or activated CD8+ T cells (Figure 5D). We 
also analyzed the frequency of inhibitory receptors CD160+ and CD244+ CD8+ T cells in the 
above cultures in the presence and absence of LRAs, however, none of the LRAs significantly 
affected the expression of these inhibitory receptors (data not shown).
Since CD279 expression is also modulated by activation with activated cells upregulating 
CD279 expression and inhibition of activation would prevent CD279 upregulation, we exam-
ined whether the reduction in CD279-expression on activated CD8+ T cells is independent 
on the activation status of the cells. We therefore calculated from activated CD8+ T cells 
the ratio of LRA-altered CD38 expression to DMSO-only CD38 expression and a comparable 
DMSO OTX-015A Bryostatin ProstratinB













































































































































































































































Figure 4. PKC agonists activate CD8+ T cells from HIV+ patients.
PBMC from HIV+ patients were cultured with indicated concentrations of LRAs either under unactivated or an-
ti-CD3/anti-CD28 antibody activating conditions for 72 hours. Expression of CD38 was analyzed by flow cytometry. 
(A) Representative facs plots depicting the frequency of CD38+CD8+ T cells of unactivated and anti-CD3/anti-CD28 
antibody activated PBMC either cultured in the presence of DMSO or OTX-015 (5µM) for 72h. Pooled date show-
ing the frequency of CD38+CD8+ T cells in cultures with PKC agonists bryostatin and prostratin (B); BETi JQ1 and 
OTX-015 (C); and BAFi pyrimethamine and CAPE (D). Each symbol represents one HIV-infected donor (n= 3 from 3 
independent experiments). Statistical significance is indicated by stars (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, 
no star = not significant = P > 0.05);
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Figure 5. BETi reduce CD279 expression on CD8+ T cells from HIV+ patients.
PBMC from HIV-infected patients were either left untreated (unactivated) or activated with anti-CD3/anti-CD28 
antibody and cultured with indicated concentrations of LRAs for 72 hours. (A) Representative facs plots depicts the 
frequency of CD279-expressing CD8+ T cells either in unactivated or activating cultures in the presence of DMSO or 
OTX-015 (5µM). Pooled data showing the frequency of CD279+ CD8+ T cells in cultures with PKC agonists bryostatin 
and prostratin (B); BETi JQ1 and OTX-015 (C); and BAFi pyrimethamine and CAPE (D). Each symbol represents one 
HIV-infected donor (n= 3 from 3 independent experiments). (E). Ratio of CD38 expression on activated CD8+ T cells 
of PKC agonist treated cultures to CD38 expression on activated CD8+ T cells of DMSO-only cultures (white column) 
and Ratio of CD279 expression on activated CD8+ T cells of PKC agonist treated cultures to CD279 expression on 
activated CD8+ T cells of DMSO-only cultures (black column) shown. (F). Ratio of CD38 expression on activated CD8+ 
T cells of BETi treated cultures to CD38 expression on activated CD8+ T cells of DMSO-only cultures (white column) 
and Ratio of CD279 expression on activated CD8+ T cells of BETi treated cultures to CD279 expression on activated 
CD8+ T cells of DMSO-only cultures (black column) shown. Column depicts mean ± SE with n=3 from 3 independent 
experiments. Statistical significance is indicated by stars (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, no star = not 














ratio of LRA-altered CD279 expression to DMSO-only CD279 expression for the PKC agonists 
(Figure 5E) and the BETi (Figure 5F). A ratio of 1 indicates that LRAs did not alter the expres-
sion of CD38 or CD279 whereas a ratio below 1 suggests that the expression of the antigen is 
reduced by the LRA compared to DMSO only. 
In activated CD8+ T cells, 50 nM bryostatin treatment resulted in the downregulation 
of CD279-expressing cells which was not accompanied by a reduction in CD38-expresssing 
CD8+ T cells, and the difference between CD38 expression and CD279 expression was highly 
significant (Figure 5E), suggesting that the effect of bryostatin was not due to an overall 
reduction of activation by bryostatin. We also observed a higher reduction in the frequency 
of CD279+CD8+ T cells than of CD38+CD8+ T cells with 1 μM and 2.5 μM prostratin, however, 
this difference did not reach significance (Figure 5E). Although both BETi reduced the fre-
quency of CD38-expression cells, the reduction of CD279-expression CD8+ T cells was signifi-
cantly higher (Figure 5F). The above findings indicate that the PKC agonist bryostatin and the 
BETi JQ1 and OTX-015 can decrease specifically the frequency of CD279 expressing CD8+ T 
cells indicating that this CD279 reduction may be independent of effects on T cell activation. 
DISCUSSION
The “shock and kill” approach has been proposed as a strategy to reactivate the latent 
HIV reservoir and successfully eliminate previously quiescent HIV infected cells [4,5] thereby 
curing HIV infection. However, the cytotoxic impact that different classes of LRAs have on 
immune cells is not fully understood. Several immune subpopulations are involved in con-
trolling HIV infection including NK cells, B cells and specifically cytotoxic CD8+ T cells (CTL). 
Since LRAs reverse HIV latency, the latently infected cells re-express HIV peptides which 
enables CTL recognition. The importance of the CTL response when using LRAs is highlighted 
by the fact that the viral cytopathic effects of reactivated virus are not generally sufficient to 
eliminate HIV-infected cells [6]. Thus it is imperative to understand the effects LRAs have on 
CTL survival and function. 
In the present study we performed a comparative analysis of the cytotoxic effect several 
different LRAs have on CTL but also CD4+ T cells, NK cell, and B cells. Overall, our data show 
that LRAs differ widely in their cytotoxic effects with different members within a class having 
very heterogeneous effects on cell viability. The sensitivity to drug-specific cell death differs 
also when immune cell subpopulations are compared. 
We show here that the HDACi romidepsin and panobinostat have little but significant 
cytotoxic effect on T cells in short term cultures. This is in accordance with several studies 
analyzing cytotoxicity of these LRA on purified CD4+ T cells [43] and PBMC from HIV-infected 
and uninfected donors [50]. However, when cytotoxicity was analyzed after long-term 3 
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day exposure, both HDACi reduced significantly viability of CD4+ and CD8+ T cells. Reduced 
viability was previously reported when cells were incubated for only 6 hours and viability 
was tested on day 2 for romidepsin [48,53] and panobinostat [48]. Concentration depen-
dent cytotoxicity of romidepsin was also observed for CD4+T cells, CD8+ T cells and NK cells 
after 48 hour exposure time [49]. Thus HDACi may induce a slow death of T cells which is 
underestimated in short term cultures. A small three week study in HIV+ patients found that 
romidepsin increase plasma HIV RNA load, however, no reduction of the latent reservoir 
was detected [61]. Although the authors conclude that romidepsin does not affect the T cell 
compartment, increased frequencies of peripheral naïve CD8+ T cells together with a small, 
non-significant decline in total CD8+ T cells could indeed indicate that effector memory cells 
are deleted by the romidepsin treatment as indicated by our study.
To further examine whether high T cell cytotoxicity is an overall characteristic of HDACi, 
we included SAHA (vorinostat) in our assay since SAHA showed no cytotoxic effects on T 
cells in previous studies when concentrations below 500 nM were used [6,46,47,50-52]. We 
indeed observed that SAHA did not compromise the viability of T cells after 3 days of con-
tinued exposure. This data indicate that even within one LRA class, cytotoxic effects differ 
significantly between inhibitors which also offers the opportunity to choose a LRA candidate 
with lowest cytotoxic potential. 
Previous studies suggested that the effect of HDACi on NK cells is drug dependent with 
lower cytotoxicity induced by romidepsin than panobinostat [46]. We also observed low 
cytotoxicity for the HDACi at short-term cultures, however, long-term exposure with both 
drugs were cytotoxic for the majority of NK cells. Detrimental effect on NK cells was also 
reported for HDACi treatment in advanced cutaneous T cell lymphoma patients where 
romidepsin treatment resulted in decreased NK cell function [49] while in HIV infected 
patients treated with panobinostat and romidepsin a decrease in NK cell viability, antiviral 
activity, and cytotoxicity was observed [46]. Thus both NK cells viability and function can be 
affected by HDACi. 
The high cytotoxic effects of HDACi on B cells may impact the clearance of virally infected 
cells since HIV-specific antibodies could support elimination of HIV-infected cells through 
mechanisms like antibody-dependent cellular cytotoxicity. In a clinical study, no increase was 
found in HIV-specific antibodies in patients treated with panobinostat despite an increase 
in HIV RNA and presumably HIV antigens [62]. The authors concluded that the panobinos-
tat-induced HIV reactivation is not sufficient to induce an increase in antibody level, however, 
our study suggests that the treatment with panobinostat may have affected the viability 
of B cells and this may contribute to the failure of panobinostat to boost antibody levels. 
Although no decrease in peripheral blood lymphocyte numbers were reported in patients 
treated with panobinostat [62], the effects of the HDACi on plasma B cells/memory B cell 














If LRA induce cytotoxicity in in vitro settings, as indicated in our study, then this leads to 
the question whether cytotoxic effects of LRA have been observed in vivo in clinical trials 
for HIV latent reversal [19]. Although no serious side effects on the immune system was 
reported in clinical studies treating HIV+ patients, transient decline in immune cells was 
observed in several studies such as romidepsin-induced significant reduced WBC [61], and 
thrombocytopenia after SAHA treatment [64,66]. A reduction in the frequency of peripheral 
blood CD4+ and CD8+ T cells was observed in cutaneous T cell lymphoma patients when 
treated with higher concentrations of romidepsin than in HIV latency reversal clinical trials 
[49]. Other adverse events reported from studies with romidepsin-treated T cell lymphoma 
patients included transient thrombocytopenia, leukopenia and granulocytopenia in the 
majority of patients [72]. Importantly, only peripheral blood was analyzed in these studies, 
an effect on immune cells in organs like lymph nodes where HIV reactivation will occur was 
not included. For LRA classes others than HDACi few clinical studies were performed so far. 
Using bryostatin in a phase Ib trial for refractory malignancies, anemia was found in around 
half of the patients whereas leukopenia and thrombocytopenia was rarely observed [73].
The question arises how HDACi like romidepsin induce immune cell death and could this 
affect HIV-specific CTL preferentially. Indeed, an impairment of anti-viral functions of HIV-
specific CD8+ T cells partially due to increased death of activated CD8+ T cells was linked 
to HDACi, specifically romidepsin [50]. Findings from HDACi studies in cancer point out that 
HDACi upregulate several pathways which increase apoptosis sensitivity of transformed cells 
including the death receptor CD95 and CD95-L [81]. Whilst non-transformed cells are resis-
tant to this apoptosis [81], HIV-specific CD8+ T cells are sensitive to CD95-induced apoptosis 
[56,60], suggesting that in patients, HIV-specific CD8+ T cells may be preferentially killed, 
which further cautions the use of HDACi in a shock and kill strategy. 
We examined a number of other potential LRAs for their toxicity. The PKC agonist bryo-
statin did not induce significant cytotoxicity in any of the immune subpopulations examined 
besides unactivated CD4+ T cells. The second PKC agonist, prostratin, significantly increased 
cell death in CD4+ T cells and CD8+ T cells but not in B cells and NK cells. This is in agreement 
with a previous study indicating that prostratin is non-toxic for NK cells [46] but induced 
death in CD4+ T cells [42]. Our findings indicate that BETi have only moderate cytotoxicity 
in T cells even at the highest concentration tested which is in line with studies analyzing the 
effect of OTX-015 [37] and JQ1 [36,42,43] on primary CD4+ T cells. Whether BETi will succeed 
in clinical trials to reactive latent HIV reservoir remains to be seen. A promising new class of 
LRAs are the BAFi for which in vitro data indicate a potent latency reversing effect [38], how-
ever, in vivo data are lacking so far. Our findings indicate that these small molecules induce 
no significant cytotoxicity in T cells with exemption of pyrimethamine at higher concentra-
tions. Finally, the cytotoxicity of LRA we tested was comparable when PBMC from uninfected 
controls and HIV+ patients were tested. This suggests that T cells from HIV+ patients are 
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not more susceptible to the cytotoxic effects of these LRAs, which is an important point to 
consider when treating HIV-infected patients.
The cytotoxicity of LRAs we observed was limited to in vitro studies, and has some con-
straints including the question of appropriate exposure time. The half-life of these LRAs are 
very different when in vitro and in vivo conditions are compared. Specifically, the absence of 
liver, kidney and other means of metabolism in vitro will influence the availability of drugs 
and metabolites. Clinical studies using LRAs on latent HIV reservoir are being conducted for 
several weeks and are aimed at achieving therapeutic concentrations in serum of patients 
[67,69,70,82]. Furthermore, LRA exert their function inside the cells in the cytoplasm and/or 
nucleus and accumulate intracellularly [54]. Therefore, half-life of drugs measured in periph-
eral blood will not necessarily reflect the exposure time of cells either due to differences in 
intracellular levels or due to differences in drug concentrations in tissues like lymph nodes 
compared to peripheral blood. We analyzed the effect of these drugs after short term (18 
hours) and long-term (72 hours) exposure which is within the exposure range previously 
published for in vitro studies [6,46,47,49-51].
It is important to keep in mind that LRAs may have additional effects beyond HIV reacti-
vation. Bryostatin acts as a Toll-like receptor 4 ligand [83] and therefore may directly activate 
TLR4-expressing CD8+ T cells [85], thereby enhance the effector function of CTL. We have 
indeed observed an upregulation of CD38 on unactivated CD8+ T cells through bryostatin, 
whether this however is due to a TLR4-mediated signalling or due to the PKC agonistic effect 
of bryostatin remains unclear. We also observed an upregulation of CD38 on CD8+ T cells 
with prostratin, the second PKC agonists tested which was also reported for CD4+ T cells 
[43]. The BETi JQ1 and OTX-15 did not induce CD38 on unactivated cells, and this is in agree-
ment with a previous study showing that OTX-015 does not induce CD69, CD25 or HLADR on 
primary CD4+ T cells after 48 hour incubation [37]. Both BETi reduced significantly the CD38 
expression on activated cells, indicating that these inhibitors may inhibit activation of CD8+ 
T cells at higher concentrations. The BAFi pyrimethamine and CAPE did not affect CD8+ T 
cell activation which is in agreement with the previously reported absence of the activation 
marker CD25 and proliferation marker Ki-67 on purified CD4+ T cells from healthy donors 
after 72 hours of incubation [38].
CTL from HIV infected patients are exhausted [7-12] leading to reduced effector functions 
and proliferative capacity of these cells. Epigenetic changes [15-18] in HIV-specific CD8+ T 
cells may lead to the increased expression of inhibitory receptors [10-14]. We have analyzed 
the effect of LRAs on the expression of the inhibitory receptors CD160, CD244 and CD279 on 
unactivated and activated CD8+ T cells from HIV infected patients. No changes in expression 
of CD160 and CD244 on CD8+ T cells in the presence of the LRAs were detected. However, 
CD279 expression on CD8+ T cells was significantly decreased by bryostatin, JQ1 and OTX-015 














This indicates that the reduced frequency of CD279 is not due to reduced activation of T cells 
but to a drug-specific downregulation of the inhibitory receptor. These preliminary results 
indicate that LRA can affect inhibitory receptor expression on CD8+ T cells and this effect of 
LRA merits further investigation. 
CONCLUSIONS
We executed a comparative study of the cytotoxic effect that different LRA classes have 
on immune cells. Although LRA-class-dependent effects on the survival of immune subpopu-
lations including CD4+ and CD8+ T cells were observed, there were differences between LRA 
even from the same class. HDACi romidepsin and panobinostat convey high T cell cytotoxicity 
while SAHA, the PKC agonist bryostatin, BETi and BAFi exhibit the lowest cytotoxicity on 
CD8+ T cells. The impact of LRAs on immune subpopulations is comparable between HIV-
uninfected and HIV-infected individuals. Finally, PKC agonist bryostatin, and BETi reduce the 
frequency of CD279 expressing CD8+ T cells without affecting activation suggesting poten-
tial ability to restore CTL immunity. Our studies suggest that different classes of LRAs have 
diverse impact on CTL viability with some LRAs having additionally the potential to reduce 
exhaustion of HIV-specific CD8+ T cells, thereby improving the elimination of HIV-infected 
cells in a “shock and kill” approach.
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Supplementary Figure 1. Gating strategy for A. cytotoxicity and B. expression of activation marker and inhibitory 
receptors.
A. Doubles were excluded using FSC height (H) and area (A), followed by a lymphocyte gate. Using immune cell 
subset defining markers, Annexin V+ cells were defined for CD3+CD4+ T cells, CD3+CD8+ T cells and CD19+ B cells. 
B. For defining CD38+ and inhibitory receptor+ populations, samples were run with Minus One Fluorescence (MFO) 
for each of these markers (CD38, CD160, CD244, CD279). Analysis was performed by first excluding doubles and 
dead cells (Annexin V+) and then gating for CD3+CD8+ T cells. The gates for CD38 and inhibitory receptors were set 
on the MFO samples.
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Supplementary Figure 2. LRA-specific cell death of unactivated and activated CD8+ T cells from HIV-infected 
patients after short-term culture.
Unactivated or anti-CD3/anti-CD28 antibody activated PBMC from HIV+ patients were cultured in the presence of 
the indicated concentrations of LRAs for 18 hours. Pooled data indicating the drug-specific cell death of CD8+ T cells 
are shown for HDACi romidepsin and panobinostat (A), PKC agonists bryostatin and prostratin (B), BETi JQ1 and OTX-
015 (C), and BAFi pyrimethamine and CAPE (D). Each symbol represents CD8+ T cells from one HIV-infected patient 
(n= 3 from 3 independent experiments), horizontal line depicts mean ± SE. Statistical significance is indicated by 

















  CD4 CD8 B cells NK cells 
  Unacvated Acvated Unacvated Acvated   
rotibihni CADH
 
Romidepsin       
1nM 6.8±5.0%^ 7.2±4.8% 7.9±5.2% 7.1±4.5% 8.6±6.7% 1.3±0.3% 
10nM 12±4.3%* 16±2.3%** 14±4.8%* 17±2.3%** 14±6.5% 0.8±1.1% 
100nM 14±4.6%* 16±3.2%** 17±4.7%** 21±2.7%*** 22±6.3%** 5.2±1.9%* 
Panobinostat       
1nM 8.5±3.3% 5.0±3.5% 9.7±3.8% 6.3±2.7% 13±8.1% 3.0±2.5% 
10nM 13±3.0%** 10±4.0%* 16±2.9%** 16±5.9%** 19±7.8%* 5.9±2.5% 







Bryostan       
0.1nM 1.1±0.9% 2.5±1.7% 1.4±1.2% 0.0±0.3% 0.8±7.0% 2.8±0.9% 
1nM 9.3±4.3% 36±8.6%*** 5.3±2.1% 9.3±4.0% 0.3±6.7% 1.9±2.3% 
10nM 41±11%*** 61±7.5%*** 23±11% 24±12% 3.3±5.0% 5.5±4.4% 
50nM 29±6.0%** 44±3.3%*** 17±5.9% 19±7.8% 0.6±5.1% 4.2±2.4% 
Prostran       
0.1µM 1.1±2.0% 6.4±0.9% 1.1±1.9% 2.0±0.6% -11±2.9% 0.4±0.2% 
1µM 56±12%*** 72±5.6%*** 26±11%* 26±9.7%* 6.4±5.4% 9.0±4.3% 








JQ1       
0.01µM 0.4±0.3% 0.7±0.3% 0.6±0.4% 0.5±0.9% 6.2±6.2% 2.0±1.2% 
0.15µM 1.5±0.5% 4.2±1.3%* 1.5±0.5% 6.9±3.1%* 5.7±7.1% 2.4±1.0% 
1µM 2.8±0.7% 7.1±1.8%*** 3.8±1.8% 9.4±3.3%** 8.3±8.8% 3.6±1.8% 
10µM 5.5±1.1%*** 7.1±1.0%*** 7.2±2.0%* 9.6±2.6%** 16±9.5% 5.0±1.7%* 
OTX-015       
0.1µM 0.4±0.2% 1.3±2.0% 0.3±1.0% 0.7±1.8% -1.3±1.6% 1.3±0.4% 
0.5µM -0.9±1.0% 3.2±1.6% 2.5±1.2% 3.9±2.3% -0.8±3.1% 3.0±0.9% 
1µM 0.7±0.7% 3.5±1.0% 2.6±1.0% 3.2±1.5% 0.2±3.6% 3.6±1.6% 








Pyrimethamine       
1µM 0.9±0.5% 1.0±0.6% 0.6±0.4% 1.5±1.0% 2.8±4.4% 0.9±0.9% 
5µM 1.4±0.5% 0.0±0.7% 1.0±0.4% 0.5±0.6% 6.7±5.9% 0.5±1.2% 
10µM 1.6±0.9% 2.5±3.0% 1.5±0.7% 3.8±2.6% 6.6±7.3% 2.7±1.3% 
CAPE       
0.1µM 0.6±0.2% 1.2±1.1% 0.9±0.2% 0.6±1.3% 0.2±1.4% 1.2±0.9% 
0.5µM 0.8±0.7% 1.2±1.4% 2.1±0.7% 0.8±1.5% 3.0±2.5% 1.7±1.3% 
1µM 1.6±0.9% 2.1±1.8% 1.9±0.7% 1.1±1.8% 1.5±1.9% 2.0±2.3% 
 ^ Mean±SE 
Statistical analysis: * = P ≤ 0.05, ** = P ≤ 0.01 and *** = P ≤ 0.001 compared to DMSO control; values without a star 
are not statistically significantly different from DMSO control;
N = 3 - 5 from 3 - 5 independent experiments
Supplementary Table 1. Drug-specific cell death of immune populations in short-term cultures.
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Exhaustion is a dysfunctional state of cytotoxic CD8+ T cells (CTL) observed 
in chronic infection and cancer. Current in vivo models of CTL exhaustion using 
chronic viral infections or cancer yield very few exhausted CTL, limiting the 
analysis that can be done on these cells. Establishing an in vitro system that 
rapidly induces CTL exhaustion would therefore greatly facilitate the study of 
this phenotype, identify the truly exhaustion-associated changes and allow the 
testing of novel approaches to reverse or prevent exhaustion. Here we show 
that repeat stimulation of purified TCR transgenic OT-I CTL with their specific 
peptide induces all the functional (reduced cytokine production and polyfunc-
tionality, decreased in vivo expansion capacity) and phenotypic (increased 
inhibitory receptors expression and transcription factor changes) characteris-
tics of exhaustion. Importantly, in vitro exhausted cells shared the transcrip-
tomic characteristics of the gold standard of exhaustion, CTL from LCMV cl13 
infections. Gene expression of both in vitro and in vivo exhausted CTL was 
distinct from T cells anergy. Using this system, we show that Tcf7 promoter 
DNA methylation contributes to TCF1 downregulation in exhausted CTL. Thus 
this novel in vitro system can be used to identify genes and signaling pathways 

























In this manuscript, we describe an in vitro method that rapidly establishes large numbers 
of exhausted CD8+ T cells. The exhaustion of CTL induced by this method has been fully 
validated by multiple approaches (cytokine production, polyfunctionality, cytotoxicity, in 
vivo proliferation, inhibitory receptors, transcription factors, RNAseq and DNA methylation). 
This method will facilitate not only the study of T cell exhaustion but also the screening of 
drugs. As proof of point, we use this method to show that TCF1 downregulation in termi-
nally exhausted T cells is accompanied by Tcf7 DNA promoter methylation and show that a 
transmethylase inhibitor can prevent TCF1 downregulation. Our method presents a critical 
resource for the study of CTL exhaustion and the screening of drugs and interventions.
INTRODUCTION
Cytotoxic CD8+ T cells (CTL) play a critical role in eliminating viral infection and controlling 
cancer development. During chronic viral infection and cancer, CTL acquire a state of dys-
function that is often referred as CTL exhaustion which was originally described in chronic 
Lymphocytic Choriomeningitis Virus (LCMV) infection of mice (1). CTL exhaustion has been 
documented in humans in chronic viral infections such as human immunodeficiency virus 
(HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) infections and in most human can-
cers (2-9) and is thought to be a central mechanism behind the failure of CTL to eliminate 
chronically infected and cancerous cells. Preventing and/or reverting exhaustion therefore 
constitutes a promising approach to restore the function of these CD8+ T cells. This requires 
however an in depth understanding of the mechanisms that lead to exhaustion and the stim-
uli that affect exhausted CD8+ T cells.
In recent years, the characteristics of exhausted CTL have been intensively researched by 
comparing antigen-specific CTL in chronic viral infection or cancer with effector and memory 
cells in acute virus infection (10-12). Exhaustion is characterized by loss of cytokine produc-
tion, such as interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ), 
decreased cytokine polyfunctionality, diminished expansion potential (13) and sustained 
high expression of multiple inhibitory receptors such as PD-1, Tim3, Lag3, TIGIT, CD160 and 
CD244 (14-17). 
The phenotypic and functional changes of exhausted CTL arise from an altered transcrip-
tional profile and modified epigenetic landscape (12, 18-20). Altered expression of transcrip-
tion factors and repressors such as T cell factor-1 (TCF1) (21, 22), Thymocyte selection-associ-
ated HMG box protein (TOX) (23-27), T-box transcription factor 21 (T-bet) (12), Eomesodermin 
(EOMES) (1), IRF4 (28), NR4a (29) and BAFT (30) are indicative for the exhaustion phenotype. 
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For example, transcription factor T-bet and TCF1 commonly expressed by functional effector 
and memory CTL, are also expressed by exhausted CTL, but are associated with distinct gene 
expression (12, 31, 32). TOX expression has been associated with molecular and epigene-
tic programs of CTL exhaustion (23, 24, 26, 27). In addition, in comparison to effector and 
memory CTL, exhausted CTL also have a distinct epigenetic landscape that contributes to 
their phenotypic changes and gene expression (19, 20). 
To study T cell exhaustion, in vivo mouse models are commonly used where T cell exhaus-
tion is either induced through chronic viral infection or cancer. LCMV infection is a well-char-
acterized mouse model for CD8+ T cell exhaustion (10, 33). The exhausted phenotype is also 
detected among tumor infiltrating lymphocytes (TIL) in tumor mouse models (34, 35). The 
persistence of the antigen has been shown to be the crucial element (36) and chronic antigen 
stimulation alone is sufficient to induce CTL exhaustion in vivo (37, 38). Previous in vitro 
exhaustion protocols have failed to validate T cell exhaustion, assuming inhibitory receptor 
expression and reduction of IL-2 production as surrogates for dysfunction (39). Some of these 
changes, however, such as expression of PD-1 and CD160 also accompanies T cell activation 
while loss of IL-2 production is a feature of effector differentiation. Thus a fully validated in 
vitro exhaustion system has yet to be established. 
The importance of CTL exhaustion in chronic infections and cancer demands rapid in vitro 
methods to screen new approaches that can prevent or revert CTL exhaustion. Inducing CTL 
exhaustion in vivo is time-consuming, requiring more than 30 days and yields limited num-
bers of exhausted cells as experimental material. Most importantly the in vivo milieu in these 
models is characterized by inflammation, high viral loads, suppressive cytokines or cells; all 
of which can obscure the phenotype of exhausted CTL and therefore make it hard to dissect 
true exhaustion-associated changes. Our newly developed in vitro method circumvents all of 
the above mentioned issues and allows gene manipulation and screening of small molecules 
or antibodies that could restore the function of exhausted CTL and/or prevent the induc-
tion of exhaustion. Using this system, we can show that the Tcf7 promotor is methylated in 
exhausted CTL and using DNA transmethylase inhibitors one can prevent the downregulation 
of TCF1. Therefore, this 5-day in vitro exhaustion system enables the rapid testing of new 
approaches to prevent and/or revert exhaustion in T cells and therefore may facilitate the 
development of new therapies for chronic infections and cancer.
RESULTS
Repeat stimulation with cognate peptide to induce CTL exhaustion
Because of the critical role sustained antigen stimulation plays in driving CD8+ T cells 























transgenic OT-I cells to induce CTL exhaustion in vitro. To induce exhaustion, CD8+ T cells 
purified from OT-I mice were stimulated daily for five days with 10ng/ml OVA(257-264) peptide 
in the presence of IL-15 and IL-7 (Repeat peptide stimulation, Fig 1A). As controls, cells were 
either left unstimulated or stimulated only once with OVA(257-264) peptide for 48 hours and 
then washed and cultured without peptide for an additional 3 days. All cells were cultured 
with IL-7 and IL-15. On day 5, cells were either harvested for analysis or in some instances 
Figure 1. Scheme of the exprimental protocol and numbers of live exhausted CTL generated by in vitro exhaustion. 
(A) Scheme of the experimental set up. (B) Purified CD8+ T cells (0.5x106 cells per well) were cultured either un-
stimulated, stimulated once with peptide or repeat peptide stimulated. Live cells were counted on day 5. Pooled 
data showing absolute cell numbers (left) and fold expansion (right). Data are from n=13 and 10 independent ex-
periments.
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cells were cultured an additional 3 days in the presence of IL-7 and IL-15 without any addi-
tional peptide stimulation (Fig 1A).
An important feature of this in vitro exhaustion system is that it rapidly yields large num-
bers of exhausted cells within 5 days (Fig 1B). Single peptide stimulations yielded comparable 
numbers while unstimulated culture numbers remained largely unchanged. The expansion 
in the numbers of exhausted T cells represents a ~9-fold increase from the T cell numbers 
seeded. Thus this in vitro exhaustion system can yield large numbers of exhausted CTL that 
can be used to further study and manipulate the pathways that drive exhaustion.
Repeat peptide stimulation reduces cytokine production and leads to loss 
of polyfunctionality
Since hierarchical loss in the capacity to produce cytokines is one of the most critical 
characteristics of exhausted CD8+ T cells (10), we first examined the capacity for cytokine 
release upon peptide re-stimulation. After five days of culture, the cells were harvested and 
stimulated with OVA(257–264) peptide in the presence of Golgi plug for 6 hours. More than 40 
percent of the unstimulated cells could produce IFN-γ upon re-stimulation (46±4%, mean 
± standard error Fig 2A and 2B). Single peptide stimulated cells were also able to produce 
IFN-γ (58±4%). In contrast, repeat peptide stimulated cells had impaired IFN-γ production 
with only 27±3% of cells able to produce IFN-γ after re-stimulation (Fig 2A and 2B). In addi-
tion, very few repeat peptide stimulated cells (4.8±0.4%) could produce TNF-α compared 
to single peptide stimulated cells (44±4%) and unstimulated cells (71±4%) (Fig 2A and 2B). 
IL-2-producing cells could barely be detected in the repeat peptide stimulated cells after 
re-stimulation, while IL-2 was readily produced by single peptide stimulated cells (37±3%) 
and unstimulated cells (60±4%) (Fig 2A and 2B). Ultimately, these results demonstrate that 
repeat peptide stimulation of CD8+ T cells in vitro leads to impaired cytokine production in a 
manner that has been previously reported in exhausted CD8+ T cells, first IL-2 production is 
lost followed by TNF-α and finally IFN-γ. 
Exhausted CD8+ T cells, unlike memory cells, cannot produce multiple cytokines at the 
same time, and we therefore assessed the polyfunctionality of our in vitro generated cells. 
For this, the percentage of single, double and triple cytokine producing cells were deter-
mined and visualized using the SPICE software. In unstimulated cultured cells, 33% produce 
all three cytokines simultaneously upon peptide stimulation while significant percentages of 
these cells were double producer (Fig 2C). Only 15% of the cells did not produce any of these 
three cytokines. Similarly, in the single peptide stimulated cells, 18% were triple positive for 
all three cytokines, large numbers were double cytokine producers, while 26% were incapa-
ble of releasing any of these cytokines (Fig 2C). In contrast, 70% of the repeat peptide stimu-
lated cells could not produce any cytokines after re-stimulation. IFN-γ single producers were 























persistence of the cytokine profile of repeat peptide stimulated cells, we rested cells without 
peptide for another 3 days before examining their cytokine production. We found that the 
Figure 2. Repeat peptide stimulated CD8+ T cells show reduced cytokine production capacity and lose polyfunc-
tionality.
Purified OT-I CD8+ T cells were cultured either without peptide (no peptide), stimulated one time for 2 days with 
OVA peptide (single peptide) or stimulated with OVA peptide daily (repeat peptide). On day 5 cells were harvest-
ed and re-stimulated with OVA peptide. (A) Representative flow cytometry plots showing frequency of cytokine 
producing live CD8+ T cells after re-stimulation. (B) Pooled data showing the frequency of cytokine producing cells 
after re-stimulating with OVA peptide. (C) SPICE figures depicting the frequency of cells producing one, two or three 
cytokines in different combinations. Each symbol represents one animal (n=11-12), 9 independent experiments per-
formed. Line depicts mean ± SE. Between the groups, Student’s t test with Welch’s correction was performed except 
for % IFN-γ+ (ANOVA with Tukey’s post hoc test). *<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
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reduced cytokine production of repeat peptide stimulated cells was maintained after resting 
(Supplementary Fig 1A).
Degranulation is an important step for the CD8+ T cell cytotoxicity. We therefore analyzed 
the degranulation marker CD107a and Granzyme B (GzmB) expression in our cells. When 
cells were analyzed without peptide re-stimulation, cells either unstimulated or single pep-
tide stimulated were negative for CD107a and GzmB (Fig 3A and 3B), while repeat peptide 
stimulated cells showed a significantly higher level of both markers (Fig 3A and 3B). When 
cells were re-stimulated with OVA(257-264) peptide, cells cultivated in the presence of no pep-
tide and single peptide stimulated cells upregulated CD107a (Fig 3A). In contrast, repeat 
peptide stimulated cells failed to increase CD107a expression after re-stimulation, indicating 
that these cells are not able to degranulate further upon re-stimulation. Granzyme B was 
increased in repeat peptide stimulated cells in agreement with the terminal differentiation 
of exhausted cells (Fig 3B). No increase of GzmB was detected after 6 hours of re-stimula-
tion for any of the conditions analyzed (Fig 3B). Repeat peptide stimulated cells exhibited 
reduced cytotoxic capacity against OVA(257–264) peptide-loaded tumor cells (Fig 3C). These 
findings clearly show that after repeat stimulation in vitro, CTL lose their ability to make 
cytokines, have reduced polyfunctionality, cannot degranulate further, have increased GzmB 
Figure 3. Repeat peptide stimulated CD8+ T cells have decreased cytotoxic function.
On day 5, cells were harvested and re-stimulated with OVA peptide. (A) Median fluorescence intensity (MFI) of the 
degranulation marker, CD107a, shown (left panel). Fold change of CD107a MFI induced by peptide re-stimulation 
depicted on the right panel. (B) MFI of Granzyme B (GzmB) depicted for the different culture conditions. Each sym-
bol represents one animal (n=11-12), 9 independent experiments performed. (C) No peptide, single peptide and 
repeat peptide stimulated cells were co-culture with target cells (OVA-pulsed AE-17 cells) at different ratios. Percent-
age of specific killing is depicted. One of five independent experiments shown. Line depicts mean ± SE. Between the 
groups, Student’s t test with Welch’s correction was performed except for CD107a MFI (Wilcoxon signed rank test). 























and reduced cytotoxicity. All of these features are characteristics of the dysfunctional state 
of in vivo exhausted CTL.
Multiple inhibitory receptors were upregulated following repeat peptide 
stimulation
An increase in inhibitory receptor expression corresponds to a more exhausted state (17). 
After harvesting on day five, the cells were stained immediately for the surface expression 
of the inhibitory receptors PD-1 (CD279), CD244, CD160, Lag3 (CD223), Tim-3 (CD366) and 
TIGIT. As expected, inhibitory receptors were barely expressed on the cells without peptide 
stimulation and single peptide stimulated cells (Fig 4A and 4B), except for PD-1, where 20±4% 
of the single peptide stimulated cells expressed this inhibitory receptor. In contrast, there 
was a significant upregulation of multiple inhibitory receptors on repeat peptide stimulated 
cells. Almost all of these cells became PD-1 positive (98±0.3%, Fig 4A and 4B). Furthermore, 
74±5% and 76±4% of the cells, respectively, express TIGIT and Lag3. The expression of Tim3 
(64±2%), CD160 (58±4%) and CD244 (14±2%) was also significantly increased on the repeat 
peptide stimulated cells.
We next examined the simultaneous co-expression of multiple inhibitory receptors 
(PD-1, Lag3, CD160 and CD244) using SPICE (Fig 4C). Repeat peptide stimulated cells were 
39% double positive for the inhibitory receptors and another 39% of the cells co-expressed 
three of these inhibitory receptors simultaneously. Furthermore, 11% of the cells expressed 
all 4 inhibitory receptors (Fig 4C). In contrast, very few of the no peptide and single peptide 
stimulated cells expressed two or more inhibitory receptors (Fig 4C). The differences in inhib-
itory receptor expression remained even after resting repeat peptide stimulated cells for 3 
days (Supplementary Fig 1B). 
To exclude that differences in inhibitory receptor expression were due to a different acti-
vation status, all the cells were re-stimulated for 6 hours after harvesting them on day 5. 
Although reactivation induces a slight upregulation of some inhibitory receptors on the no 
peptide and single peptide cultures, they still remain much lower than the repeat peptide 
stimulated cultures (Supplementary Fig 2A). The exception was CD160 which was upreg-
ulated to similar levels in all cells. Overall, these findings confirm that multiple inhibitory 
receptors are expressed on the repeat peptide stimulated cells.
Expression of transcription factors is altered in repeat peptide stimulated 
cells
Previous studies have reported that exhausted CTL express and utilize transcription fac-
tors (TF) differently compared to effector and memory cell (11, 12, 40). To characterize the 
expression pattern of TF in the in vitro exhausted cells, four of the core TFs (TCF1, TOX, T-bet, 
and EOMES) were measured. TCF1 has been reported to play a critical role in identifying 
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Figure 4. Repeat peptide stimulated cells express multiple inhibitory receptors.
The expression of the inhibitor receptors PD-1, CD244, CD160, Lag3 were determined by flow cytometry on day 5 of 
in vitro culture of OT-I CD8+ T cells. Cells were cultured either without peptide (no peptide), one time OVA peptide 
stimulation (single) or daily peptide stimulations (repeat peptide). (A) Representative flow cytometry plots depicting 
the frequency of live CD8+ T cells expressing inhibitory receptors. (B) Pooled data of frequency of CTL expressing 
individual inhibitory receptors within the different culture conditions. (C) SPICE figures depicting the frequency of 
CD8+ T cells expressing one, two, three or four inhibitor receptors (PD-1, CD244, CD160, Lag3) simultaneously. Each 
symbol representative one animal (n=7-11), with 7-9 independent experiments performed. Line depicts mean ± SE. 
Between the groups, Wilcoxon signed rank test was performed with exception of % Tim-3+ and % CD160+ for which 























subsets of exhausted T cells (22, 41). Early exhausted or the progenitor exhausted cells main-
tained TCF1 expression, while terminally exhausted T cells downregulate its expression. In 
comparison to single peptide stimulation, repeat peptide stimulation induced down-regu-
lation of TCF1 expression and upregulation of GzmB (Fig 5A and 5B). TOX expression was 
reported to be increased on exhausted cells (2, 23-25, 40), and indeed we also found TOX to 
be significantly upregulated in the repeat peptide stimulated cells in comparison to unstimu-
lated and single peptide stimulated cells (Fig 5A and 5B). These differences in TOX and TCF1 
Figure 5. Repeat peptide stimulation induces a distinct pattern of transcription factor expression.
Transcription factors (TF) were analyzed in OT-I CD8+ T cells on day 5 of culture. Cells either unstimulated (no 
peptide), stimulated one time (single peptide) or daily (repeat peptide) shown. (A) Representative flow cytometry 
plots of the frequency of TF-expressing live CD8+ T cells shown for the differently treated cultures. (B) Pooled data 
depicting the MFI of TCF1 and TOX in live CD8+ T cells. (C) Pooled data showing the frequency of EOMES and T-bet 
expressing live CD8+ T cells. Each symbol represents one animal (n=9-12), with n=7-9 independent experiments 
performed. Line depicts mean ± SE. ANOVA with Tukey’s post hoc test was performed on TCF1 MFI, Student’s t 
test with Welch’s correction was used for TOX MFI and Wilcoxon signed rank test for data in C. *<0.05, **P<0.01, 
***P<0.001, ****P<0.0001.
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expression persisted even after resting 5 day cultures for another 3 days (Supplementary 
Fig 1C and D) but also after reactivation of cells (Supplementary Fig 2B and C). T-bet and 
EOMES expression in exhausted CD8+ T cells were dependent on the stage of exhaustion (1, 
42). Although in vitro single peptide stimulation already increased the expression of T-bet, 
repeat peptide stimulation further significantly upregulated T-bet (Fig 5A and 5C). Around 
90% of the repeat peptide stimulated cells were T-bet+/PD-1+ double positive whereas in 
single peptide simulated cells T-bet+ cells were mostly PD-1 negative (Supplementary Fig 2D 
and E). In vitro peptide stimulation downregulated EOMES, with no detectable difference of 
EOMES expression comparing repeat with the single peptide stimulated cells (Fig 5A and 5C). 
The increased TOX and T-bet accompanied by decreased TCF1 expression in repeat peptide 
stimulated CTL is in agreement with the TF profile of in vivo exhausted CTL (25, 41, 42).
Repeat peptide stimulated cells have decreased in vivo expansion capacity 
To evaluate the in vivo expansion capacity of repeat peptide stimulated cells, we sorted 
live CD8+ T cells from in vitro cultures (no peptide, single peptide and repeat peptide stimu-
lated cells) and adoptively transferred 104 live CD45.1+ CD8+ T cells into wild type CD45.2+ 
mice that were infected 3h later with WSN-OVA influenza virus. Freshly isolated naïve CD8+ 
T cells from an OT-I spleen were also transferred as controls. At day 10 post infection, mice 
were harvested and the number of donor CD45.1+ cells in the lung were measured. We 
found a significant reduction in the frequency (23% versus 68% and 66%, for repeat peptide, 
single peptide and no peptide, respectively, Fig 6A) as well as absolute cell numbers (3.2x106, 
11.8x106 and 12.6x106, for repeat peptide, single peptide and no peptide respectively, Fig 6B) 
for the repeat peptide stimulated cells compared to all controls. Freshly isolated naïve cells 
did not differ from cells of single and no peptide cultures. The numbers of repeat peptide 
stimulated donor cells were also reduced in mediastinal lymph nodes (MLN) and spleens 
(Supplementary Fig 3). This indicated that repeat peptide stimulated cells are less capable of 
expanding after being exposed to their specific antigen. Meanwhile, the mice that received 
the repeat peptide stimulated cells possessed a larger frequency and number of endogenous 
CD45.2+ OVA(257–264)-specific CTL in their lungs than mice that received unstimulated or single 
peptide stimulated cells (frequency: 4.5% versus 0.8% and 1.1%, Fig 6C; cell numbers: 0.6x106 
versus 0.1x106 and 0.2x106, for repeat peptide, single peptide and no peptide respectively, 
Fig 6D). This indicates that the adoptively transferred repeat peptide stimulated cells were 
less efficient than the other donor cells to compete with the endogenous antigen-specific 
CTL response. These results indicated that in vitro repeat peptide stimulation resulted in a 
reduced capacity of CTL to expand when re-exposed to their cognate antigen. This further 
























Repeat peptide stimulated cells have the transcriptional profile of exhausted 
CTLs
To determine whether repeat peptide stimulated cells also have a distinct transcriptional 
profile, we performed RNAseq on sorted live CD8+ T cells from the different culture condi-
tions. As shown in the principle component analysis (PCA) (Fig 7A), the samples clustered 
together and where distinctly separated depending upon their in vitro treatment. We iden-
tified 1196 genes with more than 2-fold increased expression and 1218 genes with more 
than 2-fold downregulation in the repeat peptide stimulated cells relative to that in single 
peptide stimulated cells. The transcriptional prolife of the repeat peptide stimulated cells 
is clearly more distinct than those of the single and non-stimulated cells (Fig 7B and Table 
S1). Among the upregulated genes, multiple inhibitory receptors encoding genes, includ-
ing PD-1 (Pdcd1), Lag3, Tim3 (Havcr2), CD160, Tigit and CTLA4 were presented on the top 
Figure 6. Repeat peptide stimulation decreases in vivo CTL expansion capacity.
OT-I CD8+ T cells were cultured without peptide stimulation (no peptide), one-time stimulation (single peptide) or 
daily stimulation (repeat peptide) and sorted on day 5. Live CD8+ T cells were adoptively transferred into wild type 
mice which were then infected with the OVA(257–264)-expressing influenza virus WSN-OVA. Freshly isolated OT-I 
CD8+ T cells from a naïve mouse were also transferred (naïve OT-I). Lungs were harvested on day 10 post infection. 
(A) Frequency of donor CD45.1+ OT-1 CD8+ T cells within total lung CD8+ T cells shown. (B) Absolute number of 
lung donor CD45.1+ OT-1 CD8+ T cells depicted. (C) Frequency of endogenous CD45.2+ OVA-specific CD8+ T cells 
within the total lung CD8+ T cells shown. (D) Absolute number of endogenous CD45.2+ OVA-specific CD8+ T cells 
shown. Each symbol represents one animal (n=8-9) from n=3 independent experiments. Line depicts mean ± SE. To 
determine significant differences between the different animal groups, a Mann–Whitney U test was used except for 
data in a (ANOVA with Tukey’s post hoc test). ***P<0.001, ****P<0.0001. 
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of this list. As expected, the genes for the markers of the terminal differentiated effector 
cells, like GzmB, GzmC and Prf1 were also significantly upregulated on the repeat peptide 
stimulated cells (Fig 7C). The transcription factors, Eomes and Tcf7 were downregulated by 
4.0 and 6.6 fold, respectively, while Tox was found to be 2.9 fold increased in the repeat 
peptide stimulated cells compared to single peptide stimulated cells (Fig 7C), confirming our 
flow cytometry findings of these TFs (Fig 5B and 5C). Furthermore, TFs, which are associated 
with CTL exhaustion such as IRF4 (28), NR4a (29) and Batf (30) were also upregulated in the 
repeat peptide stimulated cells in comparison to single peptide and no peptide stimulated 
cells (Fig 7C).
To assess whether differentially expressed genes in repeat peptide stimulated cells were 
enriched for genes that characterize in vivo exhausted CTL from LCMV cl13 infections, we 
performed gene set enrichment analysis (GSEA). Differentially expressed genes between 
repeat peptide stimulated cell and single peptide stimulated cells were compared to public 
gene sets of upregulated or downregulated in in vivo exhausted CTLs (gene set GSE87646). 
Gene sets upregulated in exhaustion were found to be significantly more enriched in the 
repeat peptide stimulated upregulated genes compared to single peptide stimulated cells 
(Fig 7D). Conversely, the gene sets that were reported to be downregulated in exhausted 
cells were more enriched in the genes that were downregulated in repeat peptide stimulated 
cells versus the single peptide stimulated cells (Fig 7D). Thus, GSEA demonstrated signifi-
cant transcriptional similarity between in vitro repeat peptide stimulated cells and in vivo 
exhausted cells. To further investigate signaling pathways that distinguish repeat peptide 
stimulated cells from single peptide stimulated cells, we performed IPA analysis. The most 
significant pathway with upregulated activity in repeat peptide stimulated cells was the T cell 
exhaustion signaling pathway (Fig 7E). The above findings clearly show that in vitro repeat 
peptide stimulation results in the transcriptional changes of in vivo exhausted CD8+ T cells 
from LCMV cl 13 infections which serve as the benchmark of CTL exhaustion.
Figure 7 (see previous page). Repeat peptide stimulated cells have distinct transcriptional profile.
RNAseq analysis was performed on live CD8+ T cells sorted from 5 day culture of OT-I CD8+ T cells. Cells were either 
without peptide (no peptide), one-time stimulation (single peptide) or daily peptide stimulations (repeat peptide). 
(A) PCA plot of RNA-seq data show that cells from identical culture conditions cluster together and away from each 
other. (�) Heatmap shown for the top 50 differentially expressed genes within CTL from the different culture condi-
tions. (C) Heatmaps for the individual genes clustered based on function presented. (D) Repeat peptide stimulated 
CTL transcriptomes were enriched in gene signatures of LCMV-Cl13 exhausted CTL. Differentially expressed genes in 
repeat peptide stimulated CTL were analyzed by GSEA for their enrichment in gene sets found in exhausted CTL from 
LCMV-Cl13 infected mice. Enrichment in upregulated (left) and downregulated (right) genes shown. (E) Ingenuity 
pathway analysis was performed on the differentially expressed genes in repeat peptide stimulated cells (compared 
to single peptide). Significantly upregulated pathways (orange) and downregulated pathways (blue) in repeat pep-
tide stimulated cells are depicted. P values (hypergeometric test) are presented as –log10.
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Repeat peptide stimulation results in hyper-methylation of the Tcf7 
transcriptional regulatory region
Changes in methylation of transcription regulatory region have been described in 
exhausted CTLs (18, 43). In order to identify whether in vitro repeat peptide stimulated cells 
also possess similar epigenetic characteristics of exhausted CTLs, whole genome methylated 
DNA sequencing (MeD-seq) (44) was performed on the sorted live CD8+ T cells. Stimulated 
T cells undergo distinct genome wide DNA methylation changes depending on the type of 
treatment (Fig 8A and Table S2). In comparison to unstimulated and single peptide stimulated 
cells, the transcriptional regulatory region of Pdcd1 had significantly less DNA methylation in 
the repeat peptide stimulated cells (Fig 8B, left). When comparing the promotor methylation 
status (2kb region surrounding the TSS) of Tcf7, there was more DNA methylation detected 
in repeat peptide stimulated than in the single peptide stimulated cells or unstimulated cells 
(Fig 8B, center). Meanwhile, in the promotor region of the GzmB, significantly less DNA meth-
ylation was found in the repeat peptide stimulated cells than in the other cells (Fig 8B, right), 
which was in line with the higher expression of the protein upregulated in the repeat peptide 
stimulated cells (Fig 3B). Besides Pdcd1, none of the other inhibitory receptor genes’ regula-
tory or promotor regions were found to possess significant differences in methylation status, 
although some of them showed expected trends in DNA methylation changes at their TSS. 
Interestingly, the DNA methylation states of the cytokine genes IL-2, IFN-γ and TNF-α were 
not significantly different. This indicated that other gene expression control mechanisms, 
like histone modifications or transcription factor abundance, might regulate the differential 
expression of these cytokines. Overall, these findings indicate that the repeat peptide stim-
ulated cells have distinct DNA methylation patterns and reveal that the downregulation of 
TCF1 expression is accompanied by increased promotor methylation of Tcf7.
To further confirm that DNA promotor methylation contributes to the downregulation 
of TCF1 expression in exhausted cells we treated cells with a DNMT inhibitor for the last 3 
days of culture and examined whether TCF1 expression was modified in the repeat peptide 
stimulation cultures. Indeed, treatment of these cells with DNMT inhibitor resulted in an 
increase in TCF1 levels in exhausted CTL (Fig 8C). This further supports that DNA methylation 
plays a role in silencing TCF1 as exhausted cells progress from “progenitor exhausted” to the 
“terminally exhausted” subpopulation. 
DNMT inhibitor also reduced the expression of PD-1 and Tim3 in repeat peptide stimu-
lated cells (Supplementary Fig 4). Because PD-1 and Tim3 expression are controlled by pro-
moter region DNA methylation (43, 45), our findings suggest that DNMT inhibitor prevented 
exhaustion rather than reverted the exhaustion of T cells. These experiments suggest that 
























Anergy is not a feature of in vitro and in vivo exhausted CTL 
The high purity of T cells in our culture system raises the question whether the absence 
of CD28 costimulation induces anergy (46-48) and this explains some of the phenotypes we 
observe. However, this is unlikely as our cells are cultured in the presence of IL-7 that has 
been suggested to prevent anergy (49) and furthermore we still see exhaustion when cells 
Figure 8. Genome wide DNA methylation changes during T cell stimulation reveal Tcf1 promotor methylation.
Sorted live CD8+ T cells were processed and whole genome methylated DNA sequencing (MeD-seq) was performed. 
(A) Hierarchical clustering on DMRs (differentially methylated regions) found between the three different peptide 
exposure conditions are shown. (B) Boxplot of DNA methylation read count data in a 2kb window surrounding the 
TSS of mentioned genes are shown. The samples were collected from three independent experiments. (C) Rep-
resentative histogram of TCF1 expression (left) and pooled data showing TCF1 MFI on live CD8 cells (right) in the 
presence or absence of 20μM DNMT inhibitor during the last 3 days of repeat peptide stimulated cells shown. Data 
are from n=6 performed in 3 independent experiments, paired Student’s t test performed. **P<0.01.
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are cultured with IL-2 (Supplementary Fig 5A and B), another anergy preventing cytokine (50, 
51). Some CD28 costimulation, however, may be present in our culture system, as repeat 
peptide stimulated cells express CD80 mRNA levels 74-fold and 13-fold higher compared to 
unstimulated and single peptide stimulated cultures, respectively. Flow cytometry confirmed 
the high surface expression of CD80 on repeat peptide stimulated cells (Supplementary Fig. 
5C).
To further exclude that our repeat peptide stimulated cells have features of anergy, we 
performed GSEA for sets of genes identified by in vitro anergy induction (gene set GSE5960) 
(46). We find that both genes that are upregulated and downregulated in anergic T cells, are 
enriched in our repeat peptide stimulated cells (Supplementary Fig 6A and B). Thus there 
is no evidence for the presence of anergy. We found a similar enrichment for genes both 
upregulated and downregulated in anergic T cells in in vivo exhausted gp33-specific CTL from 
LCMV clone 13 infected mice (gene set GSE41867) (12) (Supplementary Fig 6C and D).  
Finally, we performed pathway enrichment analysis by IPA on the genes differentially 
expressed between repeat peptide stimulated cells and the unstimulated cells. We found 
that anergy related signaling pathway was neither up- or down-regulated in the repeat 
peptide stimulated cells (Supplementary Fig 6E). In this comparison, the T cell exhaustion 
signaling pathway was again the most significant upregulated pathway. Taken together, these 
findings argue that anergy is not a major feature of our in vitro exhausted CTL. 
DISCUSSION
Persistent antigen stimulation is a key driver of T cell exhaustion (37, 38). In this study, 
we show that repeat stimulation with peptide is sufficient to induce T cell exhaustion in 
vitro. Repeat peptide stimulation rapidly, within 5 days, induced all characteristics of CTL 
exhaustion including loss of cytokine production and polyfunctionality, the expression of 
multiple inhibitory receptors, reduced expansion capacity and competitive fitness, transcrip-
tion factor and gene expression patterns all compatible with in vivo generated exhausted CTL 
(10, 11). This phenotype was largely preserved when cells were rested for several days. Our 
in vitro repeat peptide stimulation culture conditions include cytokines IL-7 and IL-15 which 
are known to have anti-apoptotic potential and ensure T cells do not undergo activation 
induced cell death (AICD) (52). In particular, IL-15 has been shown to promote the survival 
of exhausted HIV-specific CD8+ T cells by upregulating Bcl-2 and Bcl-xL (7, 53). Its inclusion 
in the repeat peptide stimulations, we argue, promotes the survival of these cells as they 
become gradually more exhausted while avoiding the increased apoptosis mediated by IL-2, 























The in vitro exhausted CTL we generate have many of the molecular features of exhaus-
tion. In particular transcription factors that associate and orchestrate T cell exhaustion are 
clearly modulated in the same manner as seen with in vivo induced CTL exhaustion of chronic 
infection models like LCMV clone 13 infections and cancer (11, 31). The transcription factor 
TOX is known to be increased in in vivo exhausted CTL (23, 24, 26), while TCF1 is downreg-
ulated in exhausted cells and its presence is associated with precursor exhausted CTL that 
retain some proliferative capacity (11, 40). All in vitro exhausted CTL we generate have high 
protein expression for TOX and Tox mRNA is upregulated by 2.6-fold. Furthermore, in vitro 
exhausted CTL have downregulated TCF1 and at the mRNA level its gene Tcf7 is decreased by 
6.6-fold. A recent report indicated that Prdm1 and c-maf transcription factors control a co-in-
hibitory module in T cells (55). Although we found that Prdm1 expression was upregulated 
by 4.5-fold in our in vitro exhausted CTL, we did not find any changes in c-maf transcription 
factor. Activated protein C receptor (PROCR) and podoplanin (PDPN), recently reported to be 
co-inhibitory receptors (55), were not upregulated in our in vitro exhausted cells. This may 
not be surprising as these markers were only found in tumor infiltrating T cells and IL-27 
may be mediating this profile (55). Exhausted T cells from chronic infection however are not 
affected by IL-27 signaling (56) and thus PROCR and PDPN expression may depend on the 
tumor microenvironment and not characterize all exhausted CTL. Our in vitro exhaustion 
method generates exhausted T cells which may more closely reflect the core features of 
exhaustion. Our method is independent of environmental factors that may occur in the in 
vivo setting of chronic infection or tumor microenvironment. Such factors can obscure direct 
exhaustion related transcriptional changes from those induced by bystander effects such as 
high viral loads.
Our in vitro exhaustion method utilizes peptide-stimulated purified CD8+ T cells and 
therefore one could question whether TCR stimulation in the absence of costimulation 
induces anergy in our T cells. Although, T cell anergy and exhaustion may share some traits 
and potential signaling pathways of unresponsiveness to restimulation, the mechanisms of 
their induction is very different. Analyzing gene expression and signaling pathways we found 
no evidence for anergy in our in vitro exhausted CTL. Similar data were obtained with in 
vivo exhausted CTL. The reason we do not induce anergy in our cultures is because they are 
carried out in the presence of IL-7 and IL-15. It is well established that γc chain cytokines 
such as IL-2 and possibly IL-7 and IL-15 can override the induction of anergy when CD8+ T 
cells are stimulated in the absence of CD28 costimulation (47, 49-51). Cells were exhausted 
even when cultured with IL-2, albeit IL-2 in these cultures increases cell death significantly. 
Interestingly, our in vitro exhausted CTL express high levels of mRNA and surface CD80 and 
this may also contribute to preventing anergy. This is not surprising as activated mouse T 
cells can express CD80 both in vitro but also in vivo in autoimmune mice (57, 58). Thus in 
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vitro exhausted CTL do not present key anergy traits although one cannot exclude that some 
downstream signaling or inhibitory pathways are shared between exhaustion and anergy.
Previous studies have reported that there are subsets of exhausted CTLs, one known 
as “progenitor exhausted” cells which express TCF1 and TOX, corresponding to cells that 
retain the capacity to expand with checkpoint blockade therapy and the other subpopula-
tion known as the “terminally exhausted” cells which are TCF1 low and cannot respond to 
checkpoint blockade (26, 40, 41, 59). In our in vitro exhausted cell cultures, we observed 
both subsets; a subset of cells that express low levels of TCF1 and high levels of TOX and 
GzmB, which is in line with the characteristics of “terminally exhausted” T cells and a subset 
that is TCF1+TOX+ corresponding to the “progenitor exhausted” cells. All cells are T-bethi 
PD1+, thus our TOX+ cells may retain some “progenitor exhausted” characteristics as T-bethi 
cells are reported to retain proliferative capacity in the exhaustion setting (42). Thus, these 
two subsets exist in our exhausted cultures and this allows us to perform future in depth 
characterization of these cells and establish their relationship and the factors that control 
them. CXCR5+ T cells were described as “less exhausted” and responders to check-point 
blockade in chronic viral infection (21, 59). Although “progenitor exhausted” TCF1+TOX+ are 
present in our repeat peptide stimulated T cells, we could not detect any CXCR5 expression. 
CXCR5+ exhausted CD8+ T cells are found in lymphoid organs but not in peripheral blood or 
other infected organs of LCMV cl13 infected animals (21), and therefore our CXCR5- in vitro 
exhausted cells may resemble more the later than those found in lymphoid organs.
TCF1 downregulation in exhausted cells was reported to be accompanied by reduced 
chromatin accessibility (24, 25). Our findings suggest that DNA methylation also contributes 
to reduced TCF1 expression as both the Tcf7 promotor was found to be hyper-methylated 
and the inhibition of DNA methyltransferases during the last 3 days of culture results in the 
retention of TCF1 expression in our exhausted CTL. Whether these TCF1 high cells generated 
by DNMT inhibitor treatment retain all the characteristics of the “progenitor exhausted” cell 
subset remains to be determined. If true it may indicate that such inhibitors can be combined 
with checkpoint inhibition therapy as such TCF1+ cells are the major responders to therapy.
By studying these in vitro exhausted CTLs, the accumulation of inhibitory receptor expres-
sion on exhausted cells can be better understood. PD-1, Tim-3 and TIGIT are rapidly expressed 
on the early exhausted cells, while the other receptors, like CD160 and CD244, were induced 
more slowly by repeat antigen stimulation. Because of the promising effects of the check-
point blockade therapy, such as anti-PD1/PD-L1, on the treatment of human cancer(60), 
there is considerable interest to revive the function of exhausted T cells by co-blockade of 
multiple inhibitory receptors simultaneously. Our in vitro method, which induces multiple 
inhibitory receptors in just a few days, can serve as a feasible tool to test blocking approaches 
before performing in vivo animal experiments. For example, TIGIT blockade can be tested, 























same ligand, CD266, on their surface. Moreover, the underlying mechanisms of checkpoint 
blockade on reversal of T cell exhaustion need to be further investigated as do the pathways 
that restrain these cells from developing into terminally exhausted cells. Clearly the balance 
of these exhausted cells can be modulated with large effects on the numbers and poten-
tially the function of these cells. As we recently have demonstrated, by overexpressing a 
single miRNA, namely miR-155, we can ameliorate the attrition of virus-specific CTL during 
chronic infection and in vivo increase their numbers by 2 logs (61). Our in vitro system of 
T cell exhaustion can be used to screen the overexpression of genes with retroviruses or 
their inhibition or deletion using CRISPR-Cas9 to discover new targets which modulate T cell 
exhaustion.
The method we describe allows for the rapid, within 5 days, generation of large numbers 
of fully exhausted CTL and can therefore be used for medium to high throughput screening of 
compounds, reagents or gene modifications that can prevent, ameliorate, reverse or accel-
erate T cell exhaustion. In particular, the extreme loss of IL-2 and TNFα production in our 
repeat peptide stimulated cells allows for the first time a truly medium to high throughput 
approach for drug screening since changes in IL-2 or TNFα production can be easily deter-
mined in the supernatants. 
In conclusion, we have established a rapid in vitro system of CD8+ T cell exhaustion. These 
exhausted CTL exhibit all the known molecular and functional characteristics of exhaustion 
yet can be induced in large numbers within 5 days as opposed to the small numbers gener-
ated after 30 days of chronic infection of in vivo mouse models of exhaustion. This in vitro 
method can not only be used as a screening system to prevent/revert CD8+ T cell exhaustion, 
thereby identifying new therapies, but also for research aiming at revealing mechanisms 
of CD8+ T cell exhaustion. Using this in vitro method we show that TCF1 silencing during 
exhaustion is in part controlled by DNA methylation. Overall, this in vitro method makes the 
future study of CTL exhaustion more feasible and reduces the need for in vivo studies.
MATERIALS AND METHODS
Mice
OT-I CD45.1+ mice on the C57BL6/J background were generated by backcrossing C57BL/6 
Tg (TcraTcrb)1100Mjb/J (OT-I) with B6.SJL-Ptprca Pepcb/BoyJ (CD45.1+) mice (both from 
Charles River France, a registered vendor of The Jackson Laboratories C57BL/6 mice). 
C57BL/6J mice and OT-I mice were housed in a certified barrier facility at Erasmus University 
Medical Center. 
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Animal work was performed under Project Proposal (AVD101002015179) by the animal 
welfare body (AWB) of the Instantie voor Dierenwelzijn (IvD). All animal experiments were 
conducted in compliance with the Netherlands’ government laws of the Centrale Commissie 
Dierproeven (CCD).
Repeated antigen stimulation in vitro
CD8+ T cells were purified from spleens of OT-I mice by negative selection with magnetic 
beads (EasySep, Stemcell Technologies). After purification, cells were 97.7±0.5% CD8+ T cell 
and contained 0.11±0.04% CD11b+ CD11c- monocytes and 0.09±0.05% CD11b+ CD11c+ den-
dritic cells. In each well of a 24-well plate, 5x105 of the purified CD8+ T cells/ml were cultured 
in complete media (RPMI 1640, 10% FBS (Gibco), 1% 2mM L-glutamine (Life Technologies), 1% 
HEPES (Life Technologies), 1% 100nM Sodium Pyruvate (Life Technologies), 1% non-essential 
amino acides (Life Technologies), 100U/ml penicillin (Gibco) and 100µg/ml Streptomycin-
sulfate (Gibco), 0.05mM Betamercaptoethanol (Sigma)) with IL-15 (5ng/ml, Peprotech, Cat 
210-15) and IL-7 (5ng/ml, Peprotech, Cat 210-07) with or without 10ng/ml OVA(257-264) pep-
tide (Anaspec Cat AS-60193). 
For single peptide stimulation, cells were cultured in the presence of OVA(257-264) peptide 
for 48 hours. The peptide was then removed by washing the cells two times with com-
plete media. For the remaining 3 days, the cells were cultured in the complete media with 
cytokines. For repeat peptide stimulation, 10ng/ml OVA(257-264) peptide was added daily for 
five days. The cells were washed also on day 2 to allow for comparable culture conditions. 
Unstimulated control cells were cultured in media with cytokines but without adding pep-
tide. Cells from all three conditions were checked daily, and when the cells were confluent, 
they were split and cultured with fresh complete media containing cytokines. After day 5, 
some of the cell were washed two times with complete media and maintained in the media 
only with cytokines for another three days. In some experiments cell cultures were treated 
on day 2 with 20µM DNA methyltransferase (DNMT) inhibitor SGI-1027 (Tocris, Bio-techne) 
that targets DNA methyltransferases DNMT3B, DNMT3A and DNMT1.
On day five, cells were harvested and counted using an automated counting system 
(Countess, Life Technologies). Cells were stained with DAPI Viability dye (Beckman Coulter, 
Cat B30437) and Acridine Orange (Biotium, Cat 40039) to distinguish live and dead cells. 
In vitro killing assay
AE17 cells were maintained in RPMI 1640 supplemented with 10% FBS (Gibco), 100 
units/mL Penicillin/Streptomycin (Life Technologies), 2 mM L-glutamine (Life Technologies), 
0.05 mM 2-mercaptoethanol (Sigma), and were cultured at 37°C in 5% CO2. AE17 cells were 























were washed thoroughly before they were labelled with the CellTrace™ Far Red fluorescent 
dye (ThermoFisher Scientific Cat C34564/15396613). Un-pulsed cells were not labeled. A 1:1 
mix of peptide pulsed and un-pulsed AE17 cells (105 each) were mixed and different amounts 
of T cells (Effector: Target ratios: 3:1, 1:1, 0.3:1) were added. The cells were harvested after 
16 hours, the ratio of labeled and unlabeled tumor cell were detected by flow cytometry.
Flow cytometry
To investigate phenotypic and functional changes, cells were stained with monoclonal 
antibodies and analyzed using flow cytometry. The following fluorochrome-conjugated 
monoclonal antibody combinations against surface and intracellular antigens were used; 
Inhibitory receptors and ligands: anti-CD8-eFluor 450 (53-6.7, eBioscience), anti-Lag3-APC 
(C9B7W, BD Biosciences), anti-PD-1-APC-Cy7 (19F.1A12, Biolegend), anti-CD244-PE (2B4, 
BD Biosciences; eBio244F4, eBioscience), anti-Tim3-PE-Cy7 (RMT3-23, Invitrogen), anti-
CD160-PE-CF594 (CNX46-3, BD Biosciences), anti-TIGIT-FITC (GIGD7, eBioscience); Activation 
and differentiation: anti-CD44-BV785 (IM7, BD Biosciences), anti-CD25-APC-Cy7 (PC61, 
BD Biosciences); Cytokines and effector molecules: anti-IFN-γ-APC (XMG1.2, eBioscience), 
anti-TNF-α-AF488 (MP6-XT22, eBioscience), anti-IL-2-PE (JES6-5H4, eBioscience), anti-Gran-
zymB-PE-Cy7 (NGZB, eBioscience); Intracellular expression of transcription factors anti-Tbet-
PE-Cy7 (4B10, Biolegend), anti-TCF1-APC (C63D9, Cell Signaling), anti-EOMES-PE- eFluor F610 
(Dan11mag, eBioscience), anti-Tox-PE (TXRX10, eBioscience). To exclude apoptotic and dead 
cells, Annexin V conjugated with APC, Cy5.5 or PerCP-Cy5.5 (BD Biosciences) was included in 
all the stains and 2.5 mM CaCl2 was added to all solutions.
On day 5, cells were harvested and immediately stained for surface and intracellular 
antigens. For surface staining, cells were washed with FACS wash (HBSS containing 3% FBS 
and 0.02% sodium azide) and incubated with 20µL mix of the pre-determined optimal con-
centrations of the fluorochrome-conjugated monoclonal antibodies at 4°C in the dark for 20 
minutes. The cells were then washed once with FACS wash and fixed with 1% PFA. For the 
transcription factor staining, cells were first stained for surface antigens as described above. 
Following the washing step, cells were fixed with FoxP3 Fixation Buffer (005523, eBioscience) 
for 60 minutes in the dark at 4°C and then washed with Perm/Wash buffer (008333, eBio-
science) and stained with a mix of antibodies against transcription factors for 1 hour at 4°C 
in the dark. Cells were then washed twice with Perm/Wash buffer and fixed with 1% PFA. 
Appropriate isotype controls were included for staining of transcription factors.
To analyze cytokine production, cells were re-stimulated with the 10µg/ml OVA(257-264) 
SIINFEKL peptide for 6 hours at 37°C, 5% CO2 in the presence of GolgiPlug (BD Biosciences) 
and anti-CD107a-APC-Cy7 antibodies (ID4B, Biolegend). Cells were then stained with surface 
marker antibodies as described above. After washing with FACS wash, cells were fixed with 
IC Fixation Buffer (88-8824, eBioscience) at 4°C overnight, washed with Perm/Wash buffer 
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and stained for intracellular cytokines for 45 min in the dark at 4°C. After staining, cells were 
washed twice with Perm/Wash buffer and fixed with 1% PFA.
Cells were measured on a LSRFortessa (BD Biosciences) using application settings and at 
least 200,000 events were collected. Data was then analyzed with FlowJo software (Version 
9.9.4, Treestar, Ashland, OR, USA).
In vivo influenza model
For influenza virus infection studies, live CD45.1+ OT-I cells were sorted from in vitro 
cultures on a FACSAria III (BD Biosciences) using fluorochrome-conjugated Annexin V and 
anti-CD8 antibodies and 10,000 cells were intravenously transferred into 8–12 weeks old 
CD45.2+ C57BL/6J wild-type recipient mice. Naïve CTL were also freshly isolated from spleen 
of an OT-I mouse and adoptively transferred. Three hours later, mice were anesthetized with 
2.5% isoflurane gas and infected intranasally with influenza virus strain A/WSN/33-expressing 
OVA (WSN-OVA, a gift from Dr. D. Topham, University of Rochester Medical Center). Body 
weight was measured daily to track the influenza infection.
Ten days post infection, the lung, spleen and mediastinal lymph nodes were harvested 
and single cell suspensions were obtained after processing the tissues. As described previ-
ously(62), lungs were digested for 2 h at 37°C with 3.0 mg/ml collagenase A and 0.15 μg/ml 
DNase I (Roche) in RPMI 1640 containing 5% heat-inactivated FBS, 2 mM L-glutamine, 100 
IU/ml penicillin, 100 μg/ml streptomycin. Digested lungs were then filtered through a 40-μm 
cell strainer (Falcon) and washed in the same media as above. PE-conjugated tetramers of 
H-2Kb major histocompatibility complex class I loaded with OVA(257–264) were used to identi-
fied the antigen-specific CTLs in the lungs(63).
RNA sequencing
To compare the gene expression between the different culture conditions, RNA sequenc-
ing was performed. On day 5, 1x106 live CD8+ T cells were sorted from the three different 
culture conditions and immediately lysed with TRIzol LS reagent (Life Technologies) and 
stored at -80°C. RNA was extracted according to manufacturer’s instructions and a bioana-
lyzer (Agilent) was used to determine the integrity of the extracted RNA. Barcoded sequenc-
ing libraries were generated using the KAPA RNA HyperPrep kit (Roche Diagnostics) with 
RiboErase (HMR) rRNA depletion. Library quality was assessed with the bioanalyzer and 
KAPA qPCR was performed for quantification before cluster generation and 100-bp paired-
end sequencing on a Hiseq2500 machine (Illumina). Data sets are deposited in the Gene 























Analysis of differential transcript abundance, normalization of read counts 
by gene size, and downstream analyses
Four independent biological replicates were analyzed for each condition. The quality of 
the sequencing was verified using the FastQC software (http://www.bioinformatics.babra-
ham.ac.uk/projects/fastqc/). The demultiplexed fastq files were aligned using STAR software 
(v.2.5.3e) (64) with default settings and mus musculus GRCm38 as alignment reference. 
Then bam files, generated during alignment, were annotated using FeatureCount software 
(v1.6.1)(65) to obtain the annotated files (count files). The annotation reference was gene-
code.vM15.gtf.
Count data was preprocessed to remove low expressed genes. Then, rlog transformation 
was applied to the clean counts for visualization and comparison purposes which include 
correlation and clustering analysis generating the heatmaps and PCA plots during the pro-
cess. For differential expression analysis, DESeq2 (DESeq2 R package, v1.22.2)(66) was used 
directly in the clean count data.
The list of differentially expressed genes was used to perform Ingenuity Pathway Analysis 
(IPA, Qiagen, USA version 01-12) to further discern which pathways are involved in the CD8+ 
T cell exhaustion process. Pathway enrichment P-values (Fisher’s exact test) and activation 
Z-scores were calculated by IPA and used to rank the significant pathways.
The same list of significantly differentiated genes was used for enrichment analysis 
(GSEA Desktop Application, v2.2.1). The CD8+ T cell exhaustion gene-sets were downloaded 
from GMO datasets (gene set GSE87646) based on the publication of Bengsch B, et al (2). 
Enrichment analysis in CTL exhaustion genes was determined for the upregulated and 
downregulated genes separately. Normalized Enrichment Scores (NES) values were used to 
determine whether an expression gene-set was enriched or not in CTL exhaustion genes. For 
anergy GSEA analysis, gene set GSE5960 (46) and gene set GSE41867 (12) were used.
DNA methylation profiling detection
DNA methylation profiling was done as previously described by the MeD-seq method(44). 
For MeD-seq sample preparation LpnPI (New England Biolabs) digestions were carried out 
on DNA samples according to manufacturer’s protocol. Reactions contained 50 ng and diges-
tion took place overnight in the absence of enzyme activators. Digests of genomic DNA with 
LpnPI resulted in snippets of 32 bp around the fully-methylated recognition site that contains 
CpG. The DNA concentration was determined by the Quant-iT™ High-Sensitivity assay (Life 
Technologies) and 50 ng dsDNA was prepared using the ThruPlex DNA-seq 96D kit (Takara). 
Twenty microliters of amplified end product were purified on a Pippin HT system with 3% 
agarose gel cassettes (Sage Science). Stem-loop adapters were blunt end ligated to repaired 
input DNA and amplified (4 +10 cycles) to include dual indexed barcodes using a high fidelity 
polymerase to yield an indexed Illumina NGS library. Multiplexed samples were sequenced 
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on Illumina HiSeq2500 systems for single read of 50 base pairs according to manufacturer’s 
instructions. Dual indexed samples were demultiplexed using bcl2fastq software (Illumina).
MeD-seq data processing was carried out using specifically created scripts in Python 
version 2.7.5. Raw fastq files were subjected to Illumina adaptor trimming and reads were 
filtered based on LpnPI restriction site occurrence between 13-17 bp from either 5’ or 3’ end 
of the read. Reads that passed the filter were mapped to mm10 using bowtie2.1.0. Multiple 
and unique mapped reads were used to assign read count scores to each individual LpnPI 
site in the mm10 genome. BAM files were generated using SAMtools for visualization. Gene 
and CpG island annotations were downloaded from UCSC (MM10). Genome wide individ-
ual LpnPI site scores were used to generate read count scores for the following annotated 
regions: transcription start site (TSS) (1 kb before and 1 kb after), CpG islands and genebody 
(1 kb after TSS till TES).
MeD-seq data analysis was carried out in Python 2.7.5. DMR detection was performed 
between two datasets containing the regions of interest (TSS, genebody or CpG islands) 
using the Chi-Squared test on read counts. Significance was called by either Bonferroni or 
FDR using the Benjamini-Hochberg procedure. Differently methylated regions were used for 
unsupervised hierarchical clustering, the Z-score of the read counts was used for normaliza-
tion and is also shown in the heatmaps. In addition, a genome wide sliding window was used 
to detect sequentially differentially methylated LpnPI sites. Statistical significance was called 
between LpnPI sites in predetermined groups using the Chi-squared test. Neighbouring sig-
nificantly called LpnPI sites were binned and reported, DMR threshold was set at a minimum 
of ten LpnPI sites, a minimum size of 100 bp and either a twofold or fivefold change in read 
counts. Overlap of genome wide detected DMRs was reported for TSS, CpG island and gene 
body regions.
Statistical analysis
Statistical analyses were performed using Prism software (GraphPad Prism5 for 
Windows, Version 5.04). The normality of data distribution was assessed using the Shapiro-
Wilk normality test. Homogeneity of variance was tested with Bartlett’s test. When data 
were normally distributed and group variances were equal, an ANOVA with Tukey’s Multiple 
Comparison Test was performed. When data were normally distributed but group variances 
were unequal, a Student’s t test with Welch’s correction was performed. If data were not 
normally distributed a Wilcoxon signed rank test or a Mann–Whitney U test was performed. 
P values equal or lower than 0.05 were considered statistically significant with the numbers 
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Supplementary Figure 1. Exhaustion related features are retained after 3 days resting.
Cells were harvested on day 5, peptide was washed away and the cells were rested for 3 days without peptide. On 
day 8, cytokine production after restimulation is shown (A). The expression of inhibitor receptors (B) and transcrip-























Supplementary Figure 2. Repeat-peptide stimulated cells maintain inhibitory receptor and transcription factor 
differences after 6 hours of restimulation.
After extra 6 hours of stimulation with OVA peptide (10µg/ml) on day 5, the percentage and MFI of inhibitory re-
ceptors (A) and the MFI of TCF1 (B) and TOX (C) are depicted. Representative FACS plots (D) and pooled data (E) of 
the frequency of PD-1 and T-bet co-expression on day 5 shown. Line depicts mean ± SE. Each symbol represents one 
animal. Data from 5-6 experiments.
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Supplementary Figure 3. Repeat peptide stimulated cells expanded less in mediastinal lymph nodes and spleens 
in vivo.
OT-I CD8+ T cells were cultured without peptide stimulation (no peptide), one-time stimulation (single peptide) or 
daily stimulation (repeat peptide) and sorted on day 5. Live CD8+ T cells were adoptively transferred into wild type 
mice which were then infected with the Ova(257-264)-expressing influenza virus WSN-OVA. Freshly isolated OT-I CD8+ 
T cells from a naïve mouse were also transferred (naïve OT-I). Mediastinal lymph nodes (MLN) and spleens were 
harvested on day 10 post infection. Frequency of donor OT-I CD8+ T cells within spleen (A) and MLN (C) in total CD8+ 
T cells and the absolute number of donor cells in spleen (B) and MLN (D) are presented. Each symbol represents 
one animal (n=8-9) from n=3 independent experiments. Line depicts mean ± SE. To determine significant differences 
between the different animal groups, Mann-Whitney U test was used except for data in (A) (ANOVA with Tukey’s 























Supplementary Figure 4. DNMT inhibitor decreases expression of inhibitor receptors on the repeat peptide 
stimulated cells.
Pooled data showing day 5 inhibitor receptor MFI on repeat stimulated cells in the presence or absence of 20µM 
DNMT inhibitor. Inhibitor was added during the last 3 days of culture. Data are from n=6 animals, performed in 3 
independent experiments. Line depicts mean ± SE. To determine significant differences between the different treat-
ment, paired t-test was used *P<0.05, ** P<0.01, ***P<0.001. 
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Supplementary Figure 5. Exposure to IL-2 does not alter the exhaustion phenotypes in repeat peptide stimulated 
cells and CD80 is upregulated on repeat stimulated cells.
CD8+ T cell exhaustion was induced in the presence of IL-2 (20U/ml) and IL-7/IL-15 (5ng/ml each). Cytokine produc-
tion after OVA peptide restimulation for 6 hours (A) and inhibitory receptor expression on day 5 (B) are shown. n=8 
animals from 5-6 independent experiments depicted. Representative histogram of CD80 expression on the cells is 























Supplementary Figure 6. Anergy gene sets and pathways do not characterize repeat peptide exhausted T cells.
Both upregulated and downregulated genes in anergic T cells are enriched in exhausted T cells. A. GSEA of genes upregulated and 
B. downregulated in anergic T cells (gene set GSE 5960) are both enriched in differentially expressed repeat peptide stimulated 
cells (repeat peptide versus no peptide cell). C. GSEA of genes upregulated and D. downregulated in anergic T cells (gene set GSE 
5960) are both enriched in differentially expressed Day 30 gp33-specific CTL from LCMV clone 13 infected animals (Day 30 versus 
gp33-specific CTL naïve CD8+ T cells; data from GSE41867). E. In repeat peptide stimulated cells the anergy related pathway in IPA 
analysis was neither upregulated not downregulated. IPA analysis was performed on the differentially expressed genes in repeat 
stimulated cells (compared to no peptide). The “Regulation of IL-2 expression in activated and anergic T lymphocytes” pathway is 
showed enlarged and the overall positioning in the global IPA pathway analysis is indicated by the arrow and red circle. Significantly 
upregulated pathways (orange) and downregulated pathways (blue), no activity pattern available (grey) are depicted. Bar graphs 
























T cell exhaustion is a term used to define the differentiation state of dysfunctional T cells 
that develop under chronic antigen stimulation (1-5). This differentiation state was originally 
identified in the setting of chronic viral infection. However, now T cell exhaustion has also 
been widely described in cancer (6-9). The exhausted T cells from both settings share the 
similar characteristics. These include broadly expressing different inhibitory receptors, hier-
archical loss of cytokine production and polyfunctionality, decreased proliferation potential 
and a propensity to undergo apoptosis (1). The failure to control pathogen replication and 
tumor growth has been attributed to the exhaustion of responding T cells. This has resulted 
in intensive research efforts to understand the exhaustion of CD8+ T cells amongst antiviral 
and antitumor immunology studies. Especially intensive challenging has been the quest to 
improve the function of exhausted T cells with the aim to facilitate pathogen clearance in 
the chronic infectious disease and tumor control in cancer (10-13). These studies have led 
to novel tumor immunotherapies that have brought a true revolution in cancer therapy (6, 
14-16). Here in this thesis, we embarked on a series of studies to examine T cell exhaustion 
and explore potential strategies of reversing and/or preventing the development of T cell 
exhaustion.
In chapter 2 of this thesis, some of the effects of epigenetic modifiers on CD8+ T cells via-
bility and phenotype were systematically studied. The study was prompted by HIV functional 
cure strategies, such as “shock and kill” strategy, where HIV latency reversing agents (LRAs) 
are administrated to reactivate HIV transcription in the quiescent HIV latent reservoir (17). A 
large number of LRAs are currently in development, although a majority of current LRAs are 
epigenetic modifiers, like histone deacetylase inhibitors (HDACi). It is well established that 
HIV-specific CD8+ T cells are exhausted (18, 19) and exhaustion is characterized by epigenetic 
changes (20-22). The success of the “shock and kill” HIV cure strategy greatly depends on 
the ability of potent CD8+ T cells being able to kill CD4+ T cells of the reservoir that are 
expressing HIV antigens (23). We therefore examined, whether 4 major classes of LRA also 
affected T cell function and viability. We observed cytotoxicity of the four categories of LRAs 
on different immune cells and the potential of these LRAs to modulate the function of CD8+ 
T cells was also illustrated. These findings not only facilitate the study of function curing HIV 
by establishing a the immune toxicity of classes of LRA, but also provide preliminary data that 
highlight the ability of LRA to influence the function of CD8+ T cells. Understanding how LRAs 
affect exhausted T cells, however, was hampered by the very low number of HIV-specific 
CD8+ T cells in the blood of HIV+ patients or tumor antigen specific CD8+ T cell in tumor 
bearing animals. Therefore, how these LRAs could modify exhausted CTL by acting at the 
epigenetic level was not feasible with such samples in chapter 2.
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The requirement of abundant amounts of exhausted T cells needed to perform different 
functional and molecular assays, in our quest to understand T cell exhaustion and the low 
numbers of exhausted T cells isolated from patients or animals, triggered us to establish a 
method that yields large number of exhausted T cells. We therefore initiated the studies 
to establish an in vitro CTL exhaustion model, which was presented in chapter 3. Standing 
on the widely accepted knowledge that exhaustion is caused by chronic antigen stimula-
tion (24-26), especially on the absence of CD4+ T cells help, we set up the experiment by 
using purified CD8+ T cells from transgenic OT-I mice and repeatedly stimulated them with 
cognate peptide. Strikingly, we found that after repeatedly stimulating CD8+ T cells for 5 
days, the characteristic spectrum of features associated with exhausted CTL were present 
in the cells. These included upregulation of multiple inhibitory receptors, loss of polyfunc-
tionality, reduced cytotoxicity as well as the exhaustion associated transcriptional changes. 
Furthermore, exhaustion related DNA methylation changes were also detected in these 
repeated stimulated cells. Beyond using this exhaustion model to understand CTL exhaus-
tion, this model can be used to test or screen drugs that may affect exhaustion. Indeed, 
we presented that DNMT inhibitor, a DNA methylate inhibitor, could retain the expression 
of TCF1 expression, a critical transcription factor that confers proliferative capacity in pro-
genitor exhausted cells. This not only confirmed the mechanisms of TCF1 decrease but also 
highlighted the potential application of this in vitro model to drug testing. Using this model, 
we hope that we can further compare TCF1+ cells and TCF1- exhausted cell which both exist 
in these cultures. In future studies, using reporter mice we plan to use this in vitro model to 
study the effect of individual miRNA and small molecules on development or reversion of 
CTL exhaustion.
MicroRNAs (miRNAs) being important factors that regulate gene expression at the 
post-transcriptional level (27-29), play a critical role in CD8+ T cell differentiation and develop-
ment (30, 31). Some miRNAs have been shown to contribute to CTL exhaustion development 
and modify their exhausted CTL function (32-34). In chapter 4, we first identified that there 
were 120 significantly differentially expressed miRNAs when comparing effector CD8+ T cells 
to naïve CD8+ T cells in the influenza infection model. miR-139 was found to be significantly 
downregulated in the effector CD8+ T cells. In addition to our finding, other studies also 
indicated that miR-139 played an important role in regulating CD8+ T cells responses at the 
effector phase (35). Therefore, we hypothesised that further downregulating miR-139 may 
enhance effector CD8+ T cell function or expansion. However, when we overexpressed miR-
139 by using retroviral transduction or when we used the cells from miR-139 deficient mice 
in the context of influenza virus infections, we found that neither the development of naïve 
cells nor the differentiation of effector cells depended on the expression of miR-139. In the 
influenza virus infection experiments, miR-139 was also dispensable for the memory CD8+ 













different in the miR-139 overexpressing cells, which was in conflict with other studies that 
examined CTL responses in Listeria infection (35). Additionally, the results showed in chap-
ter 4 was also an application example of our in vitro CTL exhaustion model. We performed 
miRNA sequencing of in vitro exhausted cells (data not presented in this thesis). When we 
analysed the differential expressed miRNA that are shared by the in vitro exhausted cells and 
exhausted tumor infiltrating CD8+ T cells, miR-139 was significantly downregulated (data not 
presented). Therefore, we evaluated the function of miR-139 in T cell exhaustion by using the 
in vitro exhaustion model. Surprisingly, we found that the development of CTL exhaustion 
did not depend on miR-139 expression. From the results we presented in chapter 4, we con-
cluded that miR-139 was significantly differential expressed by effector CD8+ T cells compar-
ing to naïve cells, however it is dispensable for the development of functional effector and 
memory CD8+ T cells in murine influenza infection. The function and development of CTL 
exhaustion was not influenced in the absence of miR-139. Due to constraints in the number 
of miR-139 overexpressing cells obtained after transduction, we could not address whether 
overexpressing miR-139 would affect the development of CTL exhaustion. Beyond this miR-
139 study, our group is also trying to investigate other miRNAs, whose overexpression or 
knockdown could reverse CTL exhaustion. Our studies point out that the differential expres-
sion levels of certain miRNA between different CD8+ T cells should not be the only criteria 
to select the target miRNAs to study. The abundancy the miRNA, the abundancy of potential 
targets of the miRNA, the redundancy between different miRNA that share targets are all 
expected to influence the results and suggests that such complex interactions explain why 
miRNA expression levels alone do not always predict the outcome of miRNA manipulation. 
Although the effects of Ibrutinib on enhancing antitumor immune responses has been 
implicated in different tumor models (36), whether it is mediated by any direct effects on 
CD8+ T cells, the specific target and the associated mechanism are not known (37, 38). In 
chapter 5 of this thesis, we took advantage of our in vitro CTL exhaustion model, where CD8+ 
T cells are the only population present, to study the effect of Ibrutinb on exhausted CTLs. We 
discovered that one of Ibrutinib’s targets, ITK, is a key kinase in CTL exhaustion. Inhibiting 
ITK with a pharmacological small molecule inhibitor, decreased the expression of TOX, a 
crutial transcription factor of CTL exhaustion development (39-42). We also demonstrated 
that intermittent use of ITK inhibitor in combination with anti-PD-1, enhanced antitumor 
efficiency. These results indicated that the immune regulatory effects of Ibrutinib observed 
in other studies (37, 43, 44), may be mediated by its inhibitory function on ITK and that reg-
ulating the activity of ITK in exhausted CD8+ T cells could improve their function. The work 
included in chapter 5, is a further example of the applicability of the in vitro CTL exhaustion 
model for drug testing.
In line with what we found in chapter 5, other investigators also found that the factors 
of TCR activation signalling pathway play a critical role in modifying CTL exhaustion. It was 
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reported that FOXO3, member of phosphatidylinositol 3-kinase (PI3K)-Akt signalling cascade, 
was hyperphosphorylated in T cells on day 8 post infection with LCMV-Cl13, the strain that 
results in chronic infection (45). In FOXO3 deficient animals, not only were there more anti-
gen specific CD8+ T cells in the chronically infected animals, but they also preserved poly-
functionallity and more efficiently controlled virus (45). Driving the CD8+ T cells to memory 
instead of exhaustion, was another strategy of enhancing CD8+ T cells function in chronic 
antigen stimulation settings. It has been found that PI3K-Akt-mTOR signalling pathway plays 
a critical role in regulating memory CD8+ T cell formation (46). By inhibiting Akt pharmaco-
logically, tumor infiltrating T cells isolated from human tissue develop features of immuno-
logic memory (47), which improves the function of donor cells in the adoptive T cell therapy. 
Related to this signalling, PI3Kδ inhibitor leads to less differentiation of donor T cells, which 
increase CD62L and CD127 expression without influencing their expansion capacity. Donor 
CTL cells pre-treated with PI3Kδ inhibitor show more potent anti-tumor activity (48). There 
are additional reports about the effects of inhibiting MAPK/ERK kinase (MEK; also known as 
mitogen-activated protein kinase kinase) in CD8+ T cells (49, 50). Although the priming of 
the naïve CD8+ T cells could be dampened, inhibiting the downstream of TCR signalling by 
MEK selective inhibitors, reverses exhaustion related phenotypes and potentiates effector 
functions of CD8+ T cells. Combining MEK inhibitor and anti-PD-1 checkpoint blockade also 
synergized and prolonged anti-tumor effects (49). Thus, the observations that chronic TCR 
signalling is the cause of CTL exhaustion, has led to targeting and inhibiting the kinase in the 
TCR signalling pathway and this could reverse the development of CTL exhaustion. 
Beside the applications of the in vitro exhaustion model we demonstrated in this thesis, 
there are other potential ways that this in vitro model could facilitate the study of discover-
ing novel strategies to reverse CTL exhaustion. Regarding the large yield of exhausted cells 
from this in vitro model, it has the potential to be used in high throughput screening of 
molecules and reagents to reverse or prevent CTL exhaustion. This high throughput screen-
ing is especially applicable if critical cytokines, such as IL-2, or crucial transcription factors, 
such as TCF1 or TOX are tagged with reporter genes in CD8+ T cells (Figure 1A) (51). Utilizing 
techniques to manipulate the expression of genes or using pools of sgRNAs with CRISPR/
Cas approaches to screen the genes that contribute to exhaustion development and further 
identify the novel interventions of regulating CTL exhaustion are also possible applications 
of this model (Figure 1B) (52). Modulating such promising genes or targeting their pathways 
with inhibitors could be used in adoptive T cell therapy. In this way either the dysfunctional 
tumor infiltrating CD8+ T cells can be rejuvenated before transferring or antigen-specific 
CD8+ T cells from different tissues can be treated to prevent them to be exhausted. 
Although immune checkpoint blockade (ICB) for the treatment of cancer patients has 
shown great promise (53-57), there are still concerns whether blocking a single inhibitory 













Figure 1. Discovering novel interventions with fundamental research to improve the treatment of chronic infec-
tious disease and cancer. 
(A) Transgenic T cells could be used to induce CTL exhaustion in vitro, when the critical exhaustion genes or genes re-
lated to function are tagged, the in vitro exhaustion model could be utilized to screen antibodies or chemical libraries 
that prevent, reverse or accelerate T cell exhaustion. (B) CRISPR/Cas approaches using sgRNA pools could be used to 
screen exhausted T cells associated genes. By sorting exhausted versus non-exhausted cells and sequencing these, 
novel exhaustion related genes could be identified. (C) Sort the functional and dysfunctional cells from patients, 
then compare their transcriptome characteristics. By analysing differentially expressed genes, crucial factors could 
be identified. The above approaches could benefit immunotherapies and adoptive T cell therapies. Small molecules 
that prevent or promote exhaustion could be employed in chronic infection, cancer or autoimmunity patients. For 
adoptive therapies T cells are isolated from the patients and modified with identified genes or treatments. 
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patients respond to ICB therapy. Therefore, treatment combination approaches have been 
proposed to improve the ICB efficiency. This has already been shown to improve ICB effective-
ness when anti-PD-1 and anti-CTLA-4 treatments have been combined (59, 60). Additional 
combinations of different ICB therapies, such as anti-PD-1 and Tim3, were also found to be 
a promising strategy (61). Because the efficacy of ICB relies on the existence of progenitor 
exhausted CD8+ T cells (62-65), expanding or preserving these would augment antitumor 
effects of ICB. Strategies that expand such cells, such as the one we employed in chapter 
5, as we show, can enhance ICB anti-tumor activity. Recruiting additional antigen-specific T 
cells to anti-tumor responses is also expected to enhance the effect of ICB. It has been shown 
that tumor vaccines can induce de novo antigen-specific T cells responses to tumors (66, 
67) and ICB efficacy correlates with the mutational load of tumors and neoantigens (68-72). 
Therefore the combination of tumor vaccines and check point blockade is another promising 
strategy to enhance the efficacy of ICB therapies (73, 74). Further, therapeutic combination 
strategies are being tested in order to enhance ICB. Such strategies include combining ICB 
with radiotherapy or antibodies that target phosphatidylserine (75-77). 
FUTURE PERSPECTIVE
Despite the great progress in our understanding of the molecular and cellular mecha-
nisms involved in T cell exhaustion and the development of therapies such as ICB that target 
exhausted cells, there still remain major questions on the application of ICB in different dis-
ease. Below I will discuss some of those main questions. 
Does ICB work the same in chronic viral infections and in cancer?
Although exhausted CD8+ T cells from chronic viral infection and cancer shared com-
parable phenotypic and transcriptome characteristics, their response to ICB is not identi-
cal. When anti-PD-1/PD-L1 therapy was prescribed to chronic HCV infected patients, there 
were synergetic effects and improvement the antiviral efficiency (78). These effects could 
be attributed to the improved function of CD8+ T cells and CD4+ T cells (79, 80). In another 
clinical study, it was demonstrated that blocking PD-1/PD-L1 could not completely restore 
the function of HCV-specific CD8+ T cells (81). Administrating anti-PD-L1 to the chronic HBV 
patients could increase the proliferation capacity and cytokine release of intrahepatic and 
peripheral HBV-specific T cells (82). Although in vitro studies have indicated that ICB may be 
beneficial in HIV+ patients (18, 83-85), this has not been directly tested. ICB has been tested 
in SIV infected non-human primates with conflicting findings regarding the therapeutic ben-
efit of ICB (86-89). Thus the benefit of ICB in chronic infections has not been proven and 













clinically in chronic infections. Why ICB in chronic infections has failed to show clinical benefit 
whereas in the setting of cancer it has shown great promise, remains poorly understood and 
should be a subject for investigation.
In contrast to chronic infections, ICB was approved to be used in the treatment of differ-
ent cancers, such as melanoma and non-small-cell lung cancer (54, 55, 57, 73, 90). However, 
despite the tremendous progress that ICB has brought to the field of tumor immunotherapy, 
the fundamental understanding of how these therapies work to delay or halt the progres-
sion or induce the regression of cancer is still missing (91-93). So far, it was found that the 
mutation burden of tumors positively correlates with treatment efficiency (94) and this is 
attributed to increased neoantigens and responding T cells. In addition, the maintenance 
of progenitor exhausted cells are also necessary for the tumor bearing animal or patients 
to respond to ICB (62, 63, 95-98). Further efforts have focused on identifying the charac-
teristics of the population that responds to the checkpoint blockade therapy, and the more 
precise surrogate markers are required to define the responsible populations (63, 99, 100). 
Therefore, combining strategies that boost tumor neoantigen-specific T cells, such as tumor 
vaccines, or facilitate the preservation or increase of the less terminally differentiated 
progenitor exhausted T cell population would hopefully further enhance the effects of ICB 
therapy. 
From the above it is clear ICB in cancer and chronic infections has shown very differ-
ent efficacy. The reasons why this is so remain unknown and although exhaustion is shared 
in both settings, subtle differences in the molecular characteristics of exhaustion, the cells 
involved and their location may underlie these differences and beg for further investigation. 
Could other immune cells develop the exhausted state?
There is no clear answer if exhausted CD4+ T cells exist and how it should be defined, 
however, similar phenotype and state of dysfunction as CD8+ T cells exhaustion could be 
detected on CD4+ T cells after chronic antigen stimulation (101-104). Lately, by using anti-
gen-specific CD4+ T cells from TCR transgenic mice, Fu J et al showed that after their adoptive 
transfer into tumor bearing mice, there were multiple inhibitory receptors, such as PD-1, 
Tim3, Lag3, expressed on the surface of these cells. CD4+ T cells from tumor tissue also lost 
TCF1 expression, which was similar to exhausted CD8+ T cells. Surprisingly, it was found that 
anti-PD-L1 treatment could largely prevent the exhaustion of CD4+ T cells in this study (105). 
How checkpoint blockade influence the function of CD4+ T cells function and what is the con-
tribution of these exhausted CD4+ T cells in the disease development are to be determined. 
Could innate immunity members, such as natural killer cell (NK cells), be exhausted? 
It has been demonstrated that NK cell will decrease effector function, such as degranula-
tion, after over-stimulation. The hypo-functional state of NK cells was also correlated with 
poor pregnosis of different tumors (106, 107). Characteristics and mechanism of NK cell 
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exhaustion have been reviewed by J. Bi et al (108). However, we are still limited by the lack 
of deep understanding of NK cell exhaustion. It is expected that further studies into NK cell 
exhaustion may bring novel immunotherapies targeting on NK cells. Finally, currently there is 
a paucity of evidence relating to the exhaustion state of other immune cells. 
Inducing T cell exhaustion-a therapeutic strategy to overcome autoimmune 
disease?
The development of T cell exhaustion cannot be clearly classified as a positive or nega-
tive outcome. Some researchers suggest that exhaustion is an adaptive change under the 
persistence of antigen stimulation in order to restrain immunopathology and host damage 
(5, 109). Sandu. I et al reported that TCR signalling of antigen-specific CD8+ T cell from in vivo 
chronic LCMV infection was low, although there was antigen presented on MHC-class I mole-
cule (110). This inhibitory state of TCR signalling was reversed by prescribing anti-PD-1/PD-L1 
treatment to the animal. Such a depression of TCR signalling can occur in autoreactive T 
cells as demonstrated in the patients that receive ICB therapy as these are at risk to develop 
autoimmune diseases because of breaking of self-tolerance (111, 112). 
Based on the above, inducing T cell exhaustion was proposed to be a potential therapeu-
tic strategy in autoimmune disease (109). There is now further proof that inducing T cells 
exhaustion would slow down the progression of autoimmune disease, such as type 1 diabe-
tes (113). From clinical trial, it was found that Alefacept, a LFA-3-Ig fusion protein that binds 
CD2, could induce the CTL exhaustion related transcriptome profile, and this resulted in 
highly preserved endogenous insulin production (114). In contrast to the settings of chronic 
viral infection and cancer, enhancing inhibitory receptor signalling is proposed to treat auto-
immune disease, where inducing peripheral tolerance is needed (114). Whereas, it is far less 
clear how to induce CD4+ and CD8+ T cells exhaustion in the setting of autoimmunity and 
the benefit of such exhaustion induction or inhibitory receptor stimulation remains to be 
determined. Despite this, there is hope that such approaches may yield novel treatments for 
autoimmune diseases. 
Overcoming T cell exhaustion to facilitate the application of CAR T cells to 
solid tumors
CAR T cells therapy has demonstrated great success by improving the outcome of patients 
with B cell malignancies (115, 116). In patients who achieved complete remissions, a higher 
proportion of CAR T cells maintained a memory signature than the CAR T cells from partial 
remission or progressive patients (117). This indicated that infusion of less differentiated or 
memory-like autologous CAR T cells further improves the efficiency of this therapy. Despite 
its success in blood malignancies, it has been proven more difficult to design highly efficient 













receptor selection and vector designing, identifying strategies that can expand the CAR T 
cells while preventing terminal differentiation and facilitate the CAR T cell migration into lym-
phoid organs, are expected to improve CAR T cell therapy. It has been shown that expanding 
CAR T cells with IL-7/IL-15 instead of IL-2 could achieve highly functional antitumor T cells 
(120). Therefore, the strategies, such as culture conditions, pharmacological interventions 
and genetic modifications, have the potential to promote CAR T cells persistence or memory 
formation. Having in vitro exhaustion models available as the one we have developed could 
greatly facilitate the discovery of such factors.
In summary, our studies on CTL exhaustion that attempt to further define the features of 
exhaustion through different approaches in this thesis, have implications for chronic infec-
tions, tumor immunotherapy and autoimmunity. In this chapter, we further discussed the 
potential contributions of our data to understand how CTL exhaustion develops. By repeat 
stimulation of murine CD8+ T cells with cognate peptide in vitro, we successfully generate 
abundant bona fide exhausted CD8+ T cells. Subsequently, this in vitro CTL exhaustion model 
was utilized to screen the candidate pharmacological interventions and molecules to reverse 
and/or prevent CTL exhaustion. Overall, these findings deepened our understanding about T 
cell exhaustion biology and demonstrate the applicability of this platform to drug discovery. 
This in turn might contribute to the discovery of novel immune therapies for chronic infec-
tious diseases, cancer and autoimmunity. 
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ACT Adoptive T cell therapy
Aire Autoimmune regulator
Arm Armstrong strain
BAFi BRG-Brahma associated factor inhibitor
BATF Basic leucine zipper transcription factor, activating transcription 
factor ATF-like protein
BETi Bromodomain, and extra-terminal domain inhibitor
BRD4 Bromodomain-containing protein 4
BTK Bruton’s tyrosine kinase
CAPE Caffeic acid phenethyl ester
CAR Chimeric antigen receptor
cART Combination anti-retroviral treatment
CMV Cytomegalovirus
CTL Cytotoxic CD8+ T lymphocytes
CTLA-4 Cytotoxic T-lymphocyte-associated protein 4
DMSO Dimethyl sulfoxide
DNMT3a DNA methyltransferase 3a
EBV Epstein-Barr virus
FGL1 Fibrinogen-like protein 1
GSEA Gene set enrichment analysis
GzmB  Granzyme B 
HBV Hepatitis B virus
HCV Hepatitis C virus
HDACi Histone deacetylase inhibitor





ITK IL-2-inducible T-cell kinase
ITSM Immunoreceptor tyrosine-based switch motif
LAG-3 Lymphocyte activation gene-3
LCMV Cl-13 Lymphocytic choriomeningitis virus clone-13
LRAs  Latency reversing agents
LTR Long terminal repeats
MDSC Myeloid-derived suppressor cells
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MEK1/2 (MAPKK1/2) Mitogen-activated protein kinase kinase
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NFAT Nuclear factor of activated T-cells
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RBP RNA binding proteins 
SIV Simian immunodeficiency virus
STAT Signal transducer and activator of transcription
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TME Tumor microenvironment
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Tregs Regulatory CD4+ T cells








Chronic antigen stimulation drives CD8+ T cells into a dysfunctional state known as 
exhaustion, which has been documented in a variety of chronic infectious diseases and 
cancer. Under chronic antigenic stimulation, CD8+ T cells progressively develop exhaus-
tion-related characteristics such as upregulating multiple inhibitory receptors, an ordered 
loss of the capacity to produce cytokines, a diminishing potential to proliferate and finally 
an increasing propensity to apoptosis. Epigenetic modifications and transcriptional changes 
underlie these phenotypic and functional changes. The deepening of our knowledge on 
CD8+ T cells exhaustion, has revealed different differentiation stages of exhausted T cells, 
namely, progenitor exhausted T cells and terminally exhausted T cells. Progenitor exhausted 
T cells still maintain a stem-cell like potential to proliferate, and can further differentiated 
into terminally exhausted T cells, while terminally exhausted T cells only preserve some 
cytokine production and cytotoxic capacity. Due to the critical function of CTL in eliminating 
viral infections and lysing tumors, preventing or reversing T cells exhaustion is becoming a 
major research goal in the field of infectious diseases and tumor immunology, especially 
after immune check point blockade therapies have brought enormous benefits to cancer 
treatment. However, to date, the factors that can reverse or prevent T cells from undergo-
ing exhaustion remain largely unknown. The quest to identify such factors motivated us to 
embark on a series of studies to search for modulators of T cell exhaustion.
In this thesis we first introduce our current knowledge about T cell exhaustion and 
describe the characteristics, the factors that induce T cells exhaustion, and the T cell exhaus-
tion-related potential clinical applications for treating different types of diseases (Chapter 1). 
Starting off from the premise that epigenetic modifications accompany the development of 
T cells exhaustion, we began to evaluate the cytotoxicity effects of eight HIV latency reverse 
agents (LRA), which are mainly epigenetic modifiers (Chapter 2). Our reasoning was that LRA 
used to reactivate HIV need foremost to have little T cell cytotoxicity, otherwise the so called 
“shock and kill” strategy would fail, but that also some of these LRA epigenetic modifiers 
may modulate T cells exhaustion which is mediated by epigenetic changes. We found that 
different LRAs have distinct cytotoxic effects on diverse types of immune cells in human 
PBMC. Furthermore, BET inhibitors and PKC agonists could downregulate inhibitory receptor 
expression, indicating a potential role in modifying the function and exhaustion of CD8+ T 
cells (Chapter 2). 
A major bottleneck in the study of T cell exhaustion is the quantity of exhausted T cells 
that can be isolated from either animal models or human samples to perform different 
experiments. We, therefore, initiated a series of experiments to establish an in vitro T cell 
exhaustion model (Chapter 3). We found that repeatedly stimulating CD8+ T cells with the 
cognate peptide for five days could induce the development of bona fide exhausted CD8+ T 
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cells, which not only showed the whole spectrum of molecular and functional characteristics 
of exhausted cells, but also displayed the expected epigenetic modifications found in the 
exhausted cells. In these studies, we also discovered that the well-known downregulation of 
TCF1 in exhausted T cells results from hyper methylation of the promotor region of Tcf7, the 
gene encoding TCF1 (Chapter 3). By using this model, we next tested if microRNA miR-139 
played a role in T cell exhaustion development (Chapter 4). However, we found that miR-139 
deficient CD8+ T cells could still undergo exhaustion. Furthermore, miR-139 deficiency or 
overexpression could not influence the development of functional effector or memory CD8+ 
T cells in a murine influenza infection model, although miR-139 was found to be significantly 
differentially expressed between naïve and effector CD8+ T cells (Chapter 4). While searching 
for potential modulators that reverse T cell exhaustion, we identified that one small molecu-
lar inhibitor of BTK and ITK, ibrutinib, could improve the cytokine producing capacity, reduce 
inhibitory receptor expression and reverse the transcriptional features of in vitro exhausted 
T cells (Chapter 5). Since BTK is not expressed in T cells, we confirmed that ibrutinib was not 
acting via BTK by showing that BTK deficient T cells could still be driven to exhaustion and 
that they respond the same as wild type cells after ibrutinib treatment. These observations 
indicated that the effects of ibrutinib on exhausted T cells could due to its targeting of ITK, 
which we find is highly activated in exhausted cells. This was confirmed using a specific ITK 
inhibitor that could decrease inhibitory receptor expression and improve cytokine produc-
tion of exhausted cells. To examine the translational potential of these findings, we tested 
and found that combining ITK inhibitor with check point blockade enhanced anti-tumor 
effects even in check point blockade resistant solid tumors (Chapter 5). In summary, the in 
vitro T cell exhaustion model we established, enables us to deepen our understanding of T 
cell exhaustion and facilitates the studies to discover novel strategies of rejuvenating CD8+ T 
cell exhaustion and these future directions are discussed in the final chapter (Chapter 6). The 
T cell exhaustion method we developed and the modulators we identified in our research 








Chronische antigeen stimulatie drijft CD8+ T-cellen naar een disfunctionele staat van 
uitputting, wat gedocumenteerd is in een scala van chronische infectieziekten en kanker. 
Gedurende chronische antigeen stimulatie ontwikkelen CD8+ T-cellen geleidelijk uitput-
tings-gerelateerde kenmerken zoals de verhoogde expressie van diverse inhiberende 
receptoren, een geordend verlies van het vermogen om cytokines te produceren, een afne-
mende mogelijkheid om te vermeerderen en tot slot een toenemende neiging tot apoptose. 
Epigenetische modificaties en transcriptionele veranderingen liggen ten grondslag aan deze 
fenotypische en functionele veranderingen. Het vergroten van onze kennis over CD8+ T-cel 
uitputting heeft verschillende differentiatie stadia van uitgeputte T-cellen onthuld, zoals 
een voorstadium van uitgeputte T-cellen en een staat van terminale uitgeputte T-cellen. 
Uitgeputte T-cellen in het voorstadium hebben nog steeds een stamcel-achtige mogelijkheid 
om te vermeerderen, en kunnen verder differentiëren in terminaal uitgeputte T-cellen, 
terwijl terminaal uitgeputte T-cellen slechts een gelimiteerde cytokineproductie en cyto-
toxische capaciteit behouden. Vanwege de kritische functie van cytotoxische T-cellen in het 
elimineren van virale infecties en tumoren is het voorkomen van of het omkeren van T-cel 
uitputting een groot onderzoeksdoel geworden in het onderzoeksveld van infectieziekten 
en tumorimmunologie, met name nadat immuun checkpoint blokkade therapieën enorme 
voordelen hebben opgeleverd voor de behandeling van kanker. Echter, tot op heden zijn 
de factoren die T-cel uitputting kunnen omkeren of voorkomen grotendeels onbekend. De 
zoektocht om deze factoren te identificeren heeft ons gemotiveerd om een reeks studies te 
beginnen om modulatoren van T-cel uitputting te vinden.
In dit proefschrift introduceren we eerst de huidige kennis over T-cel uitputting en 
beschrijven we de kenmerken en de factoren die T-cel uitputting veroorzaken, alsmede de 
potentiële klinische toepassingen die verband houden met uitputting van T-cellen voor de 
behandeling van verschillende soorten ziekten (Hoofdstuk 1). Uitgaande van het standpunt 
dat epigenetische modificaties hand in hand gaan met de ontwikkeling van T-cel uitputting, 
zijn we de cytotoxische effecten van acht HIV latency reverse agentia (LRA), die met name 
epigenetische modificatoren zijn, gaan evalueren (Hoofdstuk 2). Onze redenering was dat 
LRA, dat gebruikt wordt om HIV te reactiveren, in de eerste plaats geen toxisch effect moet 
hebben op de T-cellen, anders zou de zogenoemde “shock and kill” strategie mislukken. In 
plaats daarvan zou de LRA T-cel uitputting kunnen beïnvloeden door middel van epigenetische 
veranderingen. We ontdekten dat diverse LRAs verschillende cytotoxische effecten hebben 
op diverse soorten immuun cellen in humane PBMC. Bovendien konden BET remmers en PKC 
agonisten de expressie van inhiberende receptoren verminderen, wat wijst op een mogelijke 
rol in het veranderen van de functie en uitputting van CD8+ T-cellen (Hoofdstuk 2).
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Een groot knelpunt in het onderzoek naar T-cel uitputting is de hoeveelheid uitgeputte T 
cellen, nodig voor diverse experimenten, die geïsoleerd kunnen worden uit diermodellen of 
humane monsters. We hebben daarom een reeks experimenten opgezet om een in vitro T-cel 
uitputtingsmodel te ontwikkelen (Hoofdstuk 3). We ontdekten dat herhaald stimuleren van 
CD8+ T-cellen met hun bijbehorend peptide voor een periode van 5 dagen de ontwikkeling 
van bonafide uitgeputte CD8+ T-cellen kan induceren. Deze cellen vertoonden niet alleen het 
hele spectrum van moleculaire en functionele kenmerken van uitgeputte cellen, maar lieten 
ook de verwachte epigenetische modificaties van uitgeputte T cellen zien. In deze studies 
hebben we ook ontdekt dat de welbekende verminderde expressie van TCF1 in uitgeputte 
T-cellen het gevolg is van hyper-methylering van de promotor regio van Tcf7, het gen dat 
codeert voor TCF1 (Hoofdstuk 3). Met dit uitputtingsmodel hebben we vervolgens getest 
of microRNA miR-139 een rol speelde in de ontwikkeling van T-cel uitputting (Hoofdstuk 4). 
Echter, miR-139 deficiënte CD8+ T-cellen raakten nog steeds uitgeput. Bovendien had miR-
139 deficiëntie of over-expressie geen effect op de ontwikkeling van functionele effector of 
geheugen CD8+ T-cellen in een muis influenza infectie model, hoewel eerder ontdekt was 
dat miR-139 significant verschillend tot expressie kwam bij naïeve en effector CD8+ T-cellen 
(Hoofdstuk 4). Zoekend naar mogelijke modulatoren die T-cel uitputting kunnen omkeren, 
ontdekten we dat ibrutinib, een kleine moleculaire remmer van BTK en ITK, de cytokine pro-
ductie capaciteit kon verbeteren, de expressie van inhiberende receptoren kon verminderen 
en de transcriptionele eigenschappen van in vitro uitgeputte T-cellen kon omkeren (Hoofdstuk 
5). Omdat BTK niet tot expressie komt in T-cellen, probeerden we te bevestigen dat ibrutinib 
niet werkt via BTK. BTK deficiënte T-cellen raakten nog steeds uitgeput en, na behandeling 
met ibrutinib reageerden deze cellen hetzelfde als wild type cellen. Deze observaties tonen 
aan dat de effecten van ibrutinib op uitgeputte T-cellen mogelijk het gevolg waren van de 
inhibitie van ITK. Tevens was ITK inderdaad sterk geactiveerd in uitgeputte cellen. Het effect 
van ibrutinib op ITK werd bevestigd door gebruik te maken van een specifieke ITK remmer 
die de expressie van inhiberende receptoren kon verlagen en de cytokine expressie van uit-
geputte cellen kon verbeteren. Om de translationele mogelijkheden van deze bevindingen 
te onderzoeken hebben we een combinatie van een ITK remmer en check point blokkade 
getest in tumoren. Uit deze experimenten bleek dat het anti-tumor effect sterk was ver-
beterd, zelfs in check point blokkade resistente, vaste tumoren (Hoofdstuk 5). Samenvattend 
stelt het in vitro T-cel uitputtingsmodel dat we opgezet hebben ons in staat om ons begrip 
van T-cel uitputting te vergroten en vergemakkelijkt dit model het onderzoek naar nieuwe 
strategieën om T-cel uitputting om te keren en te voorkomen. Deze mogelijkheden worden 
verder besproken in het laatste hoofdstuk (Hoofdstuk 6). Het T-cel uitputtingsmodel dat we 
hebben ontwikkeld en de modulatoren die we hebben geïdentificeerd in ons onderzoek 
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